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Abstract
In biotechnology and drug delivery silica materials are of interest but the controlled
generation of silicic acid is difficult. To get more insight into the molecular
mechanisms that control biosilification, it is important to study the proteins involved
in this process. The sponge protein silicatein α synthesises part of the axial filament in 
the spicules which in situ polymerises silicic acid. It has been demonstrated that the
polymerisation of siloxanes such as for example tetraethoxysilane (TEOS) can be
carried out by both wild type and recombinant silicatein α. Unfortunately, it has not 
been possible yet to get reasonable amounts of wild type or recombinant silicatein α to 
perform biophysical studies. The human cysteine protease cathepsin L has almost
50 % identical residues with silicatein α. To get more insight into the mechanism of 
silica polymerisation, cathepsin L mutants were generated by our collaborators. Those
mutants show sequence features and activity specific for silicatein α. The X-ray 
structure of one of those mutants (mutant 4SER) to 1.5 Å has allowed us to propose a
new chemical mechanism for the catalysis of silicic acid polymerisation.
ADP-β-D-glycero-D-mannoheptose and ADP-β-L-glycero-D-mannoheptose are  
interconverted by the SDR-enzyme ADP-β-L-glycero-D-mannoheptose 6-epimerase 
(AGME). This epimerisation reaction is the final reaction in the biosynthetic route of
the precursor of heptose. Heptose is a part of the inner core of the lipopolysaccharide
in Gram-negative bacteria. In mutants which do not have heptose, nonpolar
compounds can penetrate more easily through the outer membrane. These mutants
also show less pathogenicity. As a consequence the lipopolysaccharide biosynthetic
pathway represents an interesting target for antimicrobial compounds. The crystal
structure of AGME in complex with ADP-α-glucose has already been solved.  
From this structure a catalytic mechanism for this enzyme has been proposed with
Tyr140 and Lys178 operating as acid/base residues.
xThe disordered nature of the nucleotide sugar’s glucose moiety in the previous
structure due to the wrong configuration of the sugar has hindered assignment of a
mechanism. The determination of the X-ray structure of AGME Y140F in complex
with a substrate in the β-manno configuration (ADP-β-mannose) to 2.4 Å resolution  
has given new insight into the mechanism of this SDR enzyme. A mechanism is
proposed with only Tyr140 operating as catalytic acid/base.
Initially it was thought that MMP-3 participates in the synovitis cascade.
Glycoproteins, several parts of the ECM such as fibronectin and laminin and also
collagens and procollagens are targets of this matrixin. Furthermore MMP-3 can
undergo autocatalysis and is also able to cleave a range of other members of the
matrixin family. Matrixins also play an important role in diseases such as cancer,
rheumatoid arthritis and osteoporosis. This makes them targets for inhibitor design.
Many structures of matrix metalloproteinases, such as stromelysin-1, in complex with
various inhibitors have already been solved. The structures of the catalytic domain of
MMP-3 in complex with two nonpeptide inhibitors are discussed.
xi
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Chapter 1
Figure 1. (after Sajid and McKerrow, 2002) Representation of the binding of a peptide substrate to the catalytic site of a cysteine
protease. Amino acids from the peptide are indicated by P and the substrate binding sites of the protease by S. The thiol
nucleophile of the catalytic cysteine is indicated by SH, and the corresponding amide bond that is attacked before hydrolysis
(scissile bond) is marked with an arrow. The COOH side of the peptide (P'1, P'2, P'n) and corresponding substrate binding sites
(S'1,S'2, S'n) are called prime side, whereas the NH2 side of the peptide (P1, P2, Pn) and corresponding substrate binding sites
(S1,S2, Sn) are named non-prime side. (A). Representation of the SH of Cys and the imidazole ring of His (B1), and the
equilibrium with the thiolate-imidazolium charge relay. The delocalised electron density cloud is also shown (B2).
Figure 2. Ribbon digram of the structure of human cathepsin S (Pdb accession code 1ms6). Secondary structural elements of the
left (L) domain are shown in green, and secondary structural elements of the right (R) domain in cyan. This figure has been
produced using PyMol (DeLano, 2007).
Figure 3. Sequence alignment of papain and various cathepsins (based on Turk et al., 2000) The key active sites residues C25
and H159 are highlighted in yellow and marked with asterisks. Other amino acid residues, conserved in all 9 enzymes are shown
in red. The sequences are taken from the PROTEIN DATA BANK (PDB): papain from Carica papaya (Pdb accession code 9pap);
cathepsin L from Homo sapiens (Pdb accession code 1mhw); cathepsin V mutant (N108Q, N178D) from Homo sapiens (Pdb
accession code 1fh0); cathepsin K from Homo sapiens (Pdb accession code 1yt7); cathepsin S from Homo sapiens (Pdb
accession code 1nqc); cathepsin H from Sus scrofa (Pdb accession code 8pch); cathepsin C from Rattus norvegicus (Pdb
accession code 1jqp); cathepsin B from Homo sapiens (Pdb accession code 1huc); cathepsin X from Homo sapiens (Pdb
accession code 1ef7). This sequence alignment was carried out using the programme ClustalW (Chenna et al., 2003).
Figure 4. Stereo view showing residues Met75-Gln79 of the prosegment of procathepsin L (Pdb accession code 1cs8), dipping
into the substrate binding cleft of the mature part of procathepsin L (Coulombe et al., 1996). Secondary structure elements of the
propeptide and the mature part of procathepsin L are shown in cyan and green, respectively. The catalytic active site residues
Cys25 (its sulfur is oxidised to sulfonate) and His163, as well as the residues Met75-Gln79 of the prosegment are shown as sticks
(carbons in magenta). This figure has been produced using PyMol (DeLano, 2007).
Figure 5. Stereo views of the prosegment of procathepsin L (A) (based on Coulombe et al., 1996) (Pdb accession code 1cs8),
α-helices are shown incyan and loops in magenta, and procathepsin L (B). The prosegment is shown in cyan and cathepsin L in 
green. The catalytic active site residues Cys25 (its sulfur is oxidised to sulfonate; see Pdb accession code 1cs8 and Chowdhury et
al., 2002) and His163, as well as the residues His140-Asp155 of the prosegment binding loop (PBL) (Coulombe et al., 1996) are
shown in magenta. This figure has been produced using PyMol (DeLano, 2007).
Figure 6. Stereo view of procathepsins L (Pdb accession code 1cs8) (A) and B (Pdb accession code 1pbh) (B),
based on Coulombe et al., 1996. The prosegments of both enzymes are shown in cyan and cathepsins L and B in green. This
figure has been produced using PyMol (DeLano, 2007).
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Figure 7. Ribbon diagrams of papain from Carica papaya (A) (Pdb accession code 9pap), α-helices are shown in cyan 
β-strands in red and loops in magenta, and human cathepsin L (B) (Pdb accession code 3bc3). α-helices are shown in cyan, 
β-strands in magenta and loops in pink. (C) Cα tracing of cathepsin L (magenta) and papain (green) after their superposition. The 
disordered loop region (Phe172-Asn179) in cathepsin L (Fujishima et al., 1997) is shown as dashed lines. This figure has been
produced using PyMol (DeLano, 2007).
Figure 8. (based on Chowdhury et al., 2008) Location of the subsites in the active site cleft of cathepsin L (Pdb accession code
3bc3). Carbons are shown in green, oxygens in red, nitrogens in blue and sulfurs in yellow.This figure has been produced using
PyMol (DeLano, 2007).
Figure 9. (A) Close up view of the active site of cathepsin L (Pdb accession code 3bc3). The residues forming the oxyanion hole
and Cys25 (its sulfur is oxidised to sulfinate) (Chowdhury et al., 2002; Chowdhury et al., 2008). are shown as sticks (carbons in
cyan, nitrogens in blue, oxygens in red and sulfurs in yellow). (B) Surface representation of the same region. This figure has been
produced using PyMol (DeLano, 2007).
Figure 10. (A) Close up view and surface representation of the binding site for a substrate’s or an inhibitor’s P1 side chain in
papain (Pdb accession code 9pap). The same conserved region is also shown in cathepsin L (B) (Pdb accession code 3bc3). The
sulfur of Cys25 is oxidized in both shown structures, to sulfonate in papain (see Pdb accession code 9pap; Kamphuis et al., 1984)
and to sulfinate in cathepsin L(Chowdhury et al., 2002; Chowdhury et al., 2008). Conserved residues are shown as sticks
(carbons in cyan, nitrogens in blue, oxygens in red and sulfurs in yellow). This figure has been produced using PyMol (DeLano,
2007).
Figure 11. (A) Stereo view of the active site cleft of cathepsin L (Pdb accession code 3bc3). Residues forming the continuous
wall on the right hand side of the S2 subsite (Fujishima et al., 1997), Met70 at the bottom of the pocket, and the active site
residues Cys25 (its sulfur is oxidised to sulfinate) (Chowdhury et al., 2002; Chowdhury et al., 2008) and His163 are shown as
sticks (carbons in cyan, nitrogens in blue, oxygens in red and sulfurs in yellow). (B) Surface representation of the same region.
This figure has been produced using PyMol (DeLano, 2007).
Figure 12. (A) Stereo view of the S3 subsite of cathepsin L (based on Fujishima et al., 1997) (Pdb accession code 3bc3).
Residues at the centre of the S3 subsite, surrounding amino acids, and the active site residues Cys25 (its sulfur is oxidised to
sulfinate) (Chowdhury et al., 2002; Chowdhury et al., 2008). and His163 are shown as sticks (carbons in cyan, nitrogens in blue,
oxygens in red and sulfurs in yellow). (B) Surface representation of the same region. This figure has been produced using PyMol
(DeLano, 2007).
Figure 13. (A) Cathepsin B in complex with CA030 ( Pdb accession code 1csb; based on Turk et al., 1998) (Stereo view).The
inhibitor CA030, residues, important for the binding of CA030, the active site residues Cys29 and His199, and residues of the
S1’subsite and covering its top are shown as sticks (carbons in magenta (CA030) or cyan (amino acids), nitrogens in blue,
oxygens in red and sulfurs in yellow). (B) Surface representation of the same region. This figure has been produced using PyMol
(DeLano, 2007).
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Figure 14. (A) Cathepsin L in complex with 4-biphenylacetyl-Cys-D-Arg-Tyr-N-(2-phenylethyl)amide (Pdb accession code
1mhw) (Stereo view). The inhibitor, S1’-residues interacting with the inhibitor’s Cys side chain (Cys) and Cys25 with its
oxidised sulfur (to sulfinate) (Chowdhury et al., 2002; Chowdhury et al., 2008). are shown as sticks (carbons in magenta
(inhibitor) or cyan (amino acids), nitrogens in blue, oxygens in red and sulfurs in yellow). (B) Surface representation of the same
region. This figure has been produced using PyMol (DeLano, 2007).
Figure 15. (A) Cathepsin B in complex with CA030 (Pdb accession code 1csb) (Stereo view). The inhibitor, residues of the
conserved loop surface from Gln23 to Ser28 (Turk et al., 1998), amino acids of the occluding loop from Cys108 to Cys119, and
the catalytic active site residues Cys29 and His199 are shown as sticks (carbons in magenta (inhibitor) or cyan (amino acids),
nitrogens in blue, oxygens in red and sulfurs in yellow). (B) Surface representation of the same region. This figure has been
produced using PyMol (DeLano, 2007).
Figure 16. (A) Cathepsin L in complex with 4-biphenylacetyl-Cys-D-Arg-Tyr-N-(2-phenylethyl)amide (Pdb accession code
1mhw) (Stereo view). The inhibitor, S2’-residues interacting with the inhibitor’s 4-biphenylacetyl rings (4-BPA), and the
catalytic residues Cys25 (its sulfur is oxidised to sulfinate) (Chowdhury et al., 2002; Chowdhury et al., 2008) and His163 are
shown as sticks (carbons in magenta (inhibitor) or cyan (amino acids), nitrogens in blue, oxygens in red and sulfurs in yellow).
(B) Surface representation of the same region. This figure has been produced using PyMol ( DeLano, 2007).
Figure 17. (A) Cathepsin L in complex with 4-biphenylacetyl-Cys-D-Arg-Tyr-N-(2-phenylethyl)amide (Pdb accession code
1mhw) (Stereo view). The first inhibitor, 4-biphenylacetyl-Cys-D-Arg-Tyr-N-(2-phenylethyl)amide, the second inhibitor
molecule, missing the Tyr residue and the N-(2-phenylethyl)amide, residues interacting with the second inhibitor’s biphenyl
moiety (BP2), and the catalytic amino acids Cys 25 (its sulfur is oxidised to sulfinate) (Chowdhury et al., 2002; Chowdhury et al.,
2008) and His 163 are shown as sticks (carbons in magenta (inhibitor molecule 1), orange (inhibitor molecule 2) or cyan (amino
acids), nitrogens in blue, oxygens in red and sulfurs in yellow). (B) Surface representation of the same region. This figure has
been produced using PyMol (DeLano, 2007).
Figure 18. Pictures of adult sponges (left) (taken from http://upload.wikimedia.org/wikipedia/commons/6/62/
SpongeColorCorrect.jpg and a sponge larva (right) (taken from http://www.biology.ualberta.ca/CMD/Pics/ LeysLarva.jpg).
Figure 19. (taken from Shimizu et al., 1998) Scanning electron micrographs of (A) isolated silica spicules (x130) and (B) axial
filaments (x 1,000) from Tethya aurantia.
Figure 20. Sequence alignment of mature human cathepsin L (UniProtKB/TrEMBL entry P07711) with mature silicatein α from 
the sponge Tethya aurantia (O76238) (based on Shimizu et al., 1998) and also mature silicatein α from the sponges Lubomirskia
baicalensis (Q2PC18), Suberites domuncula (Q2MEV3) and Hymeniacidon perleve (Q2HYF6) (based on Fairhead et al., 2008).
Identical amino acids in all five proteins are marked with asterisks. Catalytic triad amino acid residues of the active site of
cathepsin L and corresponding residues in the silicateins are highlighted in yellow. Cysteine residues involved in disulfide
bridges in cathepsin L are highlighted in green. Hydroxy amino acid residues in cathepsin L and the silicateins are highlighted in
turquoise. The 4 amino acid loop in cathepsin L (Smith and Gottesman, 1989; Fairhead et al., 2008) that is missing in the
silicateins (Fairhead et al., 2008) is highlighted in grey. The sequence alignment was carried out using the programme ClustalW
(Chenna et al., 2003).
Figure 21. (A) The chemical reaction catalysed by the organic filament of the sponge spicule (based on Fairhead et al., 2008) and
(B) the chemical structure of tetraethoxysilane (based on Cha et al., 1999).
xiv
Figure 22. Sequence alignment of the 4SER chimera (Pdb accession code 2vhs) with mature human cathepsin L
(UniProtKB/TrEMBL entry P07711). Identical amino acids in both proteins are marked with asterisks. Catalytic triad amino
acids of the active site of cathepsin L and corresponding residues in 4SER are highlighted in yellow, and positions corresponding
to the sequence of cathepsin L are marked with asterisks. Residues, flanking the catalytic cysteine and histidine in cathepsin L
and the corresponding mutations in the chimera are highlighted in cyan. Other mutated amino acids and deletions are highlighted
in green. The 4 amino acid loop in cathepsin L (Smith and Gottesman, 1989; Fairhead et al., 2008), which is missing in 4SER
(Fairhead et al., 2008) is highlighted in grey. This sequence alignment was carried out using the programme ClustalW (Chenna et
al., 2003).
Figure 23. 0.5° oscillation X-ray image of the crystal of 4SER collected to a higher resolution pass to 1.5 Å (A) and a lower
resolution pass to 2.0 Å (B) at ID29, ESRF.
Figure 24. The asymmetric unit of 4SER showing four monomers. The Cα traces of the monomers A, B, C and D are shown in 
green, cyan, magenta and red, respectively. This figure has been produced using PyMol (DeLano, 2007).
Figure 25. Cα tracing of the four monomers A (green), B (cyan), C (magenta) and D (red) after their superposition. This figure 
has been produced using PyMol (DeLano, 2007).
Figure 26. (A) Ribbon diagram of the structure of the 4SER chimera (Pdb accession code 2vhs). α-helices (in cyan) and β-sheets 
(in red) are labelled. Loops are shown in magenta. The disordered loop between β-strands 7 and 8 is shown as dotted lines. (B) 
Stereo view of the connection of the heavy and light chain of 4SER (shown as Cα traces in magenta and green, respectively) via 
the S-S bridge between the heavy chain residue Cys156 and Cys209 (shown as sticks, carbons in cyan). The disordered loop
region is shown as dashed lines. This figure has been produced using PyMol (DeLano, 2007).
Figure 27. Stereo view of Cα tracing of chain A of 4SER (in green, Pdb accession code 2vhs) and chain A of human cathepsin L 
(in magenta, Pdb accession code 1mhw) after their superposition. Mutated residues in the chimera are shown as sticks (carbons in
cyan) and are labelled. The disordered loop region in both structures is shown as dotted lines. This figure has been produced
using PyMol (DeLano, 2007).
Figure 28. (A) Ribbon diagram of the 4SER chimera, showing the “’V’ shaped active site cleft” (Turk et al., 1998) with the
catalytic residues Ser25 and His163 (Turk et al., 1998) (in sticks, carbons in green) in its centre. The third residue of the catalytic
triad, Asn 187 (Fairhead et al., 2008), is also shown (in sticks, C-atoms in green) α-helices are shown in cyan, β-sheets in red and 
loops in magenta. The disordered loop region is shown as dashed lines. (B) Stereo view of the active site residues Ser25 and
His163 (in sticks, carbons in cyan) and their flanking residues (in sticks, C-atoms in green). The third amino acid of the catalytic
triad, Asn187 (Fairhead et al., 2008), is also shown (in sticks, carbons in cyan). This figure has been produced using PyMol
(DeLano, 2007).
Figure 29. Final 2Fo-Fc at 1σ (blue) and unbiased Fo-Fc maps at 3σ (green) around the sulfates at the active site (1) and about 17 
Å distant from Ser25 (2) of each monomer of 4SER (Stereo view). The SO42- molecules are modelled in the 2Fo-Fc densities.
This figure has been produced using PyMol (DeLano, 2007).
Figure 30. Stereo view showing one of the sulfate ions (shown as sticks) at a crystal contact between monomer A ( shown as Cα 
traces in green) and a crystallographically related monomer (shown as Cα traces in cyan). This figure has been produced using 
PyMol (DeLano, 2007).
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Figure 31. The mechanism of silica condensation.
Figure 32. (after Cha et al., 1999) Proposed reaction mechanism of tetraethoxysilane polymerisation carried out by silicatein α, 
based on the well studied catalytic reaction performed by Ser /His and Cys / His active-site proteases (Cha et al., 1999; Zhou et
al., 1999).
Figure 33. (taken from Fairhead et al., 2008) Silica condensing activity of the mutants C2S, AS2, AS2H, LOOP, 2SER, 4SER
(see Table 1) generated by our collaborators. Protein in 0.1 M sodium phosphate buffer, pH 7 was mixed with sodium silicate at a
concentration of 4.5 mM. The samples were then incubated at room temperature for one day (Fairhead et al., 2008). After the
samples had been centrifuged the precipitated silica was then collected and assayed using the Merck spectroquant silicon assay
kit (Müller et al., 2003; Fairhead et al., 2008).
Figure 34. (A) Stereo view of the active site of the C25S procathepsin L mutant (Pdb accession code 1cjl). Active site and
adjacent residues are shown as sticks. The distance of about 3.3 Å between the OG atom of Ser25 and ND1 of His163 is shown
as dashed lines. (B) Stereo view of the active site of monomer C of 4SER (Pdb accession code 2vhs) showing the close contacts
(<3.5 Å) as dashed lines. Active site and adjacent residues are shown as sticks, and waters as red spheres. The distance between
the OG atom of Ser25 and ND1 of His163 is also shown as dotted lines (after Fairhead et al., 2008). (C) As comparison the
catalytic triad (His57, Asp102, Ser195) (shown as sticks) (reviewed in Polgár, 2005) of the serine protease chymotrypsin (Pdb
accession code 4cha) is also shown. OG of Ser195 and NE2 of His57 are within H-bonding distance (Polgár, 2005) (2.8 Å)
(dashed lines). This figure has been produced using PyMol (DeLano, 2007).
Figure 35. Close up view of the active site of 4SER (residues in sticks) with tetraethoxysilane (carbons in cyan, silicon atom in
magenta) modelled at the same position as the sulfate ion (sulfur in yellow). Contacts between CAE of TEOS and OG of Ser25,
CAA of TEOS and ND1 of His163, and also CAA and O of Asn162 are shown as dashed lines. The direction of rotation around
the silicon and oxygen OAI is shown as an arrow. This figure has been produced using PyMol (DeLano, 2007).
Figure 36. (A) (after Fairhead et al., 2008) The proposed chemical mechanism for the condensation of Si(OH)4. We favour a
mechanism in which His163 abstracts H+ from silicic acid; the extensive water network could permit the shuttling of protons. (B)
The other more unlikely mechanism of deprotonation of His163 and subsequent nucleophilic attack of the OH-group of the
second silicic acid molecule on the first Si(OH)4 (Fairhead et al., 2008).
Chapter 2
Figure 37. (after Tanner, 2002) There are three distinct routes to stereochemical inversion. The top route (1) shows the cut of a
C-H bond. This could be via deprotonation (amino acid racemases (Tanner, 2002), RmlC (Dong et al., 2003) or H- transfer (UDP
galactose 4-epimerase (Frey, 1996; Tanner, 2002), ADP-L-glycero-D-mannoheptose 6-epimerase (Read et al., 2005). The central
route (2) describes cleavage of a C-O bond. An example is the epimerisation of 3-hydroxyacyl-CoA. This employs
non-stereospecific dehydration/hydration to invert stereochemistry (crotonase reactions) (Yang and Elzinga, 1993; Yang et al.,
1991; Smeland et al., 1991; Wakil, 1956). The bottom route (3) involves C-C bond cleavage. A good example is L-ribulose
5-phosphate 4-epimerase (Tanner, 2002).
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Figure 38. (after Allard et al., 2001) The epimerisation reaction: “the inversion of configuration of an asymmetrically substituted
carbon in a sugar” (Allard et al., 2001).
Figure 39. H+-abstraction and readdtion involving transient oxidation (after Tanner, 2002).
Figure 40. Ribbon diagram of 3β/17β hydroxysteroid dehydrogenase (3β/17β HSD) from Comamonas testosteroni (Pdb
accession code 1hxh). α-helices are shown in cyan, β-strands in magenta, and loops in pink. The α/β sandwich and the β-sheet in 
the centre, decorated by several α-helices represent the characteristic Rossmann fold (Oppermann et al., 2003; Jörnvall et al.,
1995; Rossmann et al., 1975). The β-strand in the centre is shown in yellow and is boxed.  
Figure 41. Reaction mechanism of 3β/17β hydroxysteroid dehydrogenase with NADH and steroid substrate (5α-androstane, 
3-one,17ol). At the beginning of the catalytic reaction an H+ is transferred from the side chain hydroxyl of Tyr 151 to C=O of the
substrate. Then H- is transferred to C3 of 5α-androstane, 3-one,17ol. Finally an H+ relay is built up including Lys155, Asn111,
H2O and the 2’-hydroxyl of the ribose. ARPP: adenosine ribose pyrophosphate part of the cofactor (after Filling et al., 2002).
Figure 42. Structural sequence alignment of members from all five families of SDRs (Kallberg et al., 2002) Conserved sequence
motifs (see Table 10) in classical SDRs (3β/17β-hydroxysteroid dehydrogenase from Comamonas testosteroni, Pdb accession
code 1hxh; 3α,20β-hydroxysteroid dehydrogenase from Streptomyces exfoliatus, Pdb accession code 2hsd) are highlighted in
yellow, the corresponding motifs in the representative of the extended SDR family (UDP-galactose 4-epimerase from Homo
sapiens, Pdb accession code 1ek6) are highlighted in green, in intermediate SDRs (alcohol dehydrogenase from Drosophila
lebanonensis, Pdb accession code 1a4u; alcohol dehydrogenase from Drosophila melanogaster, Pdb accession code 1mg5) in
turquoise, in divergent SDRs (enoyl reductase from Escherichia coli; Pdb accession code, 1qsg; enoyl-ACP reductase from
Mycobacterium tuberculosis; Pdb accession code 1bvr) in grey, and in one member of the complex SDR family
(6-methylsalicylic acid synthase from Penicillium patulum (Penicillium griseofulvum), UniProtKB/TrEMBL entry P22367) in
pink. Residues conserved in all five families are marked with an asterisk. The positions of secondary structural elements in
classical SDRs are marked on top of each motif, positions of α-helices and β-strands, as they occur in the extended family are 
shown in red at the bottom of each motif. This sequence alignment was carried out using the programme ClustalW (Chenna et al.,
2003).
Figure 43. (taken from Persson et al., 2003) The two levels of classification within the superfamily of SDR enzymes. Enzymes
belonging to the superfamily of SDRs are divided into five families. Classical and extended SDRs are further divided into seven
and three subfamilies, respectively, based on their amino acids associating to the cofactor (Persson et al., 2003; Kallberg et al.,
2002).
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Figure 44. Sequence alignment of various classical and extended SDRs, based on their coenzyme specificity (based on Kallberg
et al., 2002). The “key position” numbers refer to 3α,20β-hydroxysteroid dehydrogenase (Pdb accession code 2hsd) as a member 
of the classical family (blue asterisks) and UDP-galactose 4-epimerase (UniProt/KB/Swiss-Prot Q14376 (GALE_HUMAN)) as a
representative of the extended family (red asterisks) (Kallberg et al., 2002). Conserved residues in all eight proteins are marked
with asterisks The conserved TGxxxGhG motif of the classical SDRs (Kallberg et al., 2002) is highlighted in yellow, the
counterpart in the extended family TGxxGhaG (Kallberg et al., 2002) in green. “Key position” residues are highlighted in grey in
the classical family and in turquoise in the extended one. 3α,20β-hydroxysteroid dehydrogenase from Streptomyces exfoliatus
(Pdb accession code 2hsd), subfamily cD1d (Kallberg et al., 2002); 17-beta-hydroxysteroid dehydrogenase 4
(UniProtKB/Swiss-Prot P51659 (DHB4_HUMAN)) from Homo sapiens, subfamily cD1d (Persson et al., 2003);
17-beta-hydroxysteroid dehydrogenase 14 (UniProtKB/Swiss-Prot Q9BPX1(DHB14_HUMAN)) from Homo sapiens; subfamily
cD1d; Corticosteroid 11-beta-dehydrogenase isozyme 2 (UniProtKB/Swiss-Prot P80365 (DHI2_HUMAN)) from Homo sapiens;
subfamily cD3 (Persson et al., 2003); Estradiol 17-beta-dehydrogenase 12 (UniProtKB/Swiss-Prot Q53GQ0(DHB12_HUMAN)
from Homo sapiens, subfamily cP2; Carbonyl reductase (Pdb accession code 1cyd) from mus musculus, subfamily cP3 (Kallberg
et al., 2002); UDP-galactose 4-epimerase (UniProt/KB/Swiss-Prot Q14376 (GALE_HUMAN)) from Homo sapiens, subfamily
eD1 (Kallberg et al., 2002); R-specific alcohol dehydrogenase (UniProt/KB/Swiss-Prot Q84EX5 (Q84EX5_LACBR) from
Lactobacillus brevis, subfamily eP1 or cP2. This sequence alignment was carried out using the programme ClustalW (Chenna et
al., 2003).
Figure 45. (after Morrison and Tanner, 2007) Biosynthetic pathway of ADP-L-glycero-D-mannoheptose. The reaction carried out
by ADP-β-L-glycero-D-mannoheptose 6-epimerase is surrounded with a box. 
Figure 46. Ribbon diagram of AGME from the E. coli strain K12 (Pdb aceession code 1eq2) (based on Deacon et al., 2000)
α-helices are shown in cyan, β-strands in magenta, and loops in pink. The seven parallel β-sheets in the centre, decorated by 
seven α-helices on either side represent the characteristic Rossmann fold. The carboxyterminal domain is composed of a small 
α/β domain, which plays a role in the interaction with the substrate. NADP and the inhibitor ADP-glucose are shown as sticks 
(Deacon et al., 2000). This figure has been produced using PyMol (DeLano, 2007).
Figure 47. (A) Stereo view of Cα tracing of AGME from E. coli (in cyan, Pdb accession code 1eq2) and UGE from E. coli (in
green, Pdb accession code 1nah) after their superposition (based on Deacon et al., 2000). (B) Ribbon diagrams of both structures
after their superposition (stereo view). This figure has been produced using PyMol (DeLano, 2007).
Figure 48. (after Morrison et al., 2005 and Morrison and Tanner, 2007) The dismutation of ADP-β-D-manno-hexodialdose
employed by AGME.
Figure 49. (after Morrison and Tanner, 2007) Proposed two-base mechanism for the reaction carried out by AGME. B1 and B2
are catalytic site acid/base amino acids. The hydrated form of ADP-β-D-mannohexodialdose 1 bound in the catalytic region is 
boxed.
Figure 50. Structures of ADP-α-D-glucose, ADP-β-L-glycero-D-manno-heptose and ADP-β-D-mannose. 
Figure 51. PCR product of hldD from pET-30 Xa/LIC. Lane 1: 1 kbp ladder; lane 2: amplified 956 bp PCR product
Figure 52. Restriction analysis with NcoI and XhoI confirming the insertion of hldD into pEHISTEV. Lane 1: “clone 1” : lane 2:
“clone 2”; lane 3: “clone 3”; lane 4: 1 kbp DNA ladder
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Figure 53. SDS-PAGE showing hexa-histidine tagged AGME and AGME Y140F expressed from pET-30 Xa/LIC (A and B), and
hexa-histidine tagged AGME expressed from pEHISTEV (C). (A) Lane 1: Mark 12TM Protein Standard; lane 2: whole cell extract
of AGME (expression for two hours at 37 ºC after induction with 0.2 mM IPTG) ; lane 3: corresponding supernatant; lane 4:
whole cell extract of AGME (expression overnight at 37 ºC after induction with 0.2 mM IPTG); lane 5: corresponding
supernatant; lane 6: whole cell extract of AGME (expression overnight at 25 ºC after induction with 0.2 mM IPTG); lane 7:
corresponding supernatant; (B) lane1: Mark 12TM Protein Standard : lane 2: whole cell extract of AGME Y140F (expression
overnight at 37 ºC after induction with 0.2 mM IPTG); lane 3: corresponding supernatant; lane 4: whole cell extract of AGME
Y140F (expression for three hours at 37 ºC after induction with 0.2 mM IPTG); lane 5: corresponding supernatant; lane 6: whole
cell extract of AGME Y140F (expression overnight at 25 ºC after induction with 0.2 mM IPTG); lane 7: corresponding
supernatant; (C) lane 1: Mark 12TM Protein Standard; lane 2: whole cell extract of AGME (expression for two hours at 37 ºC after
induction with 0.2 mM IPTG) ; lane 3: corresponding supernatant; lane 4: whole cell extract of AGME (expression overnight at
37 ºC after induction with 0.2 mM IPTG); lane 5: corresponding supernatant; lane 6: whole cell extract of AGME (expression
overnight at 25 ºC after induction with 0.2 mM IPTG); lane 7: corresponding supernatant.
Figure 54. SDS-PAGE showing all the fractions obtained during the first purification step. Lane 1: Mark 12TM Protein Standard :
lane 2: supernatant after first lysis; lane 3: cell extract after second lysis; lane 4: supernatant after second lysis; lane 5: final
supernatant; lane 6: Flowthrough; lanes 7-9: wash fractions; lanes 10-13: eluted AGME containing fractions
Figure 55. SDS-PAGE showing the fractions of AGME eluted from the HiTrapTM Butyl FF column. Lane 1: Mark 12TM Protein
Standard : lane 2: AGME sample before its application to the column; lanes 3-10: eluted AGME fractions
Figure 56. SDS-PAGE showing the fractions of AGME eluted from the HiPrepTM 16/60 SephacrylTM S-200 size exclusion
column. Lane 1: Mark 12TM Protein Standard : lane 2: AGME sample before its application to the column; lanes 3-8: eluted
AGME fractions
Figure 57. SDS-PAGE showing concentrated AGME before being stored at -80 ºC. Lane 1: Mark 12TM Protein Standard : lane 2:
AGME at 4.1 mg/ml; lane 3: AGME at 7 mg/ml
Figure 58. Crystals of AGME grown in presence of ADP-β-mannose (5-6.6 mM). 1: condition # 46 from JCSG+ screen; 2:
condition # 74 from Classics screen; 3: condition # 2 from JCSG+ screen; 4: condition # 78 from JCSG+ screen; 5: condition # 5
from Classics screen
Figure 59. Optimised crystals of AGME grown in presence of 6.6 mM ADP-β-mannose under the condition 0.2 M Ca-Acetate, 
0.1 M Na-cacodylate pH 6.5 and 35 % PEG 300.
Figure 60. Optimised crystals of reconsituted AGME grown in presence of 2.5 mM ADP-β-mannose under the condition 0.2 M 
Ca-Acetate, 0.1 M Na-cacodylate pH 6.5 and 35 % PEG 300.
Figure 61. Optimised crystals of AGME Y140F grown in the presence of 2.5 mM ADP-β-mannose under the 
condition 0.2 M Ca-Acetate, 0.1 M Na-cacodylate pH 6.5 and 35 % PEG 300.
Figure 62. Crystals of AGME Y140F grown in presence of ADP-β-mannose (2.5 mM). 1: condition # 67 from PEGs screen; 2: 
condition # 54 from PEGs screen; 3: condition # 76 from PEGs screen; 4: condition # 82 from Classics screen
5: condition # 73 from Classics screen
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Figure 63. Optimised crystals of AGME Y140F grown in presence of 1 mM ADP-β-mannose under the condition 2 M 
(NH4)2SO4, 0.1 M HEPES-Na, pH 7.1, 2 % PEG 400 (A) and 2 M (NH4)2SO4, 0.1 M HEPES-Na, pH 7.5, 2 % PEG 400, 10 mM
Spermidine (B).
Figure 64. ITC analysis of AGME/ADP-β-mannose (A) and AGME Y140F/ADP-β-mannose (B) interactions. The titration 
profiles of ADP-β-mannose into AGME and AGME Y140F are shown in the top panels of (A) and (B). The integrated binding 
isotherms of the AGME/ADP-β-mannose and AGME Y140F/ADP-β-mannose titrations and experimental fits are demonstrated 
in the bottom panels. Each experiment was performed once.
Figure 65. Stereo view of the buried N-terminus of AGME (monomer A is shown) (Pdb accession code 1eq2). The
aminoterminal β-sheet (β1) is shown in red. The other secondary structure elements are shown in green. α-helices and β-strands 
surrounding β1 are labelled.   
Figure 66. Diffraction pattern of one of the AGME Y140F crystals grown from 0.2 M Ca-acetate, 0.1 M Na-cacodylate, pH 6.5
and 35 % PEG 300.
Figure 67. 0.25° oscillation X-ray images of the crystal of AGME at the start of the collection (A) and after about 30º of
collected data (B).
Figure 68. 0.1° oscillation X-ray image of the crystal of AGME Y140F collected in-house to 2.8 Å resolution.
Figure 69. 0.5° oscillation X-ray image of the crystal of AGME Y140F collected to 2.4 Å resolution at BM14, ESRF.
Figure 70. The asymmetric unit of AGME showing two pentamers. Cα traces of the ten monomers (A-J) are shown in different 
colours.
Figure 71. Unbiased Fo-Fc at 2.5σ (green) and final 2Fo-Fc at 1σ (blue) maps around the NADP+ of monomers A-J of AGME. The
NADP+-molecule is modelled in the 2Fo-Fc density. Both electron densities for the cofactor are shown in stereo view in monomer
A. Both maps were calculated after one run of restrained refinement. The weak electron density at the the nicotinamide part of
NADP+ (Fo-Fc maps) shows that this moiety of the molecule is flexible. This figure has been produced using PyMol (DeLano,
2007).
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Figure 72. Structural sequence alignment of AGME from E. coli K-12 (Pdb accession code 1eq2) with the structurally most
related enzymes, UDP-galactose 4-epimerase from E. coli (Pdb accession code 1nah) and Homo sapiens (UniProtKB/TrEMBL
entry Q14376), dTDP-D-glucose 4,6 dehydratase from E. coli (Pdb accession code 1bxk) and GDP-4-keto-6-deoxy-D-mannose
epimerase/reductase from E. coli (Deacon et al., 2000) (Pdb accession code 1bws). 3α,20β-hydroxysteroid dehydrogenase (Pdb 
accession code 2hsd) as a member of the classical SDR family is also shown as comparison to the five enzymes (Kallberg et al.,
2002). Conserved sequence motifs (see Tables 12 and 14) in AGME are highlighted in yellow, the corresponding motifs in the
two UDP-galactose 4-epimerases, in dTDP-D-glucose 4,6 dehydratase and in GDP-4-keto-6-deoxy-D-mannose
epimerase/reductase are highlighted in green. Motifs in 3α,20β-hydroxysteroid dehydrogenase are highlighted in turquoise. 
Residues conserved in all six SDR enzymes are marked with an asterisk. The positions of secondary structural elements in the
five extended SDR enzymes are marked on top of each motif, positions of α-helices and β-strands, as they occur in 
3α,20β-hydroxysteroid dehydrogenase a are shown in red at the bottom of each motif. The crucial residues (Ser116, Tyr140 and 
Lys144) in the catalytic region of AGME (Deacon et al., 2000) are labelled as well. Residues at “key positions” based on
coenzyme specificity are highlighted in magenta. The Asp residue at the end of β2 in AGME (Kallberg et al., 2002) is highlighted
in grey. Numbers (*36) refer to 3α,20β-hydroxysteroid dehydrogenase and human UDP-galactose 4-epimerase(*33) (Kallberg et
al., 2002). This sequence alignment was carried out using the programme ClustalW (Chenna et al., 2003).
Figure 73. (A) Cα traces of the monomers (A-J) forming two pentamers in the 2.4 Å structure of AGME Y140F. (B) Cα traces of 
the monomers (A-T) forming four pentamers (green, blue, red and magenta) in the 2.8 Å structure of AGME Y140F. This figure
has been produced using PyMol (DeLano, 2007).
Figure 74. Stereo view of the Cα tracing of the ten monomers of the 2.4 Å (A) and the twenty monomers of the 2.8 Å (B) AGME 
Y140F structures after their superposition. This figure has been produced using PyMol (DeLano, 2007).
Figure 75. Unbiased Fo-Fc at 3σ (green) and final 2Fo-Fc at 1σ (blue) maps around the NADP+ of monomers A-J of the 2.4 Å
structure of AGME Y140F. The NADP+-molecule is modelled in the 2Fo-Fc density. Both electron densities for the cofactor of
monomer A are shown in stereo view. Both maps were calculated at final stages of refinement before modelling of the ligands.
The weak electron density at the the nicotinamide part of NADP+ (Fo-Fc maps) shows that this moiety of the molecule is flexible.
This figure has been produced using PyMol (DeLano, 2007).
Figure 76. Unbiased Fo-Fc at 3σ (green) and final 2Fo-Fc at 1σ (blue) maps around ADP-β-mannose of monomers A-J of the 2.4 
Å structure of AGME Y140F. The sugar molecule is modelled in the 2Fo-Fc density. Both electron densities for the nucleotide
sugar of monomer A are shown in stereo view. Both maps were calculated at final stages of refinement before modelling of the
ligands. This figure has been produced using PyMol (DeLano, 2007).
Figure 77. Unbiased Fo-Fc at 3σ (green) and final 2Fo-Fc at 1σ (blue) maps around the NADP+ of monomers A-T of the 2.8 Å
structure of AGME Y140F. The NADP+-molecule is modelled in the 2Fo-Fc density. Both electron densities for the cofactor of
monomer A are shown in stereo view. Both maps were calculated at final stages of refinement before modelling of the ligands.
The weak electron density at the the nicotinamide part of NADP+ (Fo-Fc maps) shows that this moiety of the molecule is flexible.
This figure has been produced using PyMol (DeLano, 2007).
Figure 78. Unbiased Fo-Fc at 3σ (green) and final 2Fo-Fc at 1σ (blue) maps around ADP-β-mannose of monomers A and C-T and 
ADP of monomer B of the 2.8 Å structure of AGME Y140F. The sugar molecule and ADP are modelled in the 2Fo-Fc density.
Both electron densities for the nucleotide sugar of monomer A are shown in stereo view. Both maps were calculated at final
stages of refinement before modelling of the ligands. This figure has been produced using PyMol (DeLano, 2007).
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Figure 79. Stereo view of the ten superimposed NADP and ADP-β-mannose molecules of 2.4 Å AGME Y140F. This figure has 
been produced using PyMol (DeLano, 2007).
Figure 80. Stereo view of the twenty superimposed NADP and nineteen ADP-β-mannose molecules of 2.8 Å AGME Y140F. 
This figure has been produced using PyMol (DeLano, 2007).
Figure 81. Stereo view of one superimposed NADP and ADP-β-mannose molecule from monomer A of the 2.4 Å (both 
molecules in green) and 2.8 Å structure (both molecules in magenta) of AGME Y140F. This figure has been produced using
PyMol (DeLano, 2007).
Figure 82. Stereo view of the superimposed NADP-molecules from monomer A of 2.4 Å AGME Y140F and monomer A of
wildtype AGME (Deacon et al., 2000). This figure has been produced using PyMol (DeLano, 2007).
Figure 83. Close up view of the superimposed nicotinamide moieties from monomer A of 2.4 Å AGME Y140F, monomer A of
wildtype AGME (Pdb accession code 1eq2) (Deacon et al., 2000), monomer A of UGE (1ek6) (Thoden et al., 2000) and
monomer A of DGD (Pdb accession code 1bxk). This figure has been produced using PyMol (DeLano, 2007).
Figure 84. Stereo view of the superposition of NADP and ADP-β-mannose molecules from monomer A of the 2.4 Å resolution 
AGME mutant (carbons in green) with the NADP and ADP-α-glucose-moieties from monomers B (C-atoms in cyan) and D 
(carbons in magenta) of AGME (Pdb accession code 1eq2) (Deacon et al., 2000). This figure has been produced using PyMol
(DeLano, 2007).
Figure 85. Stereo view of the adenine binding site in AGME Y140F. Hydrogen bonds are shown as dashed lines. This figure has
been produced using PyMol (DeLano, 2007).
Figure 86. Stereo view of the ribose binding site in AGME Y140F. H-bonds between atoms of the pentose and amino acids
Ser180, Ala182 and His187 are shown as dotted lines. This figure has been produced using PyMol (DeLano, 2007).
Figure 87. Close up view of the pyrophosphate binding site in AGME Y140F. Hydrogen bonds between atoms of the PPi and
amino acids Thr81, Arg209 and Asn169 are shown as dotted lines. This figure has been produced using PyMol (DeLano, 2007).
Figure 88. Stereo view of the interactions of O2, O3, O4 and O6 of the mannose moiety of ADP-β-mannose (carbons in cyan) in 
AGME Y140F with closely positioned residues (C-atoms in green). H-bonds are shown as dotted lines. This figure has been
produced using PyMol (DeLano, 2007).
Figure 89. Stereo view of superimposed ADP-β-mannose (carbon atoms in green) of AGME Y140F and ADP-α-glucose (carbons 
in cyan) from monomer D of AGME (Pdb accession code 1eq2). Residues close to the hexose moieties of both molecules, and
also the highly conserved Lys144 (Deacon et al., 2000) are also shown (C-atoms of residues of AGME Y140F are shown in green
and carbons of AGME in cyan). The exactly same positions of the active site residues (Ser116, 140Phe/Try140 and Lys144
(Deacon et al., 2000)) in both structures indicate that the mutation does not perturb the catalytic region of AGME. This figure has
been produced using PyMol (DeLano, 2007).
Figure 90. Stereo view of the distances between C6 of the glucose moiety of ADP-α-glucose and C4 of NADP in monomers B
(4 Å) (A) and D (3.4 Å) (B) of AGME (Pdb accession code 1eq2) and between C6 of the mannose part of ADP-β-mannose and 
C4 of NADP (2.9 Å) (C) of 2.4 Å AGME Y140F. This figure has been produced using PyMol (DeLano, 2007).
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Figure 91. Stereo view of the distance between O6 of the mannose moiety of ADP-β-mannose and NZ of Lys178 of AGME
(7.7 Å) (A) and after a 120º rotation about the C-5″-C-6″ bond (6.2 Å) (B). Tyr140 has been modelled based on the position of 
140Phe. This figure has been produced using PyMol (DeLano, 2007).
Figure 92. Stereo view of the distances between Tyr140 and Lys 144 and the 2'OH and 3'OH of the ribose of NADP (red dotted
lines), the distances between Tyr140 and Lys144 and Tyr140 and N1N of the nicotinamide (black dashed lines), and the
intramolecular H-bond of the cofactor (blue dotted line). Amino acids, NADP and ADP-β-mannose are shown as sticks .This 
figure has been produced using PyMol (DeLano, 2007).
Figure 93. Stereo views showing the orientation of the hydrogens of C-6″ of the mannose moiety in AGME (A) and C-4″ of the 
rhamnose moiety in RmlD (Pdb accession code 1kc3) (B) in respect to C-4″ of the nicotinamide ring of the coenzymes. Sugar 
moieties, cofactors (with hydrogens) and the conserved Tyr are shown as sticks. Distances between C-6″(mannose) / C-4″ 
(rhamnose) and C-4″ of the niacinamides are 2.9 Å and 3.1 Å, respectively. This figure has been produced using PyMol (DeLano, 
2007).
Figure 94. Stereo view showing the distances (dashed lines) between Tyr140 and Ser116 and between both residues and O6 of
the sugar moiety of ADP-β-mannose in AGME. This figure has been produced using PyMol (DeLano, 2007).  
Figure 95. Stereoview of ADP-β-mannose and Tyr140 from AGME. ADP-L,D-Hep is shown as comparison. The C-6”-OH in all 
molecules is boxed. This figure has been produced using PyMol (DeLano, 2007).
Figure 96. Stereo view of ADP-β-mannose after a 120º rotation about the C-5″-C-6″ bond and Tyr140 of AGME. ADP-D,D-Hep 
is shown as comparison. The C-6”-OH in all molecules is boxed This figure has been produced using PyMol (DeLano, 2007).
Figure 97. Stereo view of the contacts between C-6″ of the sugar moiety of ADP-β-mannose (after a 120º rotation about the 
C-5″-C-6″ bond) and C-4″ of NADP+ and O6 of mannose and O of Tyr140 (2.1 Å). Hydrogens are shown in white, directions of
proton and hydride transfers as arrows, and distances as dashed lines This figure has been produced using PyMol (DeLano,
2007).
Figure 98. Stereo view of the same site as demonstrated in Figure 97. Hydrogens are shown in white. The required little
movement of Tyr140 (only 8.3º) to accommodate a proper position for adding H+ to the C=O group of the intermediate (Morrison
and Tanner, 2007) is shown as an arrow. This figure has been produced using PyMol (DeLano, 2007).
Figure 99. Stereo view of the active site of AGME. Tyr140 and atoms of the mannose moiety of ADP-β-mannose are shown as 
sticks. The required movement of the tyrosine residue into the other pocket of the catalytic region to be in an appropriate position
to add H+ the C=O group at position 6 of the rotated keto-intermediate (Morrison and Tanner, 2007) is shown as arrow. This
movement would not cause any clashes of Tyr140 with any amino acids of the protein. Ser116, as most closely located residue, is
now 2.4 Å from Tyr140. This figure has been produced using PyMol (DeLano, 2007).
Figure 100. Stereo view of contacts between C-6″ of the sugar moiety of ADP-β-mannose and C-4″ of NADPH and the location 
of the rotated intermediate in respect to the moved Tyr140. Hydrogens are shown in white, directions of proton and hydride
transfers as arrows. This figure has been produced using PyMol (DeLano, 2007)
Figure 101. Stereo views of the interactions of ADP-D,D-Hep (A) and ADP-L,D-Hep (B) with residues of AGME. The
nucleotide sugars, NADP and amino acids are shown as sticks. The 35º movement of Tyr140 is shown as an arrow. This figure
has been produced using PyMol (DeLano, 2007)
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Figure 102. Proposed one-base mechanism for the reaction catalysed by HldD. Tyr140 is the catalytic site acid/base amino acid.
Chapter 3
Figure 103. (taken from Page-McCaw et al., 2007) Possible modes of matrix metalloproteinase action. Members of this enzyme
family have the ability to cut parts of the extracullar matrix, which leads to more space for cells or tissues to migrate (a). Specific
autocrine or paracrine signalling molecules can also be produced by cleavage carried out by matrix metalloproteinases (b).
Matrix metalloproteinases are also able to directly control the composition of the tissue of the epithelium by cutting junctions
between cells or the basement membrane (c). The action of cryptic signalling molecules can also be activated or altered by this
family of proteinases which leads to various processes in cells (d). Deactivation or change of the function of signalling
compounds which leads to modifications in cell death, proliferation, cell motility or differentation can also be accomplished by
matrix metalloproteinases (Page-McCaw et al., 2007).
Figure 104. Structural sequence alignment of various MMPs (MMP-1, UniProtKB/TrEMBL entry P03956; MMP-2,
UniProtKB/TrEMBL entry P08253; MMP-3, UniProtKB/TrEMBL entry P08254; MMP-7, UniProtKB/TrEMBL entry P09237;
MMP-9, UniProtKB/TrEMBL entry P14780; MMP-10, UniProtKB/TrEMBL entry P09238; MMP-11, UniProtKB/TrEMBL
entry P24347; MMP-12, UniProtKB/TrEMBL entry P39900; MMP-14, UniProtKB/TrEMBL entry P50281) from Homo sapiens.
The conserved “Cys switch” fingerprint (Nagase et al., 2006) sequence is highlighted in yellow, the Zn2+ associating motif in
green, and the Met residue, 8 amino acids after the Zn2+ interacting cluster (Nagase et al., 2006) in turquoise. Residues conserved
in all nine matrix metalloproteinases are highlighted in magenta and marked with asterisks. This sequence alignment was carried
out using the programme ClustalW (Chenna et al., 2003).
Figure 105. (taken from Nagase et al., 2006) Organisation of the various domains of matrix metalloproteinases. sp: signal
sequence; pro: prosegment; cat: region responsible for catalysis; FNII: fibronectin type II motif; L1: linker or “hinge-region”;
Hpx: hemopexin region; CysR: cysteine rich; Ig: immunoglobulin part; L2: second connection; Mb: plasma membrane;TM:
transmembrane domain; GPI: glycosylphosphtidylinositol anchor; Cy: tail located in the cytoplasm.
Figure 106. (taken from Page-McCaw et al., 2007). Different levels of regulation of the actions of matrix metalloproteinases.
The actions of matrixins can be controlled at the levels of (1) “RNA transcription” (Page-McCaw et al., 2007), (2) translation, (3)
“secretion, intracellular trafficking, (4) subcellular or extracellular localisation, (5) activation of the zymogen form, (6)
expression of their endogenous protein inhibitors, such as tissue inhibitors of metalloproteinases (TIMPs)” (Page-McCaw et al.,
2007); Gomis-Rüth et al., 1997) “and α2-macroglobulin” (Page-McCaw et al., 2007; Sottrup-Jensen et al., 1989;), “and (7)
protease degradation” (Page-McCaw et al., 2007).
Figure 107. Stereo ribbon diagram of the prosegment of pro-MMP-3 (Pdb accession code 1slm). This figure has been produced
using PyMol (DeLano, 2007).
Figure 108. (A) Stereo view of Cα tracing of the prodomains of pro-MMP-3 from Homo sapiens (in green, Pdb accession code
1slm) and human pro-MMP-1 (in magenta, Pdb accession code 1su3) after their superposition. (B) Stereo ribbon diagrams of
both structures after their superposition. This figure has been produced using PyMol (DeLano, 2007).
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Figure 109. Stereo view of the region around the catalytic Zn2+ in pro-stromelysin-1 (Pdb accession code 1slm). Secondary
structural elements of the prosegment and the catalytic domain are coloured in green and cyan, respectively. Residues from each
of the two domains ligated with Zn2+ (grey sphere) are shown as sticks. This figure has been produced using PyMol (DeLano,
2007).
Figure 110. (A) Stereo view of the structure of RHTS (Pdb accession code 1cqr) (based on Chen et al., 1999). α-helices are 
shown in cyan, β-sheets in red and loops in magenta (flexible loop from amino acids 210-234 (Chen et al., 1999) labelled as L)).
(B) C-α tracing of the catalytic domain of stromelysin-1 from Homo sapiens (in cyan, Pdb accession code 1cqr) and porcine
MMP-1 (in magenta, Pdb accession code 1fbl) after their superposition. The rms deviation between both structures is 0.49 Å for
141 Cα positions. (C) Ribbon stereo diagrams of both structures after their superposition. This figure has been produced using 
PyMol (DeLano, 2007).
Figure 111. Close up view of the interactions between NE2 of His201, His205 and His211 and the catalytic Zn2+ in RHTS (Chen
et al., 1999) (Pdb accession code 1cqr). The three histidines are shown as sticks, and the catalytic zinc as grey sphere and
distances as dotted lines. This figure has been produced using PyMol (DeLano, 2007).
Figure 112. Close up view of the interactions of NE2 of His151 and His166, ND1 of His179 and OD2 of Asp153 with the
structural Zn2+ in RHTS (Pdb accession code 1cqr) (Chen et al., 1999). The three histidines and the aspartic acid are shown as
sticks, the catalytic zinc as grey sphere and distances as dashed lines. This figure has been produced using PyMol (DeLano,
2007).
Figure 113. (A) Close up views of the interactions of OD1 of Asp158, the O-atoms of Gly159, Gly161 and Val163, OD2 of
Asp181 and OE2 of Glu184 with Ca1 (Chen et al., 1999; Dhanaraj et al., 1996), (B) the interactions of OD1 of Asp107 and
Asp182, the O-atoms of Asp182 and Glu184 and the two H2O with Ca2 (Chen et al., 1999), and (C) the interactions of OD1 of
Asp177, O of Asp141, Gly173 and Asn175 and the two H2O with Ca3 in RHTS (Chen et al., 1999) (Pdb accession code 1cqr).
Ligating residues are shown as sticks, the calcium ion as yellow sphere, waters as red spheres and distances as dotted lines. This
figure has been produced using PyMol (DeLano, 2007).
Figure 114. (based on Finzel et al., 1998) A surface diagram to show the location of the subsites S1, S2, S3, S4, S1', S2' and S3'
in the catalytic domain of stromelysin-1 (Pdb accession code 1usn) (shown as surface). Carbons are shown in green, oxygens in
red and nitrogen sin blue. The catalytic zinc ion is shown as grey sphere. This figure has been produced using PyMol (DeLano,
2007).
Figure 115. (A) (based on Nagase et al., 2006; Gomis-Rüth et al., 1997) Stereo ribbon diagram of the catalytic region of matrixin
3 (cyan) complexed with TIMP-1 (magenta) (Pdb accession code 1uea). Amino acids Cys1-Val4 and Glu67-Cys70 of the
inhibitor are shown as spheres (based on Gomis-Rüth et al., 1997 and Nagase et al., 2006). (B) (based on Gomis-Rüth et al.,
1997) Stereo ribbon diagram of the residues in the vicinity of the catalytic Zn2+. The three conserved histidines of MMP-3 and N
and O of Cys1 of the inhibitor interact with the catalytic Zn2+ (grey sphere) (Gomis-Rüth et al., 1997). Residues of the matrixin
(carbons in green) and TIMP-1 (carbons in yellow) are shown as sticks. This figure has been produced using PyMol (DeLano,
2007).
Figure 116. Surface representation of the interactions of Ro-26-2812 with subsites of the catalytic domain of stromelysin-1 (Pdb
accession code 1c3i) The inhibitor is shown as sticks and the catalytic zinc ion as grey sphere. This figure has been produced
using PyMol (DeLano, 2007).
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Figure 117. (based on Steele et al., 2000) Stereo view of close interactions of Ro-26-2812 with residues of the catalytic domain
of stromelysin-1 (Pdb accession code 1c3i). Amino acids (carbons in green) and the inhibitor (C-atoms in magenta) are shown as
sticks, the catalytic Zn2+ as grey sphere. This figure has been produced using PyMol (DeLano, 2007).
Figure 118. Stereo view showing the binding mode of the Cys-Gly-Val sequence of the propeptide to the catalytic domain
stromelysin-1 (Pdb accession code 1slm). Amino acids (carbons in green) and the tripeptide (C-atoms in magenta) are shown as
sticks, the catalytic Zn2+ as grey sphere. This figure has been produced using PyMol (DeLano, 2007).
Figure 119. (after Becker et al., 1995; Esser et al., 1997) Chemical structures of the N-carboxyalkyl inhibitors I (Becker et al.,
1995; Chapman et al., 1993) (left) and L-764,004 (Esser et al., 1997 (right).
Figure 120. (after Esser et al., 1997) Overview of the structure-activity relationship for P1'-lemonene-ethyl carboxylate blockers
of stromelysin-1.
Figure 121. (after Pavlovsky et al., 1999) Nonpeptide inhibitors I-IV co-crystallised with the catalytic domain of MMP-3. Ki
–values for stromelysin-1 are also shown (Pavlovsky et al., 1999).
Figure 122. Surface representation of the interactions of inhibitor II with subsites of the catalytic domain of stromelysin-1 (Pdb
accession code 1caq). The inhibitor is shown as sticks and the catalytic zinc ion as grey sphere. This figure has been produced
using PyMol (DeLano, 2007).
Figure 123. Chemical structures of methoxyphenyl (A), phenyl (B) and 4-phenoxyphenyl (C).
Figure 124. (after Kohno et al., 2006) Chemical structure of SM-25453.
Figure 125. (after Pikul et al., 2001) Chemical structure of 4e.
Figure 126. (after Cheng et al., 1999) Chemical structure of compound 14.
Figure 127. Chemical structures of piperazine based inhibitors (A) (after Cheng et al., 2000), one 2,4,6-pyrimidine trione (B)
(after Dunten et al., 2001) and two thiadiazole inhibitors (C and D) (after Finzel et al., 1998). An IC50 value for the
2,4,6-pyrimidine trione (Dunten et al., 2001) and Ki values for both thiadiazole inhibitors for three different matrixins (Finzel et
al., 1998) are also presented.
Figure 128. (based on Dunten et al., 2001) Stereo view of the interactions of N3, O2 and O4 of compound 2 with the catalytic
Zn2+ of the catalytic domain of stromelysine-1 (Dunten et al., 2001) (Pdb accession code 1g4k). The three histidines ligating with
Zn2+ (carbons in green) and the inhibitor (C-atoms in magenta) are shown as sticks, the catalytic Zn2+ as orange sphere and
distances as dashed lines. This figure has been produced using PyMol (DeLano, 2007).
Figure 129. (after Finzel et al., 1998) Surface representation of the interactions of inhibitors PNU-142372 (carbons in green) and
PNU-141803 (C-atoms in magenta) with subsites of the catalytic domain of stromelysin-1 (Pdb accession codes 1usn and 2usn).
The inhibitors are shown as sticks and the catalytic zinc ion as grey sphere. This figure has been produced using PyMol (DeLano,
2007).
Figure 130. Chemical structure of inhibitor 3 and functions of its diverse moieties (after MacPherson et al., 1997).
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Figure 131. Chemical structure of inhibitor 70 (CGS 27023A) (MacPherson and Parker, 1995; MacPherson et al., 1997). Ki
values for various matrixins are also shown (after MacPherson et al., 1997).
Figure 132. Chemical structures of inhibitors based on CGS 27023A. The various moieties of CGS 27023A are shown in
different colours (hydroxamic acid in red, p-methoxybenzenesulfonamide in blue, pyridine in magenta, isopropyl in green).
Figure 133. SDS-PAGE showing lyophilised SCD dissolved in H2O. Lane 1: Mark12TM Protein Standard; lanes 2-4: SCD in H2O
in increasing dilutions.
Figure 134. (A) SDS-PAGE showing the fractions of SCD eluted from the HiPrepTM 16/60 SephacrylTM S-200 size exclusion
column. Lane 1: Mark12TM Protein Standard; lane 2: SCD before its application to the column: lanes 3-9: eluted SCD fractions;
(B) Size exclusion chromatogram of SCD.
Figure 135. SDS-PAGE showing concentrated SCD. Lane 1: Mark12TM Protein Standard; lane 2: SCD at 11.5 mg/ml
Figure 136. Crystals of SCD grown in presence of 2mM of compound 3 under the condition 0.1 M (NH4)2SO4, 0.1 M
Na-cacodylate, pH 6.5, 29% PEG 8000 (A) and in presence of 2mM of compound 4 under the condition 0.1 M (NH4)2SO4, 0.1 M
Na-cacodylate, pH 6.5, 26% PEG 8000 (B).
Figure 137. 0.5º oscillation X-ray image of the co-crystal of SCD collected in-house to 2.5 Å resolution.
Figure 138. 0.5º oscillation X-ray image of the co-crystal of SCD collected in-house to 2.4 Å resolution.
Figure 139. (A) Stereo view of the Cα tracing of SCD complexed with inhibitor 3 (cyan) and chain A of the native catalytic 
domain of stromelysin-1 (green) (Chen et al., 1999) (Pdb accession code 1cqr). (B) Stereo view of the Cα tracing of SCDs 
complexed with inhibitors 3 (cyan) and 4 (magenta). This figure has been produced using PyMol (DeLano, 2007).
Figure 140. Interactions of both SCDs with the catalytic (left) and structural (right) zinc ions. Carbons of amino acids and Zn2+
are shown in green for the SCD structure complexed with inhibitor 3 and in cyan for the SCD structure in complex with inhibitor
4. This figure has been produced using PyMol (DeLano, 2007).
Figure 141. Interactions of both SCDs with the first (A), second (B) and third (C) calcium ion. Carbons of amino acids and
waters are shown in green for the SCD structure complexed with inhibitor 3 and in cyan for the SCD structure in complex with
inhibitor 4. Calcium ions are shown in magenta. This figure has been produced using PyMol (DeLano, 2007).
Figure 142. Stereo view of superimposed sulfate ion and α-helix 1 of SCD structures in complex with inhibitors 3 (green) 4 
(cyan) and inhibitor I (magenta) (Pdb accession code 1b8y) (Pavlovsky et al., 1999). Lys110 is shown as sticks and close
interactions (< 3.5 Å) between sulfate O-atoms of SCD complexed with inhibitor 3 and N of Lys110 as dashed lines. This figure
has been produced using PyMol (DeLano, 2007).
Figure 143. Unbiased Fo-Fc at 3σ (green) and final 2Fo-Fc at 1σ (blue) maps around compound 3 of the 2.4 Å structure of SCD 
(A) and unbiased Fo-Fc at 3σ (green) and final 2Fo-Fc at 1σ (blue) maps around compound 4 of the 2.5 Å structure of SCD (B). 
Both inhibitor molecules are modelled in the 2Fo-Fc density. Both maps were calculated at final stages of refinement before
addition of the compounds. This figure has been produced using PyMol (DeLano, 2007).
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Figure 144. Stereo view of superimposed inhibitors 3 (carbons in magenta) and 4 (C-atoms in yellow) and adjacent residues
(shown as green sticks in the 2.4 Å SCD structure and as cyan sticks in the 2.5 Å SCD structure). The zinc ions located at the
exactly same position in both structures are shown as sphere(s) in green (higher resolution structure) and cyan (lower resolution
structure). This figure has been produced using PyMol (DeLano, 2007).
Figure 145. Close up view of the interactions of the hydroxamic acid moiety of inhibitor 3 (carbons in cyan) with the catalytic
zinc (grey sphere) and residues of SCD (shown as sticks with C-atoms in green). Distances are shown as dotted lines. This figure
has been produced using PyMol (DeLano, 2007).
Figure 146. Stereo views of the interactions of the sulfonamide moiety (A) and the methoxy group (B) of inhibitor 3 with
residues of SCD. Carbons of the inhibitor and residues of SCD are shown in cyan and green, respectively are The catalytic zinc is
shown as grey sphere, distances as dashed lines. This figure has been produced using PyMol (DeLano, 2007).
Figure 147. Surface representation of the interactions of inhibitor 3 with subsites of the catalytic domain of the 2.4 Å SCD
structure. The inhibitor is shown as sticks and the catalytic zinc ion as grey sphere. This figure has been produced using PyMol
(DeLano, 2007).
Figure 148. (after Wilfong, 2008) Isothermal titration calorimetry (ITC) data for CGS 27023A and inhibitors 2-4.
Figure 149. Stereo view of the interactions of the hydroxamic acid moiety of CGS 27023A (carbons in magenta) with residues of
SCD (shown as sticks with C-atoms in green) (Pdb accession code 1bm6). The catalytic zinc ion is shown as grey sphere and
distances are shown as dotted lines. This figure has been produced using PyMol (DeLano, 2007).
Figure 150. Stereo view of the interactions of the sulfonamide moiety of CGS 27023A (carbons in magenta) with residues of
SCD (shown as sticks with C-atoms in green) (Pdb accession code 1bm6). The catalytic zinc ion is shown as grey sphere and
distances are shown as dotted lines. This figure has been produced using PyMol (DeLano, 2007).
Figure 151. Stereo view of the interactions of the methoxy phenyl moiety of CGS 27023A (carbons in magenta) with residues of
SCD (shown as sticks with C-atoms in green) (Pdb accession code 1bm6). The catalytic zinc ion is shown as grey sphere and
distances are shown as dotted lines. This figure has been produced using PyMol (DeLano, 2007).
Figure 152. Close up view of the interactions of the pyridine ring of CGS 27023A (carbons in magenta) with residues of SCD
(shown as sticks with C-atoms in cyan) (Pdb accession code 1bm6). The superimposed residues and inhibitor 3 of the 2.4 Å
resolution SCD structure are also shown as sticks (C-atoms in green and orange, respectively). Zinc ions in the X-ray and NMR
structure are shown as green and cyan spheres, respectively. This figure has been produced using PyMol (DeLano, 2007).
Figure 153. Surface representation of the interactions of inhibitors CGS 27023A (carbons in magenta) and 3 with subsites of the
catalytic domain of the SCD structure. The surface of the 2.4 Å SCD crystal structure is shown. This figure has been produced
using PyMol (DeLano, 2007).
Figure 154. Ribbon diagram showing the 2.4 Å SCD structure complexed with inhibitor 3 (secondary structure elements in green,
C-atoms of the inhibitor in orange) superimposed with the NMR structure of SCD in complex with inhibitor 1 (NMR structure
with the lowest energy of the ensemble of the twenty structures deposited is used) (secondary structure elements in cyan, carbons
of the inhibitor in magenta) (Pdb accession code 1bm6) (Li et al., 1998) (Rmsd = 1.55 Å for 139 Cα positions). Both loop regions, 
amino acids 221-231 in the NMR structure, and residues 221-224 in the crystal structure are shown in magenta and orange,
respectively. Additionally disordered parts of the entire flexible loop (amino acids 210-234) (Chen et al., 1999) in the X-ray
structure are boxed. This figure has been produced using PyMol (DeLano, 2007).
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Figure 155. (after Chen et al., 1999) Chemical structure of PGV-25727.
Figure 156. Stereo view of superimposed Tyr223 of SCD complexed with inhibitor 3 (carbons in green 2Fo-Fc density at 1 σ), 
SCD in complex with inhibitor PGV-25727 (C-atoms in cyan) (Pdb accession code 1b3d) (Chen et al., 1999), native SCD
(carbons in magenta) (Pdb accession code 1cqr) (Chen et al., 1999) and the NMR structure of SCD complexed with CGS 27023A
(C-atoms in yellow) (Pdb accession code 1bm6) (Li et al., 1998). This figure has been produced using PyMol (DeLano, 2007).
Figure 157. (A) Superposition of Tyr223 residues and inhibitors of SCD structures complexed with the nonpeptide inhibitors 3
(carbons in green), PGV-25727 (C-atoms in cyan) (Pdb accession code 1b3d) (Chen et al., 1999) and I (carbons in blue) (Pdb
accession code 1b8y) (Pavlovsky et al., 1999) and the N-carboxyalkyl peptide inhibitor I (C-atoms in orange) (Pdb accession
code1sln) (Becker et al., 1995). (B) Ribbon diagram of the same four superimposed SCD structures (same colour scheme as in
(A)). The part of the loop displaying amino acids Tyr223 to Arg231 (Chen et al., 1999) is boxed. This figure has been produced
using PyMol (DeLano, 2007).
Figure 158. (A) Superposition of Tyr223 residues and inhibitors of SCD structures complexed with the nonpeptide inhibitors
PGV-25727 (C-atoms in cyan) (Pdb accession code 1b3d) (Chen et al., 1999), PNU-142372 (carbons in green) (Pdb accession
code 1usn) (Finzel et al., 1998), PNU-141803 (C-atoms in magenta) (Pdb accession code 2usn) (Finzel et al., 1998) and the
native SDR structure (carbons in yellow) (Pdb accession code 1cqr) (Chen et al., 1999). (B) Ribbon diagram of the same four
superimposed SCD structures (same colour scheme as in (A)). The part of the loop displaying amino acids Tyr223 to Arg231
(Chen et al., 1999) is boxed. This figure has been produced using PyMol (DeLano, 2007).
Figure 159. (A) Superposition of Tyr223 residues and the same N-carboxyalkyl peptide inhibitor of the crystal (C-atoms in green)
(Pdb accession code 1sln) (Becker et al., 1995) and NMR (C-atoms in cyan) (Pdb accession code 2srt) (Gooley et al., 1994)
structures of SCD. (B) Ribbon diagram of the same superimposed SCD structures (same colour scheme as in (A)). The part of the
loop displaying amino acids Tyr223 to Arg231 (Chen et al., 1999) is boxed and shown in different colours (magenta in the crystal
and yellow in the NMR structure). This figure has been produced using PyMol (DeLano, 2007).
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CHAPTER 1
THE STRUCTURE OF
A SILICATEIN α-CATHEPSIN L 
CHIMERA
1Introduction
1.1 Enzymatic peptide bond hydrolysis with emphasis on
cysteine proteases
The cleavage of amide bonds in proteins is catalysed by ubiquitous peptide hydrolase
enzymes (proteases). It is assumed that without involvement of proteases several
hundred years might be required for cleavage of a peptide bond. A protease, however,
would be able to cleave about a million amide bonds per second. The molecular
weights of proteolytic enzymes vary between monomers of 10 kDa to polymers of
several hundred kDa. Endoproteases cleave amide bonds within a protein whereas
exopeptidases act at the N- or C-terminal end of a polypeptide. Proteases have been
grouped based on the catalytic mechanism utilised to hydrolyse peptides. The most
important groups are denoted serine, aspartate, threonine, metallo and cysteine
proteases. Before hydrolysing an amide bond, a protease has to interact with its
protein or peptide substrate. The efficiency of the interaction is controlled by the
substrate binding sites of the protease and by the chemical nature of the peptide which
binds to the active site. Even though only one amide bond is cut during the catalytic
process, various amino acids flanking the cleavage site are crucial for the specificity
of a protease (Figure 1A). The mechanism employed by cysteine proteases is similar
to the one of serine proteases, but due to an additional shell of electrons in the S of the
SH-group cysteine proteases are the better nucleophiles. Cysteine proteases need a
crucial Cys in the catalytic site to perform hydrolysis. The nucleophilicity of the
mercaptan group is further increased by a closely positioned active site His which
operates as an H+-donor/general base (Sajid and McKerrow, 2002). The thiol group of
the side chain of the Cys residue, and the imidazole ring of His lead to a
“thiolate-imidazolium charge relay diad” (Sajid and McKerrow, 2002) (Figure 1B).
2This is often stabilised by an Asn residue which displays high conservation. A Gln
which is also highly conserved creates the oxyanion hole which is essential in
establishing an electrophilic centre for the stabilisation of the tetrahedral intermediate
during hydrolysis (Sajid and McKerrow, 2002). Stabilisation of the “charge relay
system” (Sajid and McKerrow, 2002) is accomplished by the chemical milieu of the
catalytic region (Sajid and McKerrow, 2002). The mechanism of hydrolysis has been
well studied. Temporary binding of protease and substrate takes place and unstable
tetrahedral intermediates are generated before the enzyme becomes active again (Sajid
and McKerrow, 2002).
Figure 1. (after Sajid and McKerrow, 2002) Representation of the binding of a peptide substrate to the catalytic site of a
cysteine protease. Amino acids from the peptide are indicated by P and the substrate binding sites of the protease by S.
The thiol nucleophile of the catalytic cysteine is indicated by SH, and the corresponding amide bond that is attacked
before hydrolysis (scissile bond) is marked with an arrow. The COOH side of the peptide (P'1, P'2, P'n) and
corresponding substrate binding sites (S'1,S'2, S'n) are called prime side, whereas the NH2 side of the peptide (P1, P2, Pn)
and corresponding substrate binding sites (S1,S2, Sn) are named non-prime side. (A). Representation of the SH of Cys
and the imidazole ring of His (B1), and the equilibrium with the thiolate-imidazolium charge relay. The delocalised
electron density cloud is also shown (B2).
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31.2 Cathepsins, members of the papain superfamily
Cysteine proteases are ubiquitous. The majority of these enzymes belong to the papain
family. Members of this family are papain, plant proteases, cruzipain and lysosomal
cysteine proteases, also called cathepsins. In Homo sapiens there are eleven
cathepsins known so far denoted B, H, L, S, C, K, O, F, V, X and W. Initially it was
thought that the main function of cathepsins is the promiscuous degradation of
proteins inside the lysosomal compartment. Later, however, it was also demonstrated
that they predominantly occur in the tissue and participate in highly specialized
processes in the cell (Turk et al., 2000). In general cathepsins show their best activity
in a slightly acidic milieu (Turk et al., 2000). The majority of cathepsins are
endopeptidases (Turk et al., 2000; Turk et al., 2001). Examples for endoproteinases
are the lysosomal cysteine proteases S and L (Dahl et al., 2001; Turk et al., 2000;
Turk et al., 2001). Most cathepsins occur as monomers apart from cathepsin C which
is composed of four subunits. The molecular weight of these enzymes varies between
20 and 30 kDa. The structure of cathepsins and papain-like proteases in general
consists of two domains. Whereas the left domain is composed of three α-helices, the 
right domain consists of five or six β-strands (Mc Grath, 1999). “The domains 
separate on the top in a ‘V’ shaped active site cleft” (Turk et al., 1998) (Figure 2).
Figure 2. Ribbon digram of the structure of human cathepsin S (Pdb accession code 1ms6). Secondary structural elements
of the left (L) domain are shown in green, and secondary structural elements of the right (R) domain in cyan. This figure
has been produced using PyMol (DeLano, 2007).
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4The left domain is usually stabilised by two S-S bridges, the right domain by only one
S-S bond. The active site residue Cys25 is situated in the left domain, whereas His159
(papain numbering) is located in the right domain (Mc Grath, 1999). The roles of the
Cys and His residues in cysteine proteases have already been discussed in Section 1.1.
An amino acid sequence alignment of papain and various cathepsins from Homo
sapiens (Turk et al., 2000) shows the high conservation of both catalytic residues
(Figure 3).
9PAP -----IPEYVDWR-QKG--AVTPVKNQGS---CGSCWAFSAVVTIEGIIKIRT-G--NLNQYSEQELLDCDRR---SYGCNGGYPWSALQLVAQYG
1MHW -----APRSVDWR-EKG--YVTPVKNQGQ---CGSCWAFSATGALEGQMFRKT-G--RLISLSEQNLVDCSGP-QGNEGCNGGLMDYAFQYVQDNG
1FH0 -----LPKSVDWR-KKG--YVTPVKNQKQ---CGSCWAFSATGALEGQMFRKT-G--KLVSLSEQNLVDCSRP-QGNQGCNGGFMARAFQYVKENG
1YT7 -----APDSVDYR-KKG--YVTPVKNQGQ---CGSCWAFSSVGALEGQLKKKT-G--KLLNLSPQNLVDCVSE---NDGCGGGYMTNAFQYVQKNR
1NQC -----LPDSVDWR-EKG--CVTEVKYQGS---CGACWAFSAVGALEAQLKLKT-G--KLVTLSAQNLVDCSTEKYGNKGCNGGFMTTAFQYIIDNK
8PCH -----YPPSMDWR-KKGN-FVSPVKNQGS---CGSCWTFSTTGALESAVAIAT-G--KMLSLAEQQLVDCAQN-FNNHGCQGGLPSQAFEYIRYNK
1JQP QQILSLPESWDWRNVRGINFVSPVRNQES---CGSCYSFASLGMLEARIRILT-NNSQTPILSPQEVVSCSPY---AQGCDGGFPYLIAGKYAQDF
1HUC -------------------VSVEVSAEDLLTCCGSMCGDGCNGGYPAEAWNFWTRKGLVSGGLYESHVGCRPY-----------SIPPCEHHVNGS
1EF7 -----LPKSWDWRNVDGVNYASITRNQHIPQYCGSCWAHASTSAMADRINIKRKGAWPSTLLSVQNVIDCG-----NAGSCEGGNDLSVWDYAHQH
25 ** *
9PAP -IHYRNTYPYEGVQRYCRSR---------EKGPYAAKTDGVRQVQPYN---QGALLYSIAN-QPVSVVLQAAGKDFQLYRGGIFVGPCG--N-----
1MHW GLDSEESYPYEATEESCKYN---------PKY-SVANDTGFVDIPK-Q---EKALMKAVATVGPISVAIDAGHESFLFYKEGIYFEPDCSSE-----
1FH0 GLDSEESYPYVAVDEICKYR---------PEN-SVAQDTGFTVVAPGK---EKALMKAVATVGPISVAMDAGHSSFQFYKSGIYFEPDCSSK-----
1YT7 GIDSEDAYPYVGQEESCMYN---------PTG-KAAKCRGYREIPEGN---EKALKRAVARVGPVSVAIDASLTSFQFYSKGVYYDESCNSD-----
1NQC GIDSDASYPYKAMDQKCQYD---------SKY-RAATCSKYTELPYGR---EDVLKEAVANKGPVSVGVDARHPSFFLYRSGVYYEPSCTQN-----
8PCH GIMGEDTYPYKGQDDHCKFQ---------PDK-AIAFVKDVANITMND---EEAMVEAVALYNPVSFAFEVTN-DFLMYRKGIYSSTSCHKTP---D
1JQP GVVEENCFPYTATDAPCKPK---------ENCLRYYSSEYYYVGGFYGGCNEALMKLELVKHGPMAVAFEV-HDDFLHYHSGIYHHTGLSDPFNPFE
1HUC RPPCTGEGDTPKCSKICEPG----------YSPTYKQDKHYGYNSYSVSNSEKDIMAEIYKNGPVEGAFSVYS-DFLLYKSGVYQHVTGEMMG----
1EF7 GIPDETCNNYQAKDQECDKFNQCGTCNEFKECHAIRNYTLWRVGDYGSLSGREKMMAEIYANGPISCGIMATER-LANYTGGIYAEYQDTTY-----
* * * *
Figure 3. (continues on next page)
.
59PAP KVDHAVAAVGYGPN--------YILIKNSWGTGWGENGYIRIKRGTGNSYGVCGLYTSSFYPVKN----
1MHW DMDHGVLVVGYGFEST-----------------------------------------------------
1FH0 NLDHGVLVVGYGFEGANSDNSKYWLVKNSWGPEWGSNGYVKIAKDKNNHCGIATAASYPNV--------
1YT7 NLNHAVLAVGYGIQKGN----KHWIIKNSWGENWGNKGYILMARNKNNACGIANLASFPKM---------
1NQC -VNHGVLVVGYGDLNG----KEYWLVKNSWGHNFGEEGYIRMARNKGNHCGIASFPSYPEI---------
8PCH KVNHAVLAVGYGEENGIP----YWIVKNSWGPQWGMNGYFLIERGK-NMCGLAACASYPIPLV-------
1JQP LTNHAVLLVGYGKDPVTG--LDYWIVKNSWGSQWGESGYFRIRRG-TDECAIESIAMAAIPIPKL-----
1HUC --GHAIRILGWGVENGTP----YWLVANSWNTDWGDNGFFKILRGQD-HCGIESEVVAGIPRTD------
1EF7 -INHVVSVAGWGISDG----TEYWIVRNSWGEPWGERGWLRIVTSTYKDGKGARYNLAIEEHCTFGDPIV
159 * * *
Figure 3. Sequence alignment of papain and various cathepsins (based on Turk et al., 2000) The key active sites residues
C25 and H159 are highlighted in yellow and marked with asterisks. Other amino acid residues, conserved in all 9 enzymes
are shown in red. The sequences are taken from the PROTEIN DATA BANK (PDB): papain from Carica papaya (Pdb
accession code 9pap); cathepsin L from Homo sapiens (Pdb accession code 1mhw); cathepsin V mutant (N108Q, N178D)
from Homo sapiens (Pdb accession code 1fh0); cathepsin K from Homo sapiens (Pdb accession code 1yt7); cathepsin S
from Homo sapiens (Pdb accession code 1nqc); cathepsin H from Sus scrofa (Pdb accession code 8pch); cathepsin C from
Rattus norvegicus (Pdb accession code 1jqp); cathepsin B from Homo sapiens (Pdb accession code 1huc); cathepsin X from
Homo sapiens (Pdb accession code 1ef7). This sequence alignment was carried out using the programme ClustalW
(Chenna et al., 2003).
Similar to most other proteolytic enzymes, lysosomal cysteine proteases are
synthesised as proenzymes which do not show any activity. Activation of these
proenzymes takes then place by removal of the aminoterminal proregion (Turk et al.,
2001). Cleavage of this prosegment can be carried out by either other proteolytic
enzymes such as cathepsin D or pepsin, or by self cleavage at acidic pH (Turk et al.,
2000; Turk et al., 2001). Rowan and coworkers reported such an autocatalytic
activation on procathepsin B (Rowan et al., 1992). The proregions have several
functions, such as blocking proteolytic activity (Carmona et al., 1996; Coulombe et
al., 1996), stabilisation of the protease under nonacidic conditions and folding of the
enzyme (Mc Grath, 1999).
61.2.1 Roles of cathepsins
Gene knock-out experiments showed that lysosomal cysteine protease have specific
functions in an organism. While lysosomal cysteine proteases such as V, K and S only
occur in specific tissues, cathepsins H, L, O, B, F, X and C for instance are widely
distributed. However, the latter lysosomal cysteine proteases can also have specific
functions (Turk et al., 2001). Details about functions of various cathepsin have been
reviewed in Mc Grath, 1999. Lysosomal cysteine proteases have also been linked to
various diseases, such as cancer (Yagel et al., 1989), arthritis (Esser et al., 1994),
muscular dystrophy (Katunuma and Kominami, 1987) or osteopetrosis (Saftig et al.,
1998). Another example of a disease associated with cathepsins, pycnodysostosis, is
an “autosomal recessive skeletal disorder” (Polymeropoulos et al., 1995) which was
described for the first time in 1962 by Maroteaux and Lamy (Maroteaux and Lamy,
1962; Polymeropoulos et al., 1995). The main characteristic features of this disease
are short stature, increased bone density, loss of phalanxes, abnormal teeth and
extremely fragile bones (Polymeropoulos et al., 1995). Pycnodysostosis was found to
be linked to a mutation in the cathepsin K gene (Gelb et al., 1996; Turk et al., 2001).
Papillon-Lefevre syndrome (keratosis palmoplantaris with periodontopathia) is also
“an autosomal recessive disorder” (Toomes et al., 1999) and characterised by severe
periodontitis which agonises patients (Gorlin et al., 1964; Hart and Shapira, 2000;
Toomes et al., 1999). Palmoplantar keratosis affects the skin of patients and usually
occurs between the age of 1 and 3. The reason for this disease is a mutation in the
gene encoding cathepsin C (Toomes et al., 1999).
71.2.2 Cathepsin L
1.2.2.1 Procathepsin L
There are two subfamilies within the papain superfamily (Karrer et al., 1993,
Coulombe et al., 1996 ). In mammals this superfamily can be divided into cathepsin
L-like and cathepsin B-like enzymes. Most enzymes are members of the cathepsin
L-like subfamily. There are not many distinctions between the groups apart from some
short parts (Coulombe et al., 1996). Members of the cathepsin B-like subfamily
contain an additional loop structure at around amino acid 95 (cathepsin L numbering),
the occluding loop (Musil et al., 1991; Coulombe et al., 1996 ), that plays an
important role in the exopeptidase activity specific for members of the cathepsin-B
like subfamily. The prosegments of both groups, compared to the mature enzymes, are
not very homologous to each other and differ in length. In cathepsin L–like enzymes
this region has 30-40 amino acids more than the one in cathepsin B-like enzymes
(Coulombe et al., 1996).
1.2.2.1.1 Structure of procathepsin L
The mature form of procathepsin L (cathepsin L) displays a fold that is common to
members of the papain superfamily (Baker and Drenth, 1987; Coulombe et al., 1996).
It consists of two domains forming an active-site cleft that comprises Cys25 and
His163 which are crucial for catalysis. Cys25 is situated in the first domain,
predominantly composed of α-helices, while His163 is in the other one, 
predominantly composed of β-strands (Coulombe et al., 1996).
Essentially no distinctions were observed in the mature region of procathepsin L
compared to the mature form of cathepsin L (Fujishima et al., 1997).
8The structure of the mature domains of procathepsin L (Pdb code 1cs8; Coulombe et
al., 1996) is essentially homologous to that of cathepsin L in complex with the MHC
class II-associated p41 li fragment, with an rmsd of 0.31 Å between equivalent Cα 
atoms. (Gunĉar et al., 1999). The rms deviation between equivalent Cα atoms in the
cathepsin L structure in the chagasin complex (Ljunggren et al., 2007) and
procathepsin L (Coulombe et al., 1996) is 0.35 Å. Both structures only differ in the
flexible loop region (residues Glu173-Asn180) (Ljunggren et al., 2007). The
prosegment consists of a globular domain, represented by the first about 80 amino
acids, and an extended carboxyterminal-terminal part with around 20 residues. The
globular domain is connected to Ala1 of cathepsin L by this extended part. The
globular domain consists of three α-helices and loops. A short loop connects the 
α1-helix with the long α2-helix in the centre. (Coulombe et al., 1996).
At the end of the helix α2 the main chain flips round and parallels the helix adopting 
an extended conformation pointing towards the active site. The chain forms α3 which 
is also part of the active site (amino acids 75-79) (Coulombe et al., 1996) (Figure 4).
Figure 4. Stereo view showing residues Met75-Gln79 of the prosegment of procathepsin L (Pdb accession code 1cs8),
dipping “into the substrate binding cleft” (Coulombe et al., 1996) of the mature part of procathepsin L (Coulombe et al.,
1996). Secondary structure elements of the propeptide and the mature part of procathepsin L are shown in cyan and
green, respectively. The catalytic active site residues Cys25 (its sulfur is oxidised to sulfonate) and His163, as well as the
residues Met75-Gln79 of the prosegment are shown as sticks (carbons in magenta). This figure has been produced using
PyMol (DeLano, 2007).
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The interactions between the prosegment and cathepsin L mainly occur along the cleft
which is involved in the interactions with the substrate and along the surface that is
built up by the loop built up residues by His140-Asp155 (Coulombe et al., 1996)
(Figure 5). The amino acids Phe71 and Met75 to Gln79 of the prosegment play a role
in the interactions between the proregion and the active site region of cathepsin L. The
proregion is orientated in the active site in a way that is reverse to that of a natural
substrate. (Coulombe et al., 1996).
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Even though there is about 25 % sequence identity between cathepsin L and cathepsinB, the prosegments of procathepsin L and B are not very homologous. However, there
is still an overall similarity in the structures of the prosegments of both enzymes
(Figure 6). The most remarkable distinctions can be observed at the aminoterminus.
Procathepsin B lacks helix α1 and the N-terminal part of α2, that do not show any 
contacts with cathepsin L at all. As a consequence the prosegment of procathepsin B
is about 30 amino acids shorter. The main interactions between the prosegment and
cathepsin B also apply to the proform of cathepsin L as well. The prosegment binding
loop is important for the interaction between the prosegment and the protease in both
cathepsins (Coulombe et al., 1996).
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The fact that the prosegment blocks the activity of procathepsins L and B by
interacting with the active site in a reverse orientation with respect to a substrate or an
inhibitor seems to apply to all members of the papain superfamily (Coulombe et al.,
1996).
1.2.2.2 The structure of cathepsin L
The overall structure of human cathepsin L displays similarity to that of papain
(Figure 7, A and B). The Rmsd between both structures is 0.82 Å for 183 Cα atoms 
(Figure 7, C). The only significant difference lies in the loop region between Phe172
and Asn179 of cathepsin L (Fujishima et al., 1997).
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1.2.2.2.1 Subsites of cathepsin L
It has been proposed by Schechter and Berger, 1967, that there are seven subsites in
papain denoted S4-S3’, but there is actually no proof that all those subsites really exist
(Chowdhury et al., 2008). The definition of substrate-binding sides has been revised
by Turk et al., 1998. Inhibitors binding to cathepsin L are usually substrate analogues
which contain groups that establish a covalent bond with Cys25 (Chowdhury et al.,
2008). However, the propeptide in procathepsin L does not show any covalent
interactions with the mature enzyme at all (Chowdhury et al., 2002; Coulombe et al.,
1996).
Consequently, various noncovalent blockers of cathepsin L have been synthesised to
mimic the binding mode of the proenzyme (Chowdhury et al., 2002; Chowdhury et al.
2008). Those inhibitors are peptide-derived and show interactions with the S’ and S
substrate binding sites of the protease’s catalytic region (Chowdhury et al., 2002). The
locations of these subsites are shown in Figure 8 (based on Chowdhury et al., 2008).
Figure 8. (based on Chowdhury et al., 2008) Location of the subsites in the active site cleft of cathepsin L (Pdb accession
code 3bc3) (Surface representation). Carbons are shown in green, oxygens in red, nitrogens in blue and sulfurs in
yellow.This figure has been produced using PyMol (DeLano, 2007).
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1.2.2.2.1.1 S1 binding site
In papain the P1 C=O group of a substrate or an inhibitor points into the oxyanion
hole that is formed at the aminoterminus of the central helix between H+ of the Cys25
amide and the amide of the side chain of Gln19. The P1 main chain amide is directed
to C=O of Asp158 (Turk et al., 1998). In cathepsin L the oxyanion hole is composed
of the amino acids Gln19, Trp189, His163 and Cys25 (Figure 9) (Fujishima et al.,
1997).
Figure 9. (A) Close up view of the active site of cathepsin L (Pdb accession code
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No equivalent amino acid for Met161 of cathepsin L is present in cathepsin B, which
leads to a more open S2 substrate binding site (Fujishima et al., 1997). The side chain
of Met70 (Pro76 in cathepsin B) at the bottom of the pocket sits across the cleft
(Figure 15) resulting in a shallower site in cathepsin L (Fujishima et al., 1997).
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1. (A) Stereo view of the active site cleft of cathepsin L (Pdb accession code 3bc3). Residues forming the
us wall on the right hand side of the S2 subsite (Fujishima et al., 1997), Met70 at the bottom of the pocket, and
e site residues Cys25 (its sulfur is oxidised to sulfinate) (Chowdhury et al., 2002; Chowdhury et al., 2008) and
are shown as sticks (carbons in cyan, nitrogens in blue, oxygens in red and sulfurs in yellow). (B) Surface
tation of the same region. This figure has been produced using PyMol (DeLano, 2007).
.1.3 S3 binding site
3 substrate binding site of cathepsin L is located in the centre of the left wall of
eft (Figure 12). Amino acids Gly67 and Gly68 are located in the centre of this
ate binding site. Both residues are decorated by the side chains of Asn66, Glu63
eu69 and the O-atom of C=O of Gly61. The S3 subsites of the cathepsins L and
w more similarity than other parts of the catalytic region.
Cys25
S22
Cys25
S22B
However, the subsite in cathepsin B is narrower than that in cathepsin L. Therefore, a
larger moiety of a substrate or an inhibitor may be accommodated by cathepsin L in
this region (Fujishima et al., 1997).
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2. (A) Stereo view of the S3 subsite of cathepsin L (based on Fujishima et al., 1997) (Pdb accession code 3bc3).
s at the centre of the S3 subsite, surrounding amino acids, and the active site residues Cys25 (its sulfur is oxidised
ate) (Chowdhury et al., 2002; Chowdhury et al., 2008). and His163 are shown as sticks (carbons in cyan, nitrogens
oxygens in red and sulfurs in yellow). (B) Surface representation of the same region. This figure has been
d using PyMol (DeLano, 2007).
.1.4 S1’ binding site
t al., 1998 illustrated the structure of this region with cathepsin B complexed
he inhibitor CA030 (Pdb accession code 1csb; Turk et al., 1995). The amino
of CA030 isoleucine points to the C=O of Gly198, while its C=O group
ipates in an H-bond interaction with the NE1 atom of Trp221 (177 in papain).
Cys25S3 S3 Cys25B
The side chain is positioned between the nonpolar residues Leu181and Val176 and is
also close to Met196. (Turk et al., 1998).
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3. (A) Cathepsin B in complex with CA030 ( Pdb accession code 1csb; based on Turk et al., 1998) (Stereo
e inhibitor CA030, residues, important for the binding of CA030, the active site residues Cys29 and His199, and
of the S1’subsite and covering its top are shown as sticks (carbons in magenta (CA030) or cyan (amino acids),
s in blue, oxygens in red and sulfurs in yellow). (B) Surface representation of the same region. This figure has
duced using PyMol (DeLano, 2007).
as well as small, nonpolar side chains of an inhibitor’s P1 group are accepted by
(Schuster et al., 1992; Turk et al., 1998). It has been demonstrated that larger
tic and nonpolar amino acids are accepted by cathepsin B and not cathepsins L
and papain (Menard et al., 1993; Turk et al., 1998) Small, neutral polar P1’
s are favoured by cathepsin L. Generally cathepsin S and papain accept small
ncharged amino acids. Cathepsin B has the largest S1’ subsite compared to the
members of the papain superfamily and its surface comprises nonpolar amino
(Turk et al., 1998).
CA030 CA030
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In the complex structure of cathepsin L with 4-biphenylacetyl-Cys-D-Arg-Tyr-N-(2-
phenylethyl)amide, an inhibitor that binds noncovalently and similar to the propeptide
to cathepsin L, the cysteine side chain of the inhibitor shows interactions with the side
chains of the residues Ala138, Asp162, His163, and Trp189 of the S1’ subsite (Figure
14). Its S- atom is in contact with a second inhibitor molecule, which only displays
electron density for the 4-biphenylacetyl-Cys-D-Arg moieties. (Chowdhury et al.,
2002).
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14. (A) Cathepsin L in complex with 4-biphenylacetyl-Cys-D-Arg-Tyr-N-(2-phenylethyl)amide (Pdb accession code
) (Stereo view). The inhibitor, S1’-residues interacting with the inhibitor’s Cys side chain (Cys) and Cys25 with its
ed sulfur (to sulfinate) (Chowdhury et al., 2002; Chowdhury et al., 2008). are shown as sticks (carbons in magenta
itor) or cyan (amino acids), nitrogens in blue, oxygens in red and sulfurs in yellow). (B) Surface representation of
me region. This figure has been produced using PyMol (DeLano, 2007).
S1' S1'B
1.2.2.2.1.5 S2’ binding site
Cathepsin B in complex with CA030 shows that the P2’ side chain group binds to a
conserved loop surface composed of Gln23-Ser28 (Turk et al., 1998) (Figure 15).
Cathepsins L and S, as well as papain have a similar binding profile (Brömme and
Kirschke, 1993; Turk et al., 1998). In contrast the associations of cathepsin B with the
same ligands are different. It has been suggested that interactions with the occluding
loop above the S2’ subsite and His110 and His111 at the bottom of the loop are the
reason for these differences (Figure 15) (Turk et al., 1998).
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igure 15. (A) Cathepsin B in complex with CA030 (Pdb accession code 1csb) (Stereo view). The inhibitor, residues of the
nserved loop surface from Gln23 to Ser28 (Turk et al., 1998), amino acids of the occluding loop from Cys108 to Cys119,
d the catalytic active site residues Cys29 and His199 are shown as sticks (carbons in magenta (inhibitor) or cyan (amino
ids), nitrogens in blue, oxygens in red and sulfurs in yellow). (B) Surface representation of the same region. This figure
as been produced using PyMol (DeLano, 2007).
the complex structure of cathepsin L with 4-biphenylacetyl-Cys-D-Arg-Tyr-N-(2-
henylethyl)amide (Pdb accession code 1mhw) the 4-biphenylacetyl groups point into
e S2’ substrate binding site. They show interactions with Gln21, Gly23, and the
ain chain of Cys22 (Figure 16) (Chowdhury et al., 2002)
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ure 16. (A) Cathepsin L in complex with 4-biphenylacetyl-Cys-D-Arg-Tyr-N-(2-phenylethyl)amide (Pdb accession code
hw) (Stereo view). The inhibitor, S2’-residues interacting with the inhibitor’s 4-biphenylacetyl rings (4-BPA), and the
alytic residues Cys25 (its sulfur is oxidised to sulfinate) (Chowdhury et al., 2002; Chowdhury et al., 2008) and His163
shown as sticks (carbons in magenta (inhibitor) or cyan (amino acids), nitrogens in blue, oxygens in red and sulfurs in
low). (B) Surface representation of the same region. This figure has been produced using PyMol ( DeLano, 2007).
.2.2.1.6 S3’ binding site
rk et al., 1998 did not see any evidence for an S3’ subsite in their revised definition
substrate binding sites in cysteine proteases (Chowdhury et al., 2008) However, in
e structure of cathepsin L in complex with 4-biphenylacetyl-Cys-D-Arg
yr-N-(2-phenylethyl)amide (Chowdhury et al., 2002), a dimerisation of the inhibitor
ok place and part of the second monomer is situated in a location denoted S3’
bstrate binding site of cathepsin L (Figure 17) (Chowdhury et al., 2008).
r the carboxyterminal part of this second inhibitor molecule consisting of the Tyr
d the N-(2-phenylethyl)amide moiety, no electron density was observed.
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In the visible part, the Cys and D-Arg residues show much higher B factors than the
enzyme and the first inhibitor molecule. Only the phenyl benzene group of the second
inhibitor molecule packs well between Asn18, Leu144 and Trp189 on one side and
Gly20 and the diphenyl group of the first inhibitor molecule on the other side (Figure
17) (Chowdhury et al., 2002). More inhibitors have been synthesised to further study
the interactions with the S' subsites (Chowdhury et al., 2008).
A
B
Figure 17. (A) Cathepsin L in complex with 4-biphenylacetyl-Cys-D-Arg-Tyr-N-(2-phenylethyl)amide (Pdb accession code
1mhw) (Stereo view). The first inhibitor, 4-biphenylacetyl-Cys-D-Arg-Tyr-N-(2-phenylethyl)amide, the second inhibitor
molecule, missing the Tyr residue and the N-(2-phenylethyl)amide, residues interacting with the second inhibitor’s
biphenyl moiety (BP2), and the catalytic amino acids Cys 25 (its sulfur is oxidised to sulfinate) (Chowdhury et al., 2002;
Chowdhury et al., 2008) and His 163 are shown as sticks (carbons in magenta (inhibitor molecule 1), orange (inhibitor
molecule 2) or cyan (amino acids), nitrogens in blue, oxygens in red and sulfurs in yellow). (B) Surface representation of
the same region. This figure has been produced using PyMol (DeLano, 2007).
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1.3 Silicate formation in sponges
During the last 3.5 billion years, firstly prokaryotic and later on higher organisms
developed strategies to synthesise minerals, predominantly biominerals consisting of
CaCO3 and Ca3(PO4)2. Only some organisms such as porifera (sponges), radiolarians
and some algae use Si(OH)4 for the formation of biominerals. However, only sponges
form biosilica enzymatically (Müller et al., 2007). At the beginning of the life cycle of
a sponge (Figure 18), the fertilized egg becomes a larva (Müller et al., 2007). During
and after the larvae (Figure 18) have been settled, firstly choanocyte chambers are
built that open this body cavity to the external environment (Müller et al., 2007). They
are built in membrane-enclosed vesicles within specialized cells called sclerocytes
(Simpson, 1984; Shimizu et al., 1998). In the centre of these siliceous spicules there is
an organic axial filament of about 2μm in diameter (Bütschli, 1901; Müller et al.,
2007).
Figure 18. Pictures of adult sponges (left) (taken from http://upload.wikimedia.org/wikipedia/commons/6/62/
SpongeColorCorrect.jpg and a sponge larva (right) (taken from http://www.biology.ualberta.ca/CMD/Pics/
LeysLarva.jpg).
The size of these spicules varies from 1 μm to 3 m. (Schulze, 1904; Müller et al.,
2007).
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The shallow-water Pacific sponge Tethya aurantia has spicules (Figure 19, A) around
2 mm length by 30 μm wide (Shimizu et al., 1998). The silica spicules contribute to
75% of the dry weight of Tethya aurantia, the axial filament (Figure 19, B) is only
about 0.1% of the mass of each spicule. About 91% of the filament consists of protein
(Shimizu et al., 1998).
Figure 19. (taken from Shimizu et al., 1998) Scanning electron micrographs of (A) isolated silica spicules (x130) and (B)
axial filaments (x 1,000) from Tethya aurantia.
To get more insight into the molecular mechanisms that control biosilification, it is
very important to study the proteins of the axial filaments (Shimizu et al., 1998). The
proteins that had been isolated from the these filaments of the spicules of Tethya
aurantia by Shimizu et al., have been named silicateins (for silica proteins).
Electrophoretical analysis of protein revealed the presence of three proteins, silicatein
α, β and γ in a ratio 12:6:1, respectively. The amino acid sequence of all three 
silicateins is also very similar (Shimizu et al., 1998).
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1.3.1 Silicatein α, a member of the cathepsin L subfamily 
It has been reported that the sequence of silicatein α displays high similarity to 
members of the papain superfamily (Berti and Storer, 1995; Shimizu et al., 1998).
Sequence comparison of silicatein α from Tethya aurantia with human cathepsin L
(Figure 20) showed almost 50 % identical residues in both enzymes. Silicatein α, like 
cathepsin L, contains the six Cys residues that create S-S bonds in the protease. That
is why it can be assumed that there is similarity between the 3-D structures of
silicatein α and cathepsin L. The prosegments of silicatein α and cathepsin L from 
Homo sapiens and sponge also display high similarity, which suggests a common
ancestry of both enzymes. The fact that both, silicatein α and cathepsin L, occur in 
subcellular compartments, also supports this suggestion. It is very interesting that the
Cys (SH) at the active site of cathepsin L is changed to Ser (OH) in silicatein α 
(Shimizu et al., 1998). It has been demonstrated by mutagenesis that this Ser is crucial
for the activity of silicatein α (Zhou et al., 1999; Fairhead et al., 2008). The other
amino acids in the catalytic triad of the cysteine protease, His163 and Asn187, display
similar conservation in silicatein α (Fairhead et al., 2008). Cathepsin L contains a loop
of four amino acids (Smith and Gottesman, 1989; Fairhead et al., 2008) which is
missing in silicatein α (Fairhead et al., 2008). Silicatein α does not contain as many 
charged residues as cathepsin L, however, it contains more hydroxyl residues than the
cysteine protease (20.3% and 17.5%, respectively). Very specific for silicatein α are 
clusters of the hydroxyl residues Tyr, Ser and Thr. Examples fur such clusters in
silicatein α are the motifs Ser-Ser-Arg-Cys-Ser-Ser-Ser-Ser, Ser-Ser-Cys-Thr-Tyr, 
Ser-Xaa-Ser-Xaa-Ser and Ser-Tyr (Shimizu et al., 1998).
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H. sapiens -APRSVDWREKGYVTPVKNQGQCGSCWAFSATGALEGQMFRKTG-RLISLSEQNLVDCS
T.aurantia AYPETVDWRTKGAVTGIKSQGDCGASYAFSAMGALEGINALATG-KLTYLSEQNIIDCS
L.baicalensis QYAESIDWRTKGAVTSVKYQGQCGASYAFAATGALEGASALAND-KQVTLSEQNIIDCS
S. domuncula DYPEAVDWRTKGAVTAVKDQGDCGASYAFSAMGALEGANALAKG-NAVSLSEQNIIDCS
H. perleve DYPEAIDWRTKGAVTAVKDQGDCGASYAFSAMGALEGAYALAHNGNQESFSEQNIIDCS
*** ** ** * ** ** ** * ***** **** ***
H. sapiens GPQGNEGCNGGLMDYAFQYVQDNGGLDSEESYPYEATEESCKYNPKYSVANDTGFVDIPK
T.aurantia VPYGNHGCKGGNMYVAFLYVVANEGVDDGGSYPFRGKQSSCTYQEQYRGASMSGSVQINS
L.baicalensis VPYGNHGCSGGDTYTAFKYVIDNGGIDTESSYSFKGKQSSCQYNNKTSGASATGVVSIGY
S. domuncula IPYGNHGCHGGNMYDAFLYVIANEGVDQDSAYPFVGKQSSCNYNSKYKGTSMSGMVSIKS
H. perleve IPYGNYGCHGGNMYDAFLYVIANGGVAKESAYPFLGKQSSCNYNRNTRGTGMSGSVAIKS
* ** ** ** ** ** * * * ** * * * *
H. sapiens -QEKALMKAVATVGPISVAIDAGHESFLFYKEGIYFEPDCSSEDMDHGVLVVGYGFEST
T.aurantia GSESDLEAAVANVGPVAVAIDGESNAFRFYYSGVYDSSRCSSSSLNHAMVITGYGIS--
L.baicalensis GSESDLLAAVATVGPVAVAVDANTNAFRFYQSGVFDSSSCSSTKLNHAMLVTGYGSY--
S. domuncula GSESDLQAAVSNVGPVSVAIDGANSAFRFYYSGVYDSSRCSSSSLNHAMVVTGYGSY--
H. perleve ESEDDLQTAVANVGPVAVAIDGANNAFRFYYSGVYDSSRCSSTSLNHAMVVTGYGTY--
* * ** *** ** * * ** * *** * ***
H. sapiens ESDNNKYWLVKNSWGEEWGMGGYVKMAKDRRNHCGIASAASYPTV
T.aurantia --NNQEYWLAKNSWGENWGELGYVKMARNKYNQCGIASDASYPTL
L.baicalensis --NGKDYWLVKNSWSKNWGDSGYILMVRNKYNQCGIASDALYPML
S.domuncula --NGKKYWLAKNSWGTNWGNSGYVMMARNKYNQCGIATDASYPTL
H.perleve --AGKKYWLAKNSWSTNWGQSGYVMMARGKYNQCGIATDASYPTL
*** **** ** ** * * **** * **
Figure 20. Sequence alignment of mature human cathepsin L (UniProtKB/TrEMBL entry P07711) with mature silicatein
α from the sponge Tethya aurantia (O76238) (based on Shimizu et al., 1998) and also mature silicatein α from the sponges 
Lubomirskia baicalensis (Q2PC18), Suberites domuncula (Q2MEV3) and Hymeniacidon perleve (Q2HYF6) (based on
Fairhead et al., 2008). Identical amino acids in all five proteins are marked with asterisks. Catalytic triad amino acid
residues of the active site of cathepsin L and corresponding residues in the silicateins are highlighted in yellow. Cysteine
residues involved in disulfide bridges in cathepsin L are highlighted in green. Hydroxy amino acid residues in cathepsin L
and the silicateins are highlighted in turquoise. The 4 amino acid loop in cathepsin L (Smith and Gottesman, 1989;
Fairhead et al., 2008) that is missing in the silicateins (Fairhead et al., 2008) is highlighted in grey. The sequence alignment
was carried out using the programme ClustalW (Chenna et al., 2003).
1.3.2 Enzymatic properties of silicateins
Silicatein α synthesises part of the axial filament in the spicules which in situ
polymerises silicic acid (Figure 21A) (Weaver and Morse, 2003; Fairhead et al., 2008).
It has been demonstrated that the polymerisation of siloxanes such as for example
tetraethoxysilane (TEOS) can be carried out by both wild type and recombinant
silicatein α (Figure 21B) (Shimizu et al., 1998; Cha et al., 1999, Fairhead et al.,
2008).
Figure 21. (A) The chemical reaction catalysed by th
2008) and (B) the chemical structure of tetraethoxysilA26
e organic filament of the sponge spicule (based on Fairhead et al.,
ane (based on Cha et al., 1999).
B
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Cha and coworkers showed that the three silicateins, α, β and γ in T. aurantia
accelerate the in vitro condensation of silica from TEOS at neutral pH (Cha et al.,
1999). Usually, under these circumstances, either an acid or a base catalyst is needed
for this reaction (Iler, 1979; Cha et al., 1999). Thermally denatured silicatein subunits
do not show any activity indicating the requirement of the native 3-D conformation of
the proteins. It has been shown that silicatein α, because of its high content in the 
silicatein filaments (about 70 % of their mass), is able to accelerate this condensation
process in absence of the silicateins β and γ. The silicateins are also able to catalyse 
the polymerisation of silicon alkoxides and organically modified silicon alkoxides to
polymerised silica or silsesquioxanes (RSiO3/2)n at neutral pH. The condenastion of
organically substituted triethoxysilane precursors (R-Si(OEt)3); R represents -C6H5,
-CH3, etc.) can also be catalysed by active silicatein filaments (Cha et al., 1999). It
has also been demonstrated that silicatein α can lead to the deposition of compounds 
at surfaces, such as l-lactide, ZrO2, TiO2 and Ti3(PO4)4 (Curnow et al., 2006; Tahir et
al., 2005; Fairhead et al., 2008). It has been shown by Müller et al., 2007, that in the
freshwater sponge L. baicalensis the filaments did have silica forming properties.
Furthermore, it was demonstrated that the specific cathepsin L substrate Rhodamine
10 + bis-(CBZ-L-Phe-L-Arg) (Leytus et al., 1983; Müller et al., 2007) can be digested
by the silicateins, suggesting that they can also act as proteases (Müller et al., 2007).
The serine, replaced by the catalytic cysteine in cathepsin L that has been proposed to
be a very good nucleophile necessary for the digestion of OR- substrates (Cha et al.,
1999; Müller et al., 2007), can act like the SH-group as a nucleophile in combination
with the H+ donor histidine in proteolytic cleavage reactions as well. This discovery of
both functions, silica condensation and protein cleavage, suggests that there are
further modifications in the silicateins, that might play a role in the reaction process. It
was also reported that silicatein is a phosphoprotein (putative protein kinase C, casein
kinase II and a tyrosine kinase-phosphorylation site(s) and is also glycosylated
(Müller et al., 2007).
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It was shown that that the 26 kDa silicatein isoform shows glycosylation (Müller et al.,
2007). This finding raises the question of whether silicatein γ (named after Shimizu et
al., 1998) is actually a different, glycosylated form of the silicateins α or β (Müller et
al., 2007).
1.4. Project aims
In biotechnology and drug delivery (Giri et al., 2007; Fairhead et al., 2008) silica
materials are of interest but the controlled generation of silicic acid is quite difficult
(Fairhead et al., 2008). To get more insight into the molecular mechanisms that
control biosilification, it is very important to study the proteins of the axial filaments
(Shimizu et al., 1998). Unfortunately, it has not been possible yet to get reasonable
amounts of wild type or recombinant silicatein α to perform biophysical studies 
(Shimizu et al., 1998; Tahir et al., 2004; Curnow et al., 2006; Fairhead et al., 2008).
Cathepsin L mutants able to condense silica from solution have been generated by our
collaborators at the University of Strathclyde, Glasgow. Those mutants (Table1) show
sequence features that are specific for silicatein α (Fairhead et al., 2008).
Table 1. (after Fairhead et al., 2008) Mutant constructs made
Cathepsin L constructa Mutations                                    Match to silicatein α 
C2S C25S Catalytic serine
AS2 S24A, W26Y Residues flanking catalytic serine
AS2H M161L, D162N, G164A, V165M Residues flanking catalytic histidine
LOOP 173ESTESDNN180 to ISSNNQ To replicate loop
2SER E159S, D160S Match serines
4SER E153S, P154S Match serines
a The mutations are additive from top to bottom,
that is why 4SER contains all the mutations
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The mechanism of silicate polymerisation is not fully understood (Fairhead et al.,
2008). Therefore, the determination of the crystal structure of the mutant 4SER (Table
1) which displays 91 % sequence identity to human cathepsin L (Figure 22) should
provide more insight into the catalytic mechanism of silicic acid polymerisation
(Fairhead et al., 2008).
*25
4SER APRSVDWREKGYVTPVKNQGQCGASYAFSATGALEGQMFRKTGRLISLSEQ
Cathepsin L APRSVDWREKGYVTPVKNQGQCGSCWAFSATGALEGQMFRKTGRLISLSEQ
*********************** *************************
4SER NLVDCSGPQGNEGCNGGLMDYAFQYVQDNGGLDSEESYPYEATEESCKYNPK
Cathepsin L NLVDCSGPQGNEGCNGGLMDYAFQYVQDNGGLDSEESYPYEATEESCKYNPK
****************************************************
4SER YSVANDVGFVDIPKQEKALMKAVATVGPISVAIDAGHESFLFYKEGIYFSS
Cathepsin L YSVANDTGFVDIPKQEKALMKAVATVGPISVAIDAGHESFLFYKEGIYFEP
****** ******************************************
*163 *187
4SER DCSSSSLNHAMLVVGYGFISN---NQKYWLVKNSWGEEWGMGGYVKMAKDR
Cathepsin L DCSSEDMDHGVLVVGYGFESTESDNNKYWLVKNSWGEEWGMGGYVKMAKDR
**** * ******* * * *************************
4SER RNHCGIASAASYPTV
Cathepsin L RNHCGIASAASYPTV
***************
Figure 22. Sequence alignment of the 4SER chimera (Pdb accession code 2vhs) with mature human cathepsin L
(UniProtKB/TrEMBL entry P07711). Identical amino acids in both proteins are marked with asterisks. Catalytic triad
amino acids of the active site of cathepsin L and corresponding residues in 4SER are highlighted in yellow, and positions
corresponding to the sequence of cathepsin L are marked with asterisks. Residues, flanking the catalytic cysteine and
histidine in cathepsin L and the corresponding mutations in the chimera are highlighted in cyan. Other mutated amino
acids and deletions are highlighted in green. The 4 amino acid loop in cathepsin L (Smith and Gottesman, 1989; Fairhead
et al., 2008), which is missing in 4SER (Fairhead et al., 2008) is highlighted in grey. This sequence alignment was carried
out using the programme ClustalW (Chenna et al., 2003).
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Molecular biology, expression, purification and
crystallisation of silicatein α-cathepsin L
Chimeras
Summary
This section describes molecular biological methods, protein expression and
purification of the diverse mutants, the assay performed on the various cathepsin L
mutants to detect silica condensation activity and crystallisation of the 4SER mutant.
Cloning, introduction of mutations, expression and purification, and the assay were
carried out by our collaborators at the University of Strathclyde, Glasgow.
Crystallisation of the 4SER mutant was carried out in The Scottish Structural
Proteomics Facility (SSPF), University of St. Andrews.
1.5 Molecular biology, protein expression and purification
Mutants were generated using a combination of the QuikchangeTM mutagenesis
technique and conventional PCR (Fairhead et al., 2008). The mutant enzymes were
then expressed as the proenzyme and purified from Pichia pastoris (Fairhead and van
der Walle, 2008; Fairhead et al., 2008). Generation of the processed cathepsin
L-silicatein  chimeras was then carried out via published procedures (Menard et al.,
1998; Fairhead et al., 2008).
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1.6 Assay for detection of silica condensation from cathepsin
L mutants
Protein in 0.1 M sodium phosphate buffer, pH 7 was mixed with sodium silicate at a
concentration of 4.5 mM. The samples were then incubated at room temperature for
one day (Fairhead et al., 2008). After the samples had been centrifuged the
precipitated silica was then collected and assayed using the Merck spectroquant
silicon assay kit (Müller et al., 2003; Fairhead et al., 2008). This assay was performed
by our collaborators in Glasgow.
1.7 Crystallisation of the 4SER mutant
The enzyme was screened for crystallisation conditions against a range of
commercially available 96-condition screens such as JCSG+, Classics and PEGs (GE
Healthcare) and Wizard 1 and 2 (Emerald Biosytems ) (Supplementary Material (ESI),
Fairhead et al., 2008). Conditions that yielded crystals were optimised by employing
stochastic screens using in-house software (Rupp et al., 2002; Fairhead et al., 2008,
Supplementary Material (ESI)). The crystal used for data collection was grown by the
hanging drop vapour diffusion method using protein at a concentration of 10 mg/ml.
Protein was mixed with mother liquor containing 17.4% PEG 3350, 0.1 M sodium
acetate, pH 4.5 and 0.1 M lithium sulfate in a 2:1 ratio (2μl : 1μl). Before data 
collection, the crystal was cryoprotected in a solution containing 20 % PEG 3350, 0.1
M sodium acetate, pH 4.5, 0.1 M lithium sulfate and 20% PEG 400. The crystal was
flash frozen in liquid nitrogen and taken to beamline ID29 at the European
Synchrotron Radiation Facility (ESRF), Grenoble. (Fairhead et al., 2008,
Supplementary Material (ESI)).
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Data collection, Processing, Molecular
Replacement and Refinement of the 4SER
chimera
Summary
A complete X-ray dataset was collected at the European Synchrotron Radiation
Facility (ESRF) beamline ID29 to a resolution of 1.5 Å. Crystals were obtained as
described in Section 1.7. The diffraction data were processed and the structure factor
amplitudes calculated.
The sequence of the 4SER chimera is almost identical to that of cathepsin L (Fairhead
et al., 2008). It was decided to use cathepsin L as a model to calculate a set of initial
phase estimates using the technique of Molecular Replacement (MR). After the
structure had been solved using PHASER (McCoy et al., 2005, Storoni et al., 2004),
the protein was modified manually to change the sequence to 4SER. Full
high-resolution anisotropic refinement, TLS parameters and Non crystallographic
symmetry (NCS) restraints were carried out in all steps of refinement using the
programme REFMAC5 (Murshudov et al., 1999). The final model was checked and
validated using PROCHECK (Laskowski et al., 1993) and MOLPROBITY (Davis et
al., 2004). The final structure and experimental data were deposited with the Pdb
(Boutselakis et al., 2003), accession code 2vhs (Fairhead et al., 2008, Supplementary
Material (ESI)).
.
1.8 Data collection and processing
Before data collection crystals were cryoprotected in a solution containing 20% PEG
3350, 0.1 M sodium acetate, pH 4.5, 0.1 M lithium sulfate and 20% PEG 400.
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Diffraction data were collected at -173.15 ºC at a wavelength of 1.27 Å on ID29 at the
ESRF. (Fairhead et al., 2008, Supplementary Material (ESI)). A high resolution pass
to 1.5 Å resolution was collected in 0.5° oscillations with a 0.25s exposure. A lower
resolution pass to 2 Å in 0.5° oscillations with a 0.1s exposure that provided
measurements of data overloaded on the first pass was collected as well (Figure 23).
Indexing and merging of the data were performed using Denzo and Scalepack in the
integrated package HKL2000 (Minor et al., 2002). All the data collection, the
indexing and merging of the data were carried out by people from the SSPF. The
crystal belonged to the space group P1 (Table 2) with unit cell parameters a = 56.8 Å,
b = 58.1 Å, c = 70.2 Å, α = 105.7º, β = 105.0º, γ = 105.1º. The data have an overall 
completeness of 92% and 74% in the highest resolution shell from 1.55 – 1.5 Å
resolution. Data collection and processing statistics are presented in Table 3.
Table 2. Output from POINTLESS (Evans, 2006)
Best Solution: space group P 1
Reindex operator: [h,k,l]
Laue group probability: 0.918
Systematic absence probability: 1.000
Total probability: 0.918
Space group confidence: 0.877
Laue group confidence: 0.877
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Table 3. (after Fairhead et al., 2008, Supplementary Material (ESI)) Data collection statistics for the 4SER crystal. Data
for the highest resolution shell are shown in brackets.
* Rmerge = ∑ │I (k) - <I>│ / ∑ I (k), where I (k) is the value of the kth measurement of the
intensity of a reflection, <I> is the mean value of the intensity of that reflection and the
summation is over all measurements.
A B
Figure 23. 0.5° oscillation X-ray image of the crystal of 4SER collected to a higher resolution pass to 1.5 Å (A) and a lower
resolution pass to 2.0 Å (B) at ID29, ESRF.
Data collection 4SER
λ (Å) 1.27 
Resolution
Last shell (Å)
28 – 1.5
(1.55 -1.5)
Spacegroup P1
Cell (Å, º) a = 56.8, b = 58.1, c = 70.2
α = 105.7, β = 105.0, γ = 105.1 
Unique reflections 108723
Average redundancy 1.9 (1.7)
I/σ 20 (2.1) 
Completeness (%) 92 (74)
Rmerge* 0.039 (0.293)
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1.9 Structure solution and refinement
The structure of the 4SER chimera was solved by molecular replacement using Phaser
(McCoy et al., 2005; Storoni et al., 2004). A monomer of cathepsin L (PDB accession
code 1mhw) showing an almost identical sequence to the chimera (Fairhead et al.,
2008) was used as a search unit. A solution was found for 4 monomers in the
asymmetric unit consistent with the Matthews coefficient calculation (Table 4)
(Matthews, 1968) and a resolution range between 28 and 2.5 Å.
Table 4. Matthews coefficient and solvent content calculated from the unit cell and the molecular weight of the molecules
in the unit cell. Nmol/asym = number of molecules in the asymmetric unit, %solvent = % solvent content, P(1.5) =
probability at 1.5 Å resolution, P(tot) = probability across all resolution ranges. A Matthews coefficient of 2.08 Å3 Da-1,
corresponding to a 40.9% solvent content at a probability of 0.81 at 1.5 Å and a total probability of 0.53 (shown in orange),
suggested 4 molecules of the 4SER chimera in the asymmetric unit.
Nmol/asym Matthews Coeff. % solvent P(1.50) P(tot)
_____________________________________________________________
1 8.32 85.22 0.00 0.00
2 4.16 70.45 0.00 0.02
3 2.77 55.67 0.17 0.44
4 2.08 40.90 0.81 0.53
5 1.66 26.12 0.01 0.00
6 1.39 11.34 0.00 0.00
__________________________________________________
Clear rotation and translation solutions were found for each of the 4 monomers. No
unfavourable molecular contacts were observed for the final solution in the crystal
packing (Table 5).
36
The Molecular Replacement solution was then applied to the coordinates of the search
model to work as the starting model in the refinement described in the following
section.
Table 5. The top solution from PHASER.
RFZ = Z-score after fast rotation function, TFZ = Z-score after fast translation function, PAK = number of clashes
(unfavourable molecular contacts in crystal packing)
Solution RFZ TFZ PAK RFZ TFZ PAK RFZ TFZ PAK RFZ TFZ PAK
1 25.6 100 0 26 28.4 0 20.5 80.2 0 27.6 75.2 0
Monomer 1 Monomer 2 Monomer 3 Monomer 4
1.9.1 Refinement
Refinement is performed to minimise the difference between experimentally observed
structure factors (Fobs) and model-derived structure factors (Fcalc). Thereby refinement
of the coordinates x, y and z and the temperature factor (B-factor) of each atom in the
model is carried out. For the judgement of the resultant model various qualitative and
quantitative factors are used. Normally, the standard crystallographic Refinement
factors Rwork and Rfree are compared and one checks that all bond-lengths, angles and
temperature factors are within normal ranges. REFMAC5 (Murshudov et al., 1999)
was used to refine to structure of the chimera. Data in the range 63 – 1.5 Å were used.
The protein was manually modified to change the sequence to 4SER and rebuilding of
several amino acid residues were performed in COOT (Emsley and Cowtan, 2004).
TLS parameters (Table 6), anisotropic B-thermal factors and NCS restraints were
employed in all cycles of refinement. Water molecules and sulfate ions were also
added in COOT (Emsley and Cowtan, 2004) (Fairhead et al., 2008, Supplementary
Material (ESI)).
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Table 6. TLS groups employed throughout the refinement of 4SER.
TLS
RANGE 'A 1.' 'A 220.' ALL
ORIGIN -4.431 -27.884 17.511
T -0.1207 -0.1366 -0.1425 -0.0046 -0.0032 -0.0076
L 2.0108 1.4785 1.2081 -0.3484 -0.3503 -0.1250
S -0.1014 0.1305 0.0815 0.0730 -0.0943 -0.0881 0.0356 0.0996
TLS
RANGE 'B 1.' 'B 220.' ALL
ORIGIN 11.117 -8.108 1.610
T -0.1060 -0.1252 -0.1227 -0.0169 0.0098 -0.0033
L 2.9163 1.2744 1.1387 0.1873 -0.3902 -0.2063
S 0.0662 -0.1209 -0.0503 -0.2041 0.0963 -0.0461 0.0421 -0.0531
TLS
RANGE 'C 1.' 'C 220.' ALL
ORIGIN 22.774 7.357 32.647
T -0.1276 -0.1383 -0.1558 -0.0104 -0.0220 -0.0078
L 1.3113 1.5386 1.0548 -0.1951 -0.3159 -0.1475
S 0.0283 -0.0353 0.0089 0.0049 0.0970 -0.0279 -0.0129 -0.0588
TLS
RANGE 'D 1.' 'D 220.' ALL
ORIGIN 7.192 -12.379 48.556
T -0.1168 -0.1331 -0.1624 -0.0121 -0.0119 -0.0145
L 1.6144 1.4337 1.0725 0.0494 0.0517 -0.3844
S -0.0310 0.0141 0.0417 0.0125 -0.0472 -0.0362 0.0545 0.0530
The Rwork and Rfree after the last round of refinement were 18.8 % and 22 %,
respectively (Table 7). The quality of the structure was judged with PROCHECK
(Laskowski et al.,1993) and MOLPROBITY (Table 8) (Davis et al., 2004).
Finally the 4SER structure and the experimental data were deposited with the Pdb
(Boutselakis et al., 2003) and have the accession code 2vhs (Fairhead et al., 2008,
Supplementary Material (ESI)).
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Table 7. Refinement statistics of 4SER (after Fairhead et al., 2008, Supplementary Material (ESI)). Values for
Rwork and Rfree in the highest resolution shell are shown in brackets.
* Rwork = ∑hkl ││Fobs - │Fcalc││ / ∑hkl │Fobs│ 
* For Rfree the same calculation applies, but for only 5-10 % of reflections which are not included in the
refinement.
Refinement 4SER
Rwork * % 18.8 (26.4)
Rfree * % 22 (32.1)
Number of atoms (average
B value (Å2))
protein (overall)
protein (chain A)
protein (chain B)
protein (chain C)
protein (chain D)
water (overall)
SO42-
NCS deviations (rmsd (Å))
(chain A - chain B)
(chain A - chain C)
(chain A - chain D)
6636 (24.4)
1661 (24.4)
1657 (24.4)
1661 (24.4)
1657 (24.4)
1172 (36.6)
40 (36.9)
0.07
0.08
0.07
rmsd bonds (Å) / angles (°) 0.006 / 0.985
Ramachandran favoured (%) 98
PDB accession code 2vhs
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Table 8. Output from MOLPROBITY (Davis et al., 2007)
* 100th percentile is the best among structures of comparable resolution; 0th precentile is the worst.
Discussion
A crystal of the 4SER chimera diffracted to a resolution of 1.5 Å at the ESRF
beamline ID29. A complete data set was obtained at this resolution combining data to
1.5 Å from a high resolution pass and to 2 Å from a lower resolution pass. This was
necessary to provide the data that were overloaded in the higher resolution pass. After
an appropriate starting orientation had been given, a 180° rotation range at 0.5°
oscillations was sufficient for the space group P1 to get a completeness of almost
100%. The presence of more than one lattice in the diffraction pattern due to multiple
crystals caused some problems in indexing and integrating the data. For Molecular
Replacement a monomer of cathepsin L was used as a search unit finding 4 monomers
in the asymmetric unit. Both sequences, the one from the 4SER chimera and
Cathepsin L are almost identical apart from some mutations in the chimera (Fairhead
et al., 2008). In PHASER the Z-scores for the rotation and translation functions for
each of the four monomers are very high (Table 5) indicating that the correct solution
was found. Z-scores more than 10 normally indicate a correct solution.
Goal: <0.5%
Goal: <1%
84th percentile* (N=4836, 1.25Å - 1.75Å)
Goal: 0
Goal: >98%
Goal: <0.2%
Goal: <1%
Clashscore is the number of serious steric overlaps (> 0.4 Å) per 1000 atoms.
94th percentile* (N=598, 1.25Å - 1.75Å)
0.00%Residues with bad angles:
0.00%Residues with bad bonds:
1.51MolProbity score
0C deviations >0.25Å
97.99%Ramachandran favored
0.00%Ramachandran outliers
2.31%Rotamer outliers
Protein
Geometry
4.59Clashscore, all atoms:All-Atom
Contacts
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Refinement of the model against the data was straightforward. High resolution data
have a hugely increased observation to parameter ratio. This means that normally in a
1.5 Å resolution structure it is not necessary to “add” observations in the form of
restraints. However, application of NCS restraints improved the values for both Rwork
and Rfree by about 1 %. The geometry of the final 4SER model agreed well with the
average geometry of well-refined structures as seen by the rmsd values of bond
lengths and angles (Rhodes, 2000). Deviations of bond lengths around 0.01 and angle
deviations of about 1.6° are expected for good quality models. Rmsd bonds and
angles of the chimera at the end of the refinement process are within this range, 0.006
Å and 0.985°, respectively (Table 7). A clashscore of all atoms of 4.59 (94rd percentile)
and a MOLPROBITY score of 1.51 (84th percentile) (Table 8) also indicate the good
quality of this structure.
Structure of the 4SER chimera
Summary
The structure of the 4SER chimera, solved to 1.5 Å resolution, is described in this
section. The structure is composed of 9 α-helices and 10 β-strands. It is highly similar 
to cathepsin L. Like cathepsin L, the chimera comprises two domains, resembling a
closed book with the spine in front (Turk et al., 1998). Both “domains separate on the
top in a ‘V’ shaped active site cleft” (Turk et al., 1998). The catalytic cysteine (C25)
in cathepsin L has been mutated to serine. The other amino acids in the catalytic triad
of cathepsin L (His163 and Asn187) are the same in the 4 SER chimera. There is a
sulfate ion at the active site of each of the four monomers due to the presence of
lithium sulfate in the crystallisation condition. A second sulfate ion is located 17 Å
distant from Ser25. The structure provides insights into the catalytic mechanism of
silicic acid condensation (Fairhead et al., 2008).
1.10 Overall structure
Unsurprisingly, because of their almost identical sequences (Fairhead et al., 2008), the
chimera shares the same fold as cathepsin L. The asymmetric unit of 4SER is
composed of four monomers (Figure 24).
Figure 24 The asymmetric unit of 4SE
shown in green, cyan, magenta and red,
The four subunits are essenti
to A shows a rmsd of 0.07
monomers are shown as Cα R showing four mon
respectively. This figu
ally identical. S
Å, 0.08 Å, 0.0
traces in Figure
A
D
omers. T
re has b
uperp
7 Å,
 25. 
aa
B41
he Cα traces of the monomers A, B, C and D are 
een produced using PyMol (DeLano, 2007).
osition of the monomers B, C and D
respectively. All four superimposed
C
42
Figure 25. Cα tracing of the four monomers A (green), B (cyan), C (magenta) and D (red) after their superposition. This 
figure has been produced using PyMol (DeLano, 2007).
The interfaces between the subunits in the asymmetric unit were analysed using the
programme PISA (Krissinel and Henrick, 2005). The interface areas between the
monomers are shown in Table 9.
Table 9. Interface areas between the monomers of 4SER in the asymmetric unit. The Complexation Significance Scores
(CSS) for each interface are also shown.
Monomers Interface area (Å2) CSS
B and A
D and C
708.9
703.8
0
0
B and D
A and C
484.8
482.4
0
0
D and A
C and B
320.6
314.2
0
0
B and C
A and D
271.3
269.3
0
0
N
C
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The analysis did not reveal any specific associations between the monomers that
could cause any formation of stable quaternary structures. Therefore it suggests that
there is no complexation in solution. This result confirms the fact that cathepsins,
except the tetrameric cathepsin C usually occur as monomers (Mc Grath, 1999; Turk
et al., 2001).
The 4SER chimera from amino acid Ala1-Val220 consists of 9 α-helices and 10 
β-strands (Figure 26A). The heavy aminoterminal chain, composed of the amino acids 
Ala1-Ser174 and the light carboxyterminal chain (Gln180-Val220) are connected via
an S-S bridge between Cys156 and Cys209 (Figure 26B). Like in cathepsin L
(Fujishima et al., 1997), the loop region between amino acids Ser174 and Gln180 is
disordered (Figure 26).
Figure 26. (A) Ribbon diagram of the structure of the 4SER chimera (Pdb accession code 2vhs). α-helices (in cyan) and 
β-sheets (in red) are labelled. Loops are shown in magenta. The disordered loop between β-strands 7 and 8 is shown as 
dotted lines. (B) Stereo view of the connection of the heavy and light chain of 4SER (shown as Cα traces in magenta and 
green, respectively) via the S-S bridge between the heavy chain residue Cys156 and Cys209 (shown as sticks, carbons in
cyan). The disordered loop region is shown as dashed lines. This figure has been produced using PyMol (DeLano, 2007).
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1.11 Comparison of 4SER to cathepsin L
The differences between 4SER and cathepsin L only lie in the mutations and deletions
introduced into the chimera. The catalytic cysteine (Cys25) in cathepsin L has been
mutated to serine in the chimera. The other amino acids in the catalytic triad of
cathepsin L (His163 and Asn187) have not been changed in the 4 SER chimera. The
residues flanking the catalytic Ser25 and His163 have also been substituted; Ser24
and Trp26 in cathepsin L to Ala24 and Tyr26 in 4SER and Met161, Asp162, Gly164
and Val165 in the cysteine protease to Leu161, Asn162, Ala164 and Met165 in the
chimera. The amino acids Glu153, Pro154, Glu159 and Asp160 in cathepsin L have
all been replaced by serines in 4SER (Fairhead et al., 2008) to create the serine rich
region Ser-Ser-Asp-Cys-Ser-Ser-Ser-Ser, which almost completely matches the cluster
Ser-Ser-Arg-Cys-Ser-Ser-Ser-Ser, present in silicatein α of Tethya aurantia (Shimizu
et al., 1998). Instead of the loop in cathepsin L (Smith and Gottesman, 1989; Fairhead
et al., 2008), that consists of the amino acids Ser177 to Asp180 and the flanking
residues Glu173 to Glu176, 4SER contains the sequence Ile-Ser-Asn-Asn-Gln of
silicatein α (Fairhead et al., 2008). The substitution of Thr110 in cathepsin L to valine
disrupts the glycosylation site in the cysteine protease (Fairhead and van der Walle,
2008).
The structure of the 4SER chimera is, unsurprisingly, very similar to cathepsin L
(Fairhead et al., 2008). The overall rms deviation between both structures is only 0.25
Å for 188 Cα positions considered equivalent (Figure 27). 
45
Figure 27. Stereo view of Cα tracing of chain A of 4SER (in green, Pdb accession code 2vhs) and chain A of human 
cathepsin L (in magenta, Pdb accession code 1mhw) after their superposition. Mutated residues in the chimera are shown
as sticks (carbons in cyan) and are labelled. The disordered loop region in both structures is shown as dotted lines. This
figure has been produced using PyMol (DeLano, 2007).
1.12 Active site of 4SER
The chimera is composed, like cathepsin L and other enzymes of the papain
superfamily, of two domains, resembling a closed book with the spine in front (Turk
et al., 1998). The domains show a separation “on the top in a ‘V’ shaped active site
cleft”. (Turk et al., 1998). In its centre there are the catalytic residues Ser25 and
His163, one from each domain (Turk et al., 1998). Ser25 is part of the central α-helix 
(α2), His163 is right at the beginning of β7, which almost spans to the end of the 
heavy chain of 4SER. The amino acids, flanking both catalytic residues in the chimera
(Ala24, Tyr26, Leu161, Asn162, Ala164 and Met165) correspond to those in silicatein
α (Fairhead et al., 2008) (Figure 28A and B).
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The importance of the sulfate at the active site of 4SER will be one of the main
subjects in the following discussion.
Discussion
Various human cathepsin L mutants have been generated by our collaborators at the
University of Strathclyde, Glasgow, that increasingly match the sequence, specific for
silicatein α from the marine sponge Tethya aurantia (Table 1) (Fairhead et al., 2008).
Our collaborators also assayed those cathepsin L mutants for silica condensation
activity (Figure 31) (detected by the precipitation of silicate).
Figure 31. The mechanism of silica condensation.
The mutant C2S, in which the catalytic Cys25 has been replaced by serine was
essentially unable to condense silica (Fairhead et al., 2008) (Figure 33). This
substitution would have been expected to be enough from the already proposed
mechanism of silicatein α (Cha et al., 1999; Fairhead et al., 2008) (Figure 32).
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Figure 32. (after Cha et al., 1999) Proposed reaction mechanism of tetraethoxysilane polymerisation carried out by
silicatein α, based on the well studied catalytic reaction performed by Ser /His and Cys / His active-site proteases (Cha et
al., 1999; Zhou et al., 1999).
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For this mechanism it has been proposed that H-bonding between N of the imidazole
ring of His165 and OH of Ser26 increases the nucleophilicity of the O-atom of the
serine which enforces its attack on the Si of tetraethoxysilane.
Due to this nucleophilic attack CH3-CH2-OH is released and a covalent enzyme-O-Si
intermediate is generated. Hydrolysis of this first RO- bond is completed by the
addition of H2O. The disiloxane product is then finally generated by the condensation
reaction. The starting point for this process is that the released Si-O- performs a
nucleophilic attack on the silicon of the second Si(OEt)4 (Cha et al., 1999; Zhou et al.,
1999).
Our collaborators in Glasgow observed that it was necessary to change the residues
flanking Ser25 to detect any significant silica precipitation (Figure 33). Additional
substitutions to cathepsin L to increase its match to silicatein α did not improve the 
ability of these mutants to condense silica (Fairhead et al., 2008) (Figure 33).
Figure 33. (taken from Fairhead et al., 2008) Silica condensing activity of the mutants C2S, AS2, AS2H, LOOP, 2SER,
4SER (see Table 1) generated by our collaborators. Protein in 0.1 M sodium phosphate buffer, pH 7 was mixed with
sodium silicate at a concentration of 4.5 mM. The samples were then incubated at room temperature for one day
(Fairhead et al., 2008). After the samples had been centrifuged the precipitated silica was then collected and assayed using
the Merck spectroquant silicon assay kit (Müller et al., 2003; Fairhead et al., 2008).
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Moreover, many of these additional substitutions actually showed a decrease in their
ability to condense silica (Figure 33) (Fairhead et al., 2008). Therefore, it is possible
that these amino acids play other roles in the sponge spicule. They could participate in
interactions of silicatein α with silicatein β and galectin (Curnow et al., 2005;
Schröder et al, 2006; Fairhead et al., 2008). The mutants were more or less able to
precipitate silica from the natural substrate sodium silicate, but not from TEOS. To
elucidate the mechanism of catalysis of silica polymerisation the crystal structure of
the 4SER chimera was solved to 1.5 Å resolution (Fairhead et al., 2008). The C25S
mutant of procathepsin L (Pdb accession code 1cjl) cannot function as a protease,
which indicates that this mutation from Cys (SH) to Ser (OH) caused a significant
decrease in nuleophilicity. In 4SER an increase of the distance between the OG atom
of Ser25 and ND1 of His163 to 3.6 Å (Fairhead et al., 2008) (average distance over
the four monomers) can be observed (Figure 34), which further lowers the
nucleophilicity of Ser25. Mutation of the residues flanking Ser25 perturbs a cluster of
amino acids that are located behind Ser25. The substitution S24A leads to a removal
of an H-bond and the replacement of Trp26 with Tyr decreases a hydrophobic
interaction. The substitutions are both to amino acids smaller than in the wildtype
protein. As a consequence Ser25 would be able to decrease its distance to His163 and
the volume of the catalytic region would be increased (Fairhead et al., 2008).
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ure 34. (A) Stereo view of the active site of the C25S procathepsin L mutant (Pdb accession code 1cjl). Active site and
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wn as dashed lines. (B) Stereo view of the active site of monomer C of 4SER (Pdb accession code 2vhs) showing the
se contacts (<3.5 Å) as dashed lines. Active site and adjacent residues are shown as sticks, and waters as red spheres.
e distance between the OG atom of Ser25 and ND1 of His163 is also shown as dotted lines (after Fairhead et al., 2008).
As comparison the catalytic triad (His57, Asp102, Ser195) (shown as sticks) (reviewed in Polgár, 2005) of the serine
tease chymotrypsin (Pdb accession code 4cha) is also shown. OG of Ser195 and NE2 of His57 are within H-bonding
tance (Polgár, 2005) (2.8 Å) (dashed lines). This figure has been produced using PyMol (DeLano, 2007).
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At a concentration above 100 ppm, spontaneous condensation of silicic acid takes
place, because the concentration of nucleophilic ionised molecules is sufficient. There
are two ways that may explain how enzyme catalysis can take place. The first one is
that one molecule of deprotonated Si(OH)4 is stabilised at the active site (the
nucleophile), which will then undergo a reaction with a second molecule of silicic
acid. The alternative is the stabilisation of a protonated Si(OH)4 molecule (the
electrophile), which will then undergo a reaction with a second molecule of silicic
acid as well. The SO42- at the active site suggests that the former mechanism may
operate. The crystal structure shows that it would be difficult to place the Si(OEt)4 at
the active site without causing any conformational change of this region (Fairhead et
al., 2008). Modelling of tetraethoxysilane at the same position as the sulfate ion in the
4SER structure (Figure 39) shows that one of the CH3-CH2 groups would clash either
with Ser25 (distance 1.9 Å), His163 (distance 1.3 Å) or Asn162 (distance 2.2 Å)
depending on the performed rotation (Figure 35). This could be an explanation for the
absence of activity of the chimera against tetraethoxysilane indicating a larger
catalytic region in silicatein α than in 4SER. This larger active site could allow to fit 
the bulky Si(OEt)4 into it (Fairhead et al., 2008).
Figure 35. Close up view of the active site of 4SER (residues in sticks) with tetraethoxysilane (carbons in cyan, silicon
atom in magenta) modelled at the same position as the sulfate ion (sulfur in yellow). Contacts between CAE of TEOS and
OG of Ser25, CAA of TEOS and ND1 of His163, and also CAA and O of Asn162 are shown as dashed lines. The direction
of rotation around the silicon and oxygen OAI is shown as an arrow. This figure has been produced using PyMol (DeLano,
2007).
His163
Asn162
Asn187
Ser25
Gln19
His163
Asn162
Ser25
Asn187
Gln19
55
The tetrahedral SO42- at the active site represents a good mimic of the tetrahedral
Si(OH)4. The sulfate has an H-bond with Ser25. Consequently one could expect that
Ser25 performs a nucleophilic attack on silicic acid to form a covalent enzyme
intermediate (see Figure 32). With silicic acid, however, a high energy intermediate
would not appear to be chemically likely and as a consequence a hydrolysis back to
silicic acid would take place. There is also an H-bond between SO42- and His163
(Fairhead et al., 2008), the amino acid which increases the nucleophilicity of the
nucleophile in proteases (Sajid and McKerrow, 2002; Fairhead et al., 2008). The
structure suggests a procedure in which His163 interacts with the deprotonated form
of silicic acid and then stabilises it at the active site. The extensive network of H2O
molecules and H-bonds (Figure 34) would lead to significant shuttling of protons. As
a consequence, the negative charge can move to another O-atom. This deprotonated
protein bound can then perform a nucleophilic attack on Si(OH)4 solution species
starting the condensation process (Figure 36A). The abstraction of a silicic acid
OH-group caused by H+-abstraction and elimination of H2O could also promote the
reaction. However, there is no evidence for an acid. It is not likely either that at
neutral pH silicic acid represents a sufficient base to first abstract H+ from His163
(whose pKa is probably less than 7 because of Asn187) and then for the OH-group of
the second silicic acid molecule to carry out a nucleophilic attack (Figure 36B). We
propose that Ser25 and the adjacent amino acid substitutions simply form a pocket of
sufficient size. Then recognition of the silicic acid molecule would be possible in such
a way that H+-abstraction by His163 can occur. The deprotonated silicic acid enzyme
complex can be seen as a starting point for the polymerisation reaction. A high energy
covalent intermediate would not have to be involved (Fairhead et al., 2008). A
specific silicic acid transporter in sponges (Schröder et al., 2004; Fairhead et al., 2008)
indicates that the real substrate in vivo is Si(OH)4 and not high energy silicon
alkoxides. That is why our proposed mechanism appears to be a reasonable model for
the biological process (Fairhead et al., 2008).
Figure 36. (A) (after Fairhead et al., 2008) The proposed chemical
a mechanism in which His163 abstracts H+ from silicic acid; the
protons. (B) The other more unlikely mechanism of deprotonatio
OH-group of the second silicic acid molecule on the first Si(OH)4 (FA56
mechanism for the condensation of Si(OH)4. We favour
extensive water network could permit the shuttling of
n of His163 and subsequent nucleophilic attack of the
airhead et al., 2008).
B
57
Future aims
The structure of the 4SER chimera has been solved to 1.5 Å. The tetrahedral sulfate
ion at the active site helped us to propose a mechanism for the polymerisation of the
also tetrahedral silicic acid (Fairhead et al., 2008). A structure in complex with silicic
acid, the real substrate would definitely give even more insight into the mechanism of
silica polymerisation. Further objectives could also include finding a method to
express a higher amount of soluble silicatein α in order to produce enough for 
crystallisation. The structure of silicatein α in complex with silicic acid and the bulky 
Si(OEt)4 would also contribute greatly to the elucidation of the mechanism of silica
condensation.
CHAPTER 2
THE STRUCTURE OF
AGME Y140F IN COMPLEX
WITH ADP-β-MANNOSE
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Introduction
2.1 Epimerases and Racemases
Inversion of stereochemistry in molecules such as amino acids or sugars is carried out
by specific enzymes called epimerases and racemases. For the catalysis of this
reaction the bond has to be cleaved and reformed stereospecifically. A C-H connection
is the usual target for this reaction (Figure 37) (Tanner, 2002).
Figure 37. (after Tanner, 2002) There are three distinct routes to stereochemical inversion. The top route (1) shows the cut
of a C-H bond. This could be via deprotonation using amino acid racemases (Tanner, 2002), RmlC (Dong et al., 2003) or
H- transfer using UDP galactose 4-epimerase (Frey, 1996; Tanner, 2002), ADP-L-glycero-D-mannoheptose 6-epimerase
(Read et al., 2005). The central route (2) describes cleavage of a C-O bond. An example is the epimerisation of
3-hydroxyacyl-CoA. This employs non-stereospecific dehydration/hydration to invert stereochemistry (crotonase
reactions) (Yang and Elzinga, 1993; Yang et al., 1991; Smeland et al., 1991; Wakil, 1956). The bottom route (3) involves
C-C bond cleavage. A good example is L-ribulose 5-phosphate 4-epimerase (Tanner, 2002).
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Epimerisation of carbohydrates is defined as an “inversion of stereochemistry at a
stereogenic centre in a sugar” (Figure 38) (Samuel and Tanner, 2002). This can be
seen as a reaction where an H-atom is abstracted from one face and returns to the
opposite face of the C-atom in the centre.
Figure 38. (after Allard et al., 2001) The epimerisation reaction: “the inversion of configuration of an asymmetrically
substituted carbon in a sugar” (Allard et al., 2001).
Each stereogenic centre in a sugar can be targeted by an epimerase. A few of these
enzymes are even able to carry out epimerisation at two stereocentres (Allard et al.,
2001). Any epimerases and racemases operate at stereogenic centres that are activated
where abstraction and readdition of H+ take place (Tanner and Kenyon, 1998; Tanner,
2002). Unactivated stereocentres are targeted by a smaller number of epimerases and
racemases. In most of these reactions transient oxidation takes place whereby a
coenzyme such as nicotinamide adenine dinucleotide is involved (Tanner, 1998;
Tanner, 2001; Tanner, 2002). Activation of a stereogenic centre can be accomplished
by oxidation of an adjacent OH-group. As a consequence the acidity of the α-H+
increases (Figure 39). Inversion of stereochemistry occurs by a mechanism of
H+-abstraction and readdition and at the end the epimer is formed by reduction of the
keto-intermediate (Tanner, 2002).
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Figure 39. H+-abstraction and readdtion involving transient oxidation (after Tanner, 2002).
There is a small number of epimerases which act at unactivated stereogenic centres
and do not require a coenzyme (Tanner, 2002). Examples for such enzymes are
L-ribulose 5-phosphate 4-epimerase and UDP-N-Acetylglucosamine 2-epimerase
(Tanner, 2002; Allard et al., 2001). L-ribulose 5-phosphate and D-xylulose
5-phosphate are interconverted in the presence of a zinc ion by L-ribulose
5-phosphate 4-epimerase, which occurs in bacteria (Tanner and Kenyon, 1998; Tanner,
2002). In this reaction inversion of stereochemistry takes place by cleavage of a C-C
connection (reviewed in Allard et al., 2001; Tanner et al., 2002).
UDP-N-acetylglucosamine and UDP-N- acetylmannosamine are reversibly
interconverted by the bacterial UDP-N-Acetylglucosamine 2-epimerase (Kawamura et
al., 1979; Tanner, 2002). In this case epimerisation takes place by removing and
readding uridine diphosphate.
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2.2 Short-chain dehydrogenases/reductases (SDRs)
The family of short-chain dehydrogenases/reductases (SDRs) was described in the
early 1980s. The first known enzymes of this protein family were an alcohol
dehydrogenase from Drosophila and a bacterial ribitol dehydrogenase (Persson et al.,
2003; Jörnvall et al., 1981). There are more than 3000 amino acid sequences of
short-chain dehydrogenases/reductase in sequence databases, and around 70 members
of this enzyme family in humans (Oppermann et al., 2003; Kallberg et al., 2002 and
2002a). Their definition and identification derives from some specific regions in their
sequence. They represent oxidoreductases that differ from other families with similar
functions such as medium-chain dehydrogenases/oxidoreductases (MDRs)
(Oppermann et al., 2003; Jörnvall et al., 1995; Oppermann et al., 1997; Filling et al.,
2002) or aldo-keto reductases (AKR) (Oppermann et al., 2003; Jez et al., 1997).
SDR-enzymes operate on a variety of substrates such as xenobiotics, steroids,
prostaglandins and alcohols (Persson et al., 2003; Oppermann et al., 2003). Pair-wise
alignments of various short-chain dehydrogenases/reductases usually show 15-30 %
identity (Oppermann et al., 2003; Persson et al., 2003; Kallberg et al., 2002 and
2002a; Jörnvall et al., 1995). However, proteins of this family have a highly
conserved α/β sandwich fold, where a β-sheet in the centre is surrounded by several 
α-helices (Rossmann fold) (Figure 40) (Oppermann et al., 2003; Jörnvall et al., 1995;
Rossmann et al., 1975).
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Figure 40. Ribbon diagram of 3β/17β hydroxysteroid dehydrogenase (3β/17β HSD) from Comamonas testosteroni (Pdb
accession code 1hxh). α-helices are shown in cyan, β-strands in magenta, and loops in pink. The α/β sandwich and the
β-sheet in the centre, decorated by several α-helices represent the characteristic Rossmann fold (Oppermann et al., 2003;
Jörnvall et al., 1995; Rossmann et al., 1975). The β-strand in the centre is shown in yellow and is boxed.  
The majority of enzymes from this family are 250-350 amino acids long (Oppermann
et al., 2003; Kallberg et al., 2002, Persson et al., 2003; Filling et al., 2002). The
aminoterminal part of short chain dehydrogenases/reductases is involved in the
interaction with a cofactor, nicotinamide adenine dinucleotide or nicotinamide
adenine dinucleotide phosphate. The carboxyterminal region interacts with substrate
(Kallberg et al., 2002; Oppermann et al., 2003; Persson et al., 2003; Filling et al.,
2002). Highly conserved motifs in SDRs are a glycine rich cluster at the
aminoterminus, and the catalytic triad Ser, Tyr and Lys in the carboxyterminal part
(Oppermann et al., 2003; Filling et al., 2002; Jörnvall et al., 1995). A more detailed
discussion on the functions and positions of those two and other conserved motifs in
SDR enzymes is given in a recent review (Oppermann et al., 2003).
o
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2.2.1 Reaction mechanism of SDR enzymes: 3β/17β hydroxysteroid 
dehydrogenase from Comamonas testosteroni as an example
Filling and coworkers discovered that the catalytic triad Ser, Tyr and Lys of SDR
enzymes (Oppermann et al., 2003; Filling et al., 2002; Jörnvall et al., 1995) can be
extended to a tetrad including a conserved Asn residue (Filling et al., 2002;
Oppermann et al., 2003). The roles of the active site residues Ser138 Tyr151, and
Lys155 in 3β/17β hydroxysteroid dehydrogenase had already been known before their 
studies (Filling et al., 2002). Tyr151 acts as a base (Filling et al., 2002; Jörnvall et al.,
1995), Ser138 plays an important role in the stabilisation of the substrate and Lys155
generates H-bonds with the ribose adjacent to the cofactor’s niacinamide whereby the
pKa value of the side chain hydroxyl of Tyr151 is lowered. As a consequence
H+-transfer can occur. In the crystal structure of bacterial 3β/17β hydroxysteroid 
dehydrogenase, it has been discovered that Asn111 interacts with Lys155 via H2O.
Because of this observation it has been proposed that this asparagine residue plays an
essential role in the stabilisation of Lys155 and consequently an H+ relay (Figure 41)
occurs in the majority or even all short chain dehydrogenases/reductases with Tyr151,
the 2’ hydroxyl of ribose, cofactor, substrate, H2O, Asn111 (or Ser in other SDRs) and
Lys155 involved (Filling et al., 2002). However, there is a possibility that there are
differences in the active sites and catalysis. Crucial residues could be at other
positions, substrates could be converted sequentially, or other amino acids such as His
Arg or Thr could play an essential role in catalysis (Oppermann et al., 2003; Kallberg
et al., 2002; van Hylckama Vlieg et al., 2001; Gourley et al., 2001).
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Figure 41. Reaction mechanism of 3β/17β hydroxysteroid dehydrogenase with NADH and steroid substrate
(5α-androstane, 3-one,17ol). At the beginning of the catalytic reaction an H+ is transferred from the side chain hydroxyl of
Tyr 151 to C=O of the substrate. Then H- is transferred to C3 of 5α-androstane, 3-one,17ol. Finally an H+ relay is built up
including Lys155, Asn111, H2O and the 2’-hydroxyl of the ribose. ARPP: adenosine ribose pyrophosphate part of the
cofactor (after Filling et al., 2002).
2.2.2 Families of SDR enzymes
A full classification of SDR families and subfamilies was reported in two publications
(Kallberg et al., 2002; Persson et al., 2003). The second paper largely supercedes the
first one.
Short chain dehydrogenases/reductases have been classified into two families named
“classical” and “extended” (Kallberg et al., 2002; Jörnvall et al., 1995).
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Whereas members of the classical family contain about 250 amino acids,
representatives of the extended family have about 350 amino acids (Kallberg et al.,
2002; Jörnvall et al., 1995). Oxidoreductases and carbonyl reductases, for instance,
belong to the classical family. Extended SDRs are for example epimerases and
dehydratases (Figure 42). There are small distinctions in the conserved glycine-rich
motif at the aminoterminus between these two families. Several amino acids are
exactly at identical positions in the classical and extended SDRs whereas other
sequence motifs show differences (Table 10) (Persson et al., 2003). A more detailed
analysis of conserved regions in short chain dehydrogenases/reductases revealed that
apart from those already established families, SDRs can be further separated into three
other families named “intermediate”, “divergent” and “complex” (Figure 43)
(Kallberg et al., 2002). Representatives of the intermediate family are alcohol
dehydrogenases from Drosophila (Figure 42). Bacterial and herbal enoyl reductases
(Figure 42) belong to the divergent family. A member of the complex family is for
instance fatty acid synthase (Persson et al., 2003).
A sequence alignment of representatives from all five families (Kallberg et al., 2002)
is shown in Figure 42. Conserved motifs (Table 10) (after Persson et al., 2003) in all
eight aligned enzymes are highlighted.
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Table 10. (after Persson et al., 2003) Conserved sequence motifs in classical and extended SDRs
In the motifs, “a” stands for an aromatic amino acid, “c” for a charged amino acid, “h” for a hydrophobic amino acid,
“p” for a polar amino acid and “x” for any amino acid. Other residues at a position in a motif are shown in brackets.
Secondary structure
element
Classical SDR motifs Extended SDR
motifs
Function (see
references in
Kallberg et al., 2002
and Persson et al.,
2003)
β1 + α1 
β3 + α3 
β4 
α4 
β5 
α5 
β6 
TGxxxGhG
Dhx[cp]
GxhDhhhNNAGh
hNhxG
GxhhxhSSh
Yx[AS][ST]K
h[KR]h[NS]xhxPGxxxT
TGxxGahG
DhxD
[DE]xhhHxAA
hNhhGTxxhhc
hhhxSSxxhaG
PYxx[AS]Kxxh[DE]
h[KR]xxNGP
Structural role in
cofactor binding site
Adenine ring
interaction of cofactor
Structural role in the
stabilisation of the
central β-sheet 
Part of catalytic region
Part of catalytic region
Part of catalytic region
Structural function,
reaction direction
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β1 + α1   
2HSD ------NDLSGKTVIITGGARGLGAEAARQAVAAGAR--VVLADVL----
1HXH -----TNRLQGKVALVTGGASGVGLEVVKLLLGEGAK--VAFSDIN----
1EK6 ---------MAEKVLVTGGAGYIGSHTVLELLEAGYLPVVIDNFHNAFRG
1A4U ------MDLTNKNVIFVAALGGIGLDTSRELVKRNLKNFVILDRVE----
1MG5 -----SFTLTNKNVIFVAGLGGIGLDTSKELLKRDLKNLVILDRIE----
1QSG --GSHMGFLSGKRILVTGVASKLSIAYGIAQAMHREGAELAFTYQN----
1BVR -----TGLLDGKRILVSGIITDSSIAFHIARVAQEQGAQLVLTGFDR---
P22367|MSAS_PENPA SEGPRLLPRPEGTYLITGGLGVLGLEVADFLVEKGARRLLLISRRALPPR
β3 + α3   
2HSD -------DEEGAATARELGDAA--RYQHLDVTIEEDWQ-RVVAYARE
1HXH -------EAAGQQLAAELGERS--MFVRHDVSSEADWT-LVMAAVQR
1EK6 -----GGSLPESLRRVQELTGRSVEFEEMDILDQGALQRLFKKYSFM
1A4U -------NPTALAELKAINPKVNITFHTYDVTVPVAESKKLLKKIFD
1MG5 -------NPAAIAELKAINPKVTVTFYPYDVTVPIAETTKLLKTIFA
1QSG -------DKLKGRVEEFAAQLGSDIVLQCDVAEDAS-IDTMFAELGK
1BVR -------LRLIQRITDRLPAKAPLLELDVQNEEHLASLAGRVTEAIG
P22367|MSAS_PENPA -QVSEDLQPTIAKIRLLESRGASVHVLPLDITKPDAVEQLTTALDRL
β4              α4
2HSD EFGSVDGLVNNAGIST----------GMFLETESVERFR---KVVEINLT
1HXH RLGTLNVLVNNAGILL----------PGDMETGRLEDFS---RLLKINTE
1EK6 AVIHFAGLKAVGESVQKPLDYYRVNLTGTIQLLEIMKAHGVKNLVFSSSA
1A4U QLKTVDILINGAGILD----------DHQIERTIAINFT---GLVNTTTA
1MG5 QLKTVDVLINGAGILD----------DHQIERTIAVNYT---GLVNTTTA
1QSG VWPKFDGFVHSIGFAP----------GDQLDGDYVNAVTREGFKIAHDIS
1BVR AGNKLDGVVHSIGFMP----------QTGMGINPFFDAPYADVSKGIHIS
P22367|MSAS_PENPA SLPSVQGVVHAAGVLDN-------ELVMQTTRDAFNRVLAPKIAGALALH
α4               β5 
β5              α5
2HSD GVFIGMKTVIPAMKDAGGGSIVNISSAAGLMGLALTSSYGASKWGVRGLS
1HXH SVFIGCQQGIAAMKETGG-SIINMASVSSWLPIEQYAGYSASKAAVSALT
1EK6 TVYGNPQYLPLDEAHPTGGCTNPYGKSKFFIEEMIRDLCQADKTWNAVLL
1A4U ILDFWDKR-----KGGPGGIIANICSVTGFNAIHQVPVYSASKAAVVSFT
1MG5 ILDFWDKR-----KGGPGGIICNIGSVTGFNAIYQVPVYSGTKAAVVNFT
1QSG SYSFVAMAKACRSMLNPGSALLTLSYLGAERAIPNYNVMGLAKASLEANV
1BVR AYSYASMAKALLPIMNPGGSIVGMDFDP-SRAMPAYNWMTVAKSALESVN
P22367|MSAS_PENPA EVFPPKSVDFFVMFSSCGNLVGFTGQASYGSGNAFLDTLATHRARLGDAA
* α5
Figure 42. (continues on next page)
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β6  
2HSD KLAAVELG--------TDRIRVNSVHPGMTYTPMTAETGIR--QGEGNYP
1HXH RAAALSCRK------QGYAIRVNSIHPDGIYTPMMQASLPKGVSKEMVLH
1EK6 RYFNPTGAHASGCIGEDPQGIPNNLMPYVSQVAIGRREALNVFGNDYDTE
1A4U NSLAKLAP--------ITGVTAYSINPGITRTPLVHTFNSWLDVEPRVAE
1MG5 SSLAKLAP--------ITGVTAYTVNPGITRTTLVHKFNSWLDVEPQVAE
1QSG RYMANAMG--------PEGVRVNAISAGPIRTLAASGIKDFR---KMLAH
1BVR RFVAREAG--------KYGVRSNLVAAGPIRTLAMSAIVGGALGEEAGAQ
P22367|MSAS_PENPA VSFQWTSWRGLGMGASTDFINAELESKGITDVTRDEAFAAWQHLAKYDMD
Figure 42. Structural sequence alignment of members from all five families of SDRs (Kallberg et al., 2002) Conserved
sequence motifs (see Table 10) in classical SDRs (3β/17β-hydroxysteroid dehydrogenase from Comamonas testosteroni,
Pdb accession code 1hxh; 3α,20β-hydroxysteroid dehydrogenase from Streptomyces exfoliatus, Pdb accession code 2hsd)
are highlighted in yellow, the corresponding motifs in the representative of the extended SDR family (UDP-galactose
4-epimerase from Homo sapiens, Pdb accession code 1ek6) are highlighted in green, in intermediate SDRs (alcohol
dehydrogenase from Drosophila lebanonensis, Pdb accession code 1a4u; alcohol dehydrogenase from Drosophila
melanogaster, Pdb accession code 1mg5) in turquoise, in divergent SDRs (enoyl reductase from Escherichia coli; Pdb
accession code, 1qsg; enoyl-ACP reductase from Mycobacterium tuberculosis; Pdb accession code 1bvr) in grey, and in one
member of the complex SDR family (6-methylsalicylic acid synthase from Penicillium patulum (Penicillium griseofulvum),
UniProtKB/TrEMBL entry P22367) in pink. Residues conserved in all five families are marked with an asterisk. The
positions of secondary structural elements in classical SDRs are marked on top of each motif, positions of α-helices and 
β-strands, as they occur in the extended family are shown in red at the bottom of each motif. This sequence alignment was 
carried out using the programme ClustalW (Chenna et al., 2003).
The alignment shows that 3β/17β-hydroxysteroid dehydrogenase and 
3α,20β-hydroxysteroid dehydrogenase (Kallberg et al., 2002) contain the conserved
aminoterminal glycine-rich Thr-Gly-X-X-X-Gly-h-Gly (see Table 10) specific for
members of the family of classical SDRs (Kallberg et al., 2002). In UDP-galactose
4-epimerase which is a representative of the extended family (Kallberg et al., 2002),
the same motif has a slightly different pattern (Thr-Gly-X-X-Gly-h-a-Gly) (Table 10)
(Persson et al., 2003). In both Drosophila alcohol dehydrogenases which are members
of the intermediate family (Kallberg et al., 2002) the unique aminoterminal
Gly(Ala)-X-X-Gly-X-X-Gly(Ala) sequence cluster which displays similarity the
glycine-rich region of extended SDRs can be found (Kallberg et al., 2002).
Additionally an Asn-Gly-Ala-Gly fingerprint sequence in β-strand 4 can be observed 
which is almost identical with the Asn-Asn-Ala-Gly motif (Table 10) of classical
SDRs (Persson et al., 2003).
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Enoyl reductase and enoyl-ACP reductase contain the Gly-X-X-X-X-X-Ser-X-Ala
motif at the aminoterminus typical for members of the divergent family. Additionally
the conserved cluster at the active site also differs from the members of the other SDR
families (Kallberg et al., 2002). The Tyr is replaced by a Met whereas the Tyr is
located “three positions upchain” (Kallberg et al., 2002). 6-methylsalicylic acid
synthase which belongs to the family of complex short chain
dehydrogenases/reductases contains the specific active site cluster Tyr-X-X-X-Asn
instead of the Tyr-X-X-X-Lys motif of classical, extended and intermediate SDR
enzymes (Persson et al., 2003).
Classical SDRs are most common, extended short chain dehydrogenases/reductases
next and the intermediate third. The families with the least number of members are the
divergent and complex families (Kallberg et al., 2002).
Apart from this classification into five different SDR families, another classification
of classical and extended short chain dehydrogenases based on their cofactor
preference for nicotinamide adenine dinucleotide or nicotinamide adenine
dinucleotide phosphate was performed (Figure 43 and Table 11) (Kallberg et al.,
2002). NAD(H)-interacting enzymes usually contain an aspartic acid or glutamic acid
at end of β-strand 2 (Table 11) (Kallberg et al., 2002; Wierenga et al., 1986), whereas
NADP(H) specific enzymes normally contain an arginine or lysine (Kallberg et al.,
2002; Tanaka et al., 1996). One of these basic amino acids is in the glycine rich
cluster, directly before the second glycine. The other basic amino acid can usually be
found after the essential aspartic acid or glutamic acid of NAD(H)-binding enzymes
(Table 11) (Kallberg et al., 2002).
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Figure 43. (taken from Persson et al., 2003) The two levels of classification within the superfamily of SDR enzymes.
Enzymes belonging to the superfamily of SDRs are divided into five families. Classical and extended SDRs are further
divided into seven and three subfamilies, respectively, based on their amino acids associating to the cofactor (Persson et al.,
2003; Kallberg et al., 2002).
Table 11. (after Persson et al., 2003; Kallberg et al., 2002) “Key positions” for assignments of cofactor preference of
classical (A) and extended short chain dehydrogenases/reductases (B). Numbers refer to 3α,20β-hydroxysteroid 
dehydrogenase (Pdb accession code 2hsd) in A and UDP-galactose 4-epimerase (Pdb accession code 1ek6) in B.
“Key positions“
Subfamily Cofactor 15 36 37 38
(A)Classical SDRs
cD1d NAD(H) D
cD1e NAD(H) E
cD2 NAD(H) D/E
cD3 NAD(H) D/E
cP1 NADP(H) K/R
cP2 NADP(H) K/R
cP3 NADP(H) K/R K/R
33 34 35
(B) Extended SDR enzymes
cD1 NAD(H) D/E
cD2 NAD(H) D/E
cP1 NADP(H) K/R
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A sequence alignment of representatives from several subfamilies of classical and
extended SDRs is shown in Figure 44, (based on Kallberg et al., 2002). Residues at
“key positions” specific for the respective subfamily (Table 11 and Figure 43) Persson
et al., 2003) in all seven aligned enzymes are highlighted.
*15
2HSD ---------------------------NDLSGKTVIITGGARGLGAEAAR
P51659|DHB4_HUMAN -----------------------MGSPLRFDGRVVLVTGAGAGLGRAYAL
Q9BPX1|DHB14_HUMAN -----------------------MATGTRYAGKVVVVTGGGRGIGAGIVR
P80365|DHI2_HUMAN LLPPPAALAVLAAAGWIALSRLARPQRLPVATRAVLITGCDSGFGKETAK
Q53GQ0|DHB12_HUMAN VAYLALRISYSLFTALRVWGVGNEAGVGPGLGEWAVVTGSTDGIGKSYAE
1CYD -------------------------MKLNFSGLRALVTGAGKGIGRDTVK
Q14376|GALE_HUMAN ------------------------------MAEKVLVTGGAGYIGSHTVL
** *12*
*36
2HSD QAVAAGARVVLADVLDEEGAATARELG--DAARYQHLD-------VTIEE
P51659|DHB4_HUMAN AFAERGALVVVNDLGGDFKGVGKGSLAADKVVEEIRRRGGKAVANYDSVE
Q9BPX1|DHB14_HUMAN AFVNSGARVVICDKDESGGRALEQELP---GAVFILCD-------VTQED
P80365|DHI2_HUMAN KLDSMGFTVLATVLELNSPGAIELRTCCSPRLRLLQMDLT-----KPGDI
Q53GQ0|DHB12_HUMAN ELAKHGMKVVLISRSKDKLDQVSSEIKEKFKVETRTIA-------VDFAS
1CYD ALHASGAKVVAVTRTNSDLVSLAKECPG-------IEP-------VCVDL
Q14376|GALE_HUMAN ELLEAGYLPVVIDNFHNAFRGGGSLPESLRRVQELTGR--------SVEF
Q84EX5|Q84EX5_LACBR KFVEEGAKVMITGRHSDVGEKAAKSVGTPDQIQFFQHD-------SSDED
* *33
Figure 44. Sequence alignment of various classical and extended SDRs, based on their coenzyme specificity (based on
Kallberg et al., 2002). The “key position” numbers refer to 3α,20β-hydroxysteroid dehydrogenase (Pdb accession code 
2hsd) as a member of the classical family (blue asterisks) and UDP-galactose 4-epimerase (UniProt/KB/Swiss-Prot
Q14376 (GALE_HUMAN)) as a representative of the extended family (red asterisks) (Kallberg et al., 2002). Conserved
residues in all eight proteins are marked with asterisks The conserved TGxxxGhG motif of the classical SDRs (Kallberg et
al., 2002) is highlighted in yellow, the counterpart in the extended family TGxxGhaG (Kallberg et al., 2002) in green. “Key
position” residues are highlighted in grey in the classical family and in turquoise in the extended one.
3α,20β-hydroxysteroid dehydrogenase from Streptomyces exfoliatus (Pdb accession code 2hsd), subfamily cD1d (Kallberg
et al., 2002); 17-beta-hydroxysteroid dehydrogenase 4 (UniProtKB/Swiss-Prot P51659 (DHB4_HUMAN)) from Homo
sapiens, subfamily cD1d (Persson et al., 2003); 17-beta-hydroxysteroid dehydrogenase 14 (UniProtKB/Swiss-Prot
Q9BPX1(DHB14_HUMAN)) from Homo sapiens; subfamily cD1d; Corticosteroid 11-beta-dehydrogenase isozyme 2
(UniProtKB/Swiss-Prot P80365 (DHI2_HUMAN)) from Homo sapiens; subfamily cD3 (Persson et al., 2003); Estradiol
17-beta-dehydrogenase 12 (UniProtKB/Swiss-Prot Q53GQ0(DHB12_HUMAN) from Homo sapiens, subfamily cP2;
Carbonyl reductase (Pdb accession code 1cyd) from mus musculus, subfamily cP3 (Kallberg et al., 2002); UDP-galactose
4-epimerase (UniProt/KB/Swiss-Prot Q14376 (GALE_HUMAN)) from Homo sapiens, subfamily eD1 (Kallberg et al.,
2002); R-specific alcohol dehydrogenase (UniProt/KB/Swiss-Prot Q84EX5 (Q84EX5_LACBR) from Lactobacillus brevis,
subfamily eP1 or cP2. This sequence alignment was carried out using the programme ClustalW (Chenna et al., 2003).
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The classical short chain dehydrogenases/reductases 3α,20β-hydroxysteroid 
dehydrogenase and 17-beta-hydroxysteroid dehydrogenase 4 belong both to the cD1d
subfamily (Kallberg et al., 2002) as they are NAD(H) specific and contain an acidic
amino acid, aspartic acid, at key position 36 (Persson et al., 2003) (Table 11). Another
member of this subfamily is 17-beta-hydroxysteroid dehydrogenase 14. Corticosteroid
11-beta-dehydrogenase isozyme 2 can be identified as a member of the cD3 subfamily
of classical SDRs (Persson et al., 2003) because it is NAD(H) dependent and contains
an acid residue, glutamic acid, at key position 38 (Table 11) (Kallberg et al., 2002).
Estradiol 17-beta-dehydrogenase 12 can be classified into the cP2 subfamily of
classical short chain dehydrogenases/reductases as it can be NADP(H) specific (see
http://srs.ebi.ac.uk/srsbin/cgi-bin/wgetz?-e+[UNIPROT:DHB12_HUMAN]+-newId)
and contains a basic residue, arginine, at key position 37 (Table 11) (Persson et al.,
2003). Carbonyl reductase is an example for a representative of the cP3 subfamily of
classical SDRs (Kallberg et al., 2002). It prefers NADP(H) and there are basic amino
acids at both key positions, a lysine at position 15 and an arginine at position 37
(Table 11) (Kallberg et al., 2002). UDP-galactose 4-epimerase which is an NAD(H)
dependent (Thoden et al., 1996; Kallberg et al., 2002) member of the extended family
(Kallberg et al., 2002) belongs to the eD1 subfamily as it contains an acidic amino
acid, aspartic acid, at key position 33 (Table 11) (Kallberg et al., 2002).
R-specific alcohol dehydrogenase from Lactobacillus brevis could be classified into
either the eP1 subfamily of extended short chain dehydrogenases/reductases or the
eP2 subfamily of classical SDR enzymes. It contains the basic amino acid Arg (key
position 37 in 3α,20β-hydroxysteroid dehydrogenase and 34 in UDP-galactose 
4-epimerase) (Table 11) and is NADP(H)-dependent (Schlieben et al., 2005). Both
features are specific for those subfamilies. It has been referred to as the extended SDR
family (Schlieben et al., 2005).
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However, the glycine rich motif Thr-Gly-Gly-Thr-Leu-Gly-Ile-Gly resembles the
conserved Thr-Gly-X-X-X-Gly-h-Gly motif, which occurs in the classical SDR family
(Persson et al., 2003), and also the subunit length of about 250 amino acids is a
common feature of classical short chain dehydrogenases/reductases (Jörnvall et al.,
1995; Persson et al., 2003). That is why this enzyme belongs to the cP2 subfamily of
classical SDRs rather than to the extended family.
Members of the classical family have a higher preference for NADP(H) than NAD(H)
correlated with higher preference for reduction. Most extended SDRs, unlike the
classical ones, prefer NAD(H) as their coenzyme suggesting that the extended
SDR-family probably comprises more dehydrogenases than reductases (Kallberg et
al., 2002).
2.2.3 ADP-L-glycero-D-mannoheptose 6-epimerase (AGME)
2.2.3.1 Biosynthetic pathway of ADP-L-glycero-D-mannoheptose
Two membranes occur in Gram-negative bacteria which divide the cytoplasm
from the milieu outside of the cell. One of them is the cytoplasmic membrane and the
other one the outer membrane (Deacon et al., 2000; Osborn et al., 1972).
The cytoplasmic membrane is composed of two layers of phospholipids. The outer
membrane contains two parts. In the outer part one can find a specific lipid called
lipopolysaccharide. The bacterial lipopolysaccharide itself is composed of
lipid A, the core and the O-antigen determinants.
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The core domain is structured in two parts. The outer part contains six carbon sugars
and N-acetylglucosamine, whereas the inner one contains the 7 C sugar
L-glycero-D-mannoheptose (or heptose) and 2-keto-3-deoxyoctulosonic acid
(Kneidinger et al., 2002; Deacon et al., 2000; Reeves et al., 1996; Raetz and
Whitfield, 2002). L-glycero-D-mannoheptose as part of the core domain of
lipopolysaccharide shows a high degree of conservation among a great number of
Enterobacteriaceae and other Gram-negative bacteria (Deacon et al., 2000; Adams et
al., 1967). Lipopolysaccharide is involved in keeping the integrity of the structure of
the outer membrane whereby it associates with other components (Kneidinger et al.,
2002; Deacon et al., 2000). It also protects the organism against destructive intruders
and a few bacteria infecting viruses (Deacon et al., 2000; Coleman and Leive, 1979).
In mutants which do not have heptose, nonpolar compounds can penetrate more easily
through the outer membrane. These mutants also show less pathogenicity (Deacon et
al., 2000; Taylor, 1983). As a consequence the lipopolysaccharide biosynthetic
pathway represents an interesting target for antimicrobial compounds (Deacon et al.,
2000).
ADP-D-glycero-D-mannoheptose and ADP-L-glycero-D-mannoheptose are
interconverted in the final reaction in the biosynthetic route of the precursor of
heptose (Figure 45) carried out by ADP-β-L-glycero-D-mannoheptose 6-epimerase  
(AGME) (Deacon et al., 2000; Eidel and Osborn, 1974; Raetz, 1990; Coleman, 1983;
Pegues et al., 1990).
In the first reaction of this pathway an isomerisation of sedoheptulose 7-phosphate
to D,D-Hep 7-phosphate catalysed by GmhA occurs. This sugar is then
phosphorylated to give β-D,D-Hep 1,7-bisphosphate. This step is catalysed by 
HldE, an enzyme which is involved in two different reactions.
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It displays kinase activity and also acts as an aldenylyltranferase in a later reaction in
this pathway. Then cleavage of the phosphate group from the carbon at position 7 of
β-D,D-Hep 1,7-bisphosphate takes place, carried out by the phosphatase GmhB, to  
form β-D,D-Hep 1-phosphate. ADP-D,D-Hep is then generated from β-D,D-Hep 
1-phosphate by the action of again, HldE. The formation of ADP-L,D-Hep due to a
reversible epimerisation reaction carried out by ADP-β-L-glycero-D-mannoheptose  
6-epimerase represents the last step in the biosynthesis of the heptose precursor.
L,D-Hep is then added to the growing lipopolysaccharide which is mediated by
heptosyltransferases (Morrison and Tanner, 2007; Kneidinger et al., 2002; Valvano et
al., 2002, Morrison et al., 2005).
Figure 45. (after Morrison and Tanner, 2007) Biosynthetic pathway of ADP-L-glycero-D-mannoheptose. The reaction
carried out by ADP-β-L-glycero-D-mannoheptose 6-epimerase is surrounded with a box.
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2.2.3.2 AGME, a member of the SDR superfamily
In the early 1980s, activity of ADP-β-L-glycero-D-mannoheptose 6-epimerase was 
detected for the first time in extracts of the Escherichia coli strain K-12
(Deacon et al., 2000; Coleman, 1983). About ten years later the RfaD gene which
encodes AGME was cloned (Deacon et al., 2000). Partial purification of the enzyme
was then performed and it was demonstrated that its aminoterminus comprises the
highly conserved motif Gly-Gly-X-Gly-X2-Gly, involved in the interaction with ADP
of the cofactor (Deacon et al., 2000; Pegues et al., 1990; Wierenga et al., 1986). In
2001, it was demonstrated that AGME displays specificity to nicotinamide adenine
dinucleotide phosphate. It is also able to be active in the presence of NAD instead of
NADP, however, activity is then significantly lower. The apo-form of AGME is
inactive (Deacon et al., 2000; Ni et al., 2001).
Due to the fact that AGME is present in various Gram-negative bacteria and not in
mammals, it represents a target for the design of novel antimicrobial
compounds. AGME is a pentameric enzyme which contains five identical subunits.
Each of them is composed of two domains (Deacon et al., 2000). The aminoterminal
domain is composed of a modified Rossmann fold (Rossmann et al., 1974) with seven
parallel β-strands in the centre. These are decorated on either side by seven α-helices.  
This domain is involved in the tight association with the coenzyme. The smaller
carboxyterminal domain contains three α-helices and two small parallel β-strands  
(Figure 46). This part of the structure is involved in the interaction with the substrate,
which associates with residues of the cleft formed by both domains (Deacon et al.,
2000).
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Figure 46. Ribbon diagram of AGME from the E. coli strain K12 (Pdb aceession code 1eq2) (based on Deacon et al., 2000)
α-helices are shown in cyan, β-strands in magenta, and loops in pink. The seven parallel β-sheets in the centre, decorated
by seven α-helices on either side represent the characteristic Rossmann fold. The carboxyterminal domain is composed of 
a small α/β domain, which plays a role in the interaction with the substrate. NADP and the inhibitor ADP-glucose are 
shown as sticks (Deacon et al., 2000). This figure has been produced using PyMol (DeLano, 2007).
AGME shows structural similarities to other members of the SDR family, such as
UDP-galactose 4-epimerase (UGE, Pdb accession codes 1nah and 1nai) (Thoden et al.,
1996). The overall rms deviation between both structures is 1.88 Å for 238 Cα 
positions considered equivalent (Deacon et al., 2000) (Figure 47).
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(A) Stereo view of Cα tracing of AGME from E. coli (in cyan, Pdb accession code 1eq2) and UGE from E. coli
db accession code 1nah) after their superposition (based on Deacon et al., 2000). (B) Ribbon diagrams of both
after their superposition (stereo view). This figure has been produced using PyMol (DeLano, 2007).
om UGE, AGME also displays similarity to dTDP-D-glucose 4,6 dehydratase
Pdb accession code 1bxk) with an rmsd of 1.85 Å for 237 Cα positions 
et al., 2000), and GDP-4-keto-6-deoxy-D-mannose epimerase/reductase
, Pdb accession code 1bws) (Rizzi et al., 1998; Somers et al., 1998) with an
iation of 2.14 Å for 226 Cα positions (Deacon et al., 2000).
B
N N
79
The crucial amino acids in the catalytic region of UGE show a high degree of
conservation in AGME. In ADP-β-L-glycero-D-mannoheptose 6-epimerase 
Ser116, Tyr140 and Lys144 represent the catalytic triad (Deacon et al., 2000).
2.2.3.3 Reaction mechanism of AGME
It has been reported that ADP-β-L-glycero-D-mannoheptose 6-epimerase operates at 
an “unactivated” stereogenic centre which misses an acidic carbon-hydrogen
connection (Tanner and Morrison, 2007; Morrison et al., 2005; Samuel and Tanner,
2002; Tanner, 2002; Read et al., 2004). This rules out a mechanism based on
H+-abstraction and readdition at the site where inversion occurs (Morrison and Tanner,
2007; Morrison et al., 2005; Read et al., 2004). However, AGME shows a tight
interaction with nicotinamide adenine dinucleotide phosphate and is a short chain
dehydrogenase/reductase (Morrison and Tanner 2007; Morrison et al., 2005; Read et
al., 2004; Ding et al., 1994; Deacon et al., 2000; Ni et al., 2001). This suggests that
during epimerisation the substrate is transiently oxidised (Morrison and Tanner, 2007;
Morrison et al., 2005; Read et al., 2004). The fact that ADP-β-D-manno-hexodialdose
1 could be reduced to the alcohol ADP-β-mannose and oxidised to the acid
ADP-β-mannuronate in a 1:1 ratio in the presence of
ADP-β-L-glycero-D-mannoheptose 6-epimerase showed that in the reaction 
mechanism of AGME a redox step at the carbon at position 6 of a nucleotide sugar
takes place (Figure 48) (Morrison et al., 2005; Morrison and Tanner, 2007).
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Figure 48. (after Morrison et al., 2005 and Morrison and Tanner, 2007) The dismutation of ADP-β-D-manno-hexodialdose
employed by AGME.
A mechanism for AGME has been proposed including transient oxidation of
ADP-D,D-heptose at the carbon at position 6 to form a 6″-keto intermediate 
(Morrison and Tanner, 2007) (Figure 49). It has been suggested that two pockets have
to be present, and each of them is able to bear either the OH- or HCOH-substituent at
position 6. There is an acid/base amino acid at each site which has the ability to
abstract a proton from the C-6″-OH of the substrate or the product in the oxidative 
part of the reaction. The C=O of the keto-intermediate undergoes a flip to the other
site, caused by a rotation about the C-5″-C-6″ bond (Morrison and Tanner, 2007; 
Morrison et al., 2005) and the second acid/base adds H+ to the C=O in the reduction
step on the opposite face. To accomplish H--transfer during this reaction each of both
epimers have to bind to the catalytic side in such a way that the H- at C-6″ of the sugar 
moiety is orientated toward the coenzyme (Morrison and Tanner, 2007; Morrison et
al., 2005).
O
HO
OH
HO
OADP
HO
OH
hydrated aldehyde 1
O
HO
OH
HO
OADP
O-
O
Epimerase .
NADP+
Epimerase .
NADPH
O
HO
OH
HO
OADP
H
O
aldehyde 1
O
HO
OH
HO
OADP
OH
ADP--mannose
ADP--mannuronate
81
Figure 49. (after Morrison and Tanner, 2007) Proposed two-base mechanism for the reaction carried out by AGME. B1
and B2 are catalytic site acid/base amino acids. The hydrated form of ADP-β-D-mannohexodialdose 1 bound in the
catalytic region is boxed.
To support this hypothesis, mutational studies were performed to find out which
residues are candidates to function as the catalytic acid/base (Morrison and Tanner,
2007). These studies revealed that Tyr140 and Lys178 are the crucial amino acids,
involved in catalysis as Y140F and K178 are inactive.
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This indicates that “a non-stereospecific reduction of the ketone intermediate that
leads to epimerization” (Morrison and Tanner, 2007) can only take place when both
residues are present. Both mutants, however, were still able to dismutate
ADP-β-D-manno-hexodialdose which shows that only one base is needed for the
dismutation reaction (Morrison and Tanner, 2007). “One of the two stereoselective
hydride transfers” (Morrison and Tanner, 2007) can still be carried out. The fact that
the Y140F/K178M mutant could not even perform dismutation proved that at least
one catalytic amino acid has to be present to perform H--transfer (Morrison and
Tanner, 2007).
It has been proposed that the Tyr always functions as the catalytic base which
abstracts the H+ of the OH-group to oxidise an alcohol (or adds H+ to the C=O when
reduction takes place) (Morrison and Tanner, 2007). It has been suggested that Tyr
directly abstracts H+ from the substrate (Naismith, 2006; Morrison and Tanner, 2007),
however, it has also been proposed that H+-shuttling, in which the catalytic Ser plays a
role, may take place (Liu et al., 1997; Berger et al., 2001; Morrison and Tanner, 2007).
In dTDP-6-deoxy-L-lyxo-4-hexulose reductase, for instance (Blankenfeldt et al.,
2002), H- are transported to only one face of the C=O group. In epimerases, however,
which prefer to transfer H- directly, an H- has to be transported to both faces of the
C=O intermediate (Morrison and Tanner, 2007).
2.3 Project aims
Studies on the catalytic mechanism of ADP-β-L-glycero-D-mannoheptose 
6-epimerase revealed that the amino acids Tyr140 and Lys178 operate as acid/base
residues. However it still remains unclear which amino acid abstracts H+ from the
OH-group of ADP-D-glycero-D-mannoheptose or ADP-L-glycero-D-mannoheptose.
The crystal structure of AGME with ADP-α-D-glucose bound (Deacon et al., 2000)
suggests that Tyr140 abstracts H+ from ADP-L-glycero-D-mannoheptose, whereas
Lys178 could perform H+-abstraction from ADP-D-glycero-D-mannoheptose.
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However, it cannot be concluded from this structure, at which site oxidation takes
place (Morrison and Tanner, 2007). The fact that the glucose moiety of the nucleotide
sugar is not well defined in most of the subunits in the asymmetric unit of the AGME
structure makes this difficult (Morrison and Tanner, 2007). Furthermore, the hexose is
orientated differently in the catalytic sites of the monomers, in which
ADP-α-D-glucose has been modelled in (Deacon et al., 2000; Morrison and Tanner, 
2007). The reason for that is probably the difference in the stereochemistry between
ADP-α-D-glucose and ADP-β-L-glycero-D-mannoheptose at C-1″ and at C-2″ as well 
(Figure 50) (Morrison and Tanner, 2007; Morrison et al., 2005) . Further experiments
are therefore needed to elucidate the exact roles of Tyr140 and Lys178 in the
epimerisation process of AGME (Morrison and Tanner, 2007). One approach to
achieve this is to determine the crystal structure of HldD in complex with a sugar
nucleotide in the β-manno configuration. One such a sugar is ADP-β-mannose (Figure 
50), the reduced product (alcohol) in the dismutation reaction (Morrison and Tanner,
2007; Morrison et al., 2005). This sugar, provided by our collaborators Martin Tanner
and James Morrison at the University of British Columbia, Vancouver, Canada, was
used in my crystallographic studies.
Figure 50. Structures of ADP-α-D-glucose, ADP-β-L-glycero-D-manno-heptose and ADP-β-D-mannose. 
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Molecular biology, expression, purification
crystallisation and Isothermal Titration
Calorimetry (ITC) of AGME and
mutant Y140F
Summary
This section describes molecular biological methods, protein expression, purification,
crystallisation and Isothermal Titration Calorimetry (ITC) of AGME and the AGME
mutant Y140F.
2.4 Molecular biology
2.4.1 Sub-cloning of hldD into pEHISTEV
The hldD gene (UniProtKB/TrEMBL entry P67910) from E. coli K-12 W3110
comprising 933 bp, cloned into the pET-30Xa/LIC vector (Novagen) (see Appendix)
(Morrison et al., 2005) was provided by our collaborators Martin Tanner and James
Morrison from the University of British Columbia, Vancouver, Canada.
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A design of forward and reverse primers was carried out to add the appropriate
restriction endonuclease cleavage sites. This is necessary to clone hldD into the
expression plasmid pEHISTEV (see Appendix) (Liu and Naismith, 2009).
An NcoI site was introduced at the start of hldD (forward primer 5’ –
GAGGGTCCCATGGTCATCGTTACC – 3’). Right at the end of the open reading
frame, after the stop codon, an XhoI site was incorporated (reverse primer 5’ –
GGAGAGCTCGAGCCTTATGCGTC – 3’). A Polymerase Chain Reaction (PCR)
was performed using 1μM of each oligonucleotide and 1.5 U of Pfu DNA polymerase 
(Promega) (Table 12).
Table 12. Details of the PCR reaction for the amplification of hldD. The reaction was carried out in the GeneAmp® PCR
System 2400 thermal cycler (Applied Biosystems)
Reagent Amount/concentration of stock solution final concentration/ PCR programme
sterile H2O   38.5 μl                                       amount
2 min, 95 ºC
Pfu buffer     5 μl              10x                         1 x          30 sec, 95 ºC
(+MgSO4) 30x 30 sec, 55 ºC
dNTP Mix     1 μl              10 mM                     0.2 mM             2 min/kb, 72 ºC
(dATP,dTTP, 10 min, 72 ºC
dGTP,dCTP)
forward primer  1 μl              50 μM                      1μM   
reverse primer   1 μl              50 μM                      1μM 
template DNA   3 μl              89 ng/μl                     267 ng 
Pfu DNA      0.5 μl              3 U/μl                       1.5 U 
Polymerase
Electrophoresis on a 1 % agarose gel confirmed the 956 bp PCR product (Figure 51).
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Figure 51. PCR product of hldD from pET-30 Xa/LIC. Lane 1: 1 kbp ladder; lane 2: amplified 956 bp PCR product
The amplified hldD fragment was excised from the 1 % agarose gel according to the
protocol provided in the QIAquickTM Gel Extraction Kit (Qiagen). 50 μl sterile water 
was used to elute the DNA from the spin column. Then a restriction digest of eluted
amplified hldD and the pEHISTEV plasmid (provided by Huanting Liu) using NcoI
and XhoI (New England BioLabs® Inc.) was performed in a water bath for 3.5 hours
at 37 ºC (Table 13).
Table 13. Reagents used in the restriction digest of amplified hldD and pEHISTEV
Reaction 1: Reaction 2:
2 μl buffer D (10x)                    2 μl buffer D (10x)
0.2 μl acetylated BSA (10 μg/ml)         0.2 μl acetylated BSA (10 μg/ml)
15 μl amplified hldD                   15 μl pEHISTEV 
1.8 μl H2O                           1.8 μl H2O
0.5 μl NcoI                           0.5 μl NcoI
0.5 μl XhoI                           0.5 μl XhoI
1500 bp
1000 bp
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The double digested gene and vector as well were then solution cleaned, following the
protocol provided in the QIAquickTM Gel Extraction Kit (Qiagen) to remove the
restriction endonucleases and buffers. Ligating the hldD fragment into the pEHISTEV
vector, which contains a kanamycin resistance marker was the next step. Ligation was
carried out overnight at 4 ºC with 3U of T4 DNA Ligase (Promega) using an insert to
vector ratio of 3 : 1. TAM1 and JM109 competent E. coli cells were then transformed
with the ligation mixture and plated onto agar plates containing 50 μg/ml kanamycin 
(Melford). Amplification reactions with the T7 forward and reverse primers were
carried out for the identification of the colonies with the pEHISTEV plasmid and the
inserted hldD gene. Colonies were picked from a kanamycin containing agar plate and
suspended in 10 μl sterile water filled into PCR tubes. The samples were then boiled 
for 5 min at 100 ºC and centrifuged. After that 5μl of sample were taken out of each of 
the tubes and transferred to sterile ones. The amplification reactions were performed
using 0.5 μM of each oligonucleotide and 1.36 U of GoTaq® DNA-Polymerase
(Promega) (Table 14).
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Table 14. Details of the PCR reactions for the amplification of hldD cloned into pEHISTEV. Reactions were carried out in
the GeneAmp® PCR System 2400 thermal cycler (Applied Biosystems)
“Master Mix” for 25 reactions
Reagent Amount/concentration of stock solution final concentration/ PCR programme
sterile H2O   139.1 μl                                   
GoTaq® DNA   1.9 μl             5 U/μl                    1.36 U         2 min, 95 ºC
Polymerase 20 sec, 95 ºC
GoTaq® Green   70 μl              5x                        1x       30x 50 sec, 46 ºC
Reaction Buffer 1 min, 72 ºC
dNTP Mix        7 μl        10 mM 0.2 mM 5 min, 72 ºC
(dATP,dTTP,
dGTP,dCTP)
T7 forward primer  3.5 μl           50 μM                    0.5 μM   
T7 reverse primer   3.5 μl           50 μM                    0.5 μM 
9 μl of “Master Mix” were added to each of the 22 PCR tubes 
Of 22 colonies screened 3 were confirmed as containing the 1 kb hldD fragment
(“clones 1, 2 and 3”). Restriction analysis and DNA sequencing (University of
Dundee Sequencing service) were also carried out to identify the presence of the hldD
insert in pEHISTEV (Table 15 and Figure 52).
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Table 15. Reagents used in the restriction digest
Reaction 1: Reaction 2: Reaction 3:
1 μl buffer D (10x)                  1 μl buffer D (10x)                1 μl buffer D (10x)
0.1 μl acetylated BSA (10 μg/ml)   0.1 μl acetylated BSA (10 μg/ml)       0.1 μl acetylated BSA (10 μg/ml)
5 μl “clone 1”                      5 μl “clone 2”                       5 μl “clone 3” 
1.9 μl H2O                        1.9 μl H2O                          1.9 μl H2O
1 μl NcoI                          1 μl NcoI                           1 μl NcoI
1 μl XhoI                          1 μl XhoI                           1 μl XhoI
1 2 3 4
Figure 52. Restriction analysis with NcoI and XhoI confirming the insertion of hldD into pEHISTEV.
Lane 1: “clone 1” : lane 2: “clone 2”; lane 3: “clone 3”; lane 4: 1 kbp DNA ladder
The hldD gene was sequenced to make sure that no nucleotide substitutions had been
introduced. The hldD-pEHISTEV construct was purified from 10 ml overnight
cultures of the TAM1 or JM109 transformed E. coli cells grown in Luria-Bertani (LB)
media (Formedium) containing 50 μg/ml kanamycin at 37 ºC. The plasmid DNA was 
then purified according to the QIAprep Spin Miniprep Kit Protocol using a
microcentrifuge (Qiagen).
~ 5400 bp vector
~ 1000 bp insert
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2.5 Protein expression
E. coli cells BL21 (DE3), C43 (DE3), Rosetta (DE3) and BL21 (DE3) pLysS were
transformed with hldD-pEHISTEV and hldD-pET-30 Xa/LIC vector DNA for
overexpression of the hldD gene. Colonies of these cells were inoculated in various 10
ml overnight cultures of Luria Bertani media containing kanamycin and also
chloramphenicol (Sigma) (only in the case of Rosetta (DE3) and BL21 (DE3) pLysS),
at a final concentration of 50 μg/ml and 34 μg/ml, respectively. Growing of these 
starter cultures was performed overnight at 37 ºC in a shaking incubator (InnovaTM
4430, New Brunswick) at 200 rpm. The next day, inoculation of 10 ml of pre-warmed
LB (supplemented with 50 μg/ml kanamycin and 34 μg/ml chloramphenicol) with 100 
μl overnight culture was carried out. These 10 ml cultures were then grown at 37 ºC in 
a shaking incubator at 200 rpm. E. coli cells were grown until an optical density
(A600nm) of 0.4-0.8 (Helios Unicam Spectrophotometer). Then cells were induced
with Isopropyl β-D-thio-galactopyranoside (IPTG) (Melford) in a range of 
concentrations between 0.2 and 2 mM and grown for a further 12 hours at 37 ºC or at
a lower temperature at 25 ºC or 16 ºC. In some experiments (see Table 16) tubes
containing the growing cells were put on ice for 10 min (“cold shocked”) or in a
waterbath at 42 ºC for 10 min (“heat shocked”) and then cells were induced with IPTG.
The media were then centrifuged for 20 min at 3000 rpm (Heraeus Labofuge 400,
DJB labcare) at 4 ºC and the supernatants discarded. Then the pelleted cells were
resuspended in 500 μl BugBuster® Protein Extraction Reagent (Novagen) The 
resuspended cells were then spun at 3000 rpm for 25 min at 4 ºC and the supernatants
collected. Crude extracts and supernatants were mixed with sample buffer (Invitrogen
NuPageTM LDS 4x sample buffer) and denatured for 5 min at 100 ºC.
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Then they were loaded onto a Sodium Dodecyl Sulfate (SDS) polyacrylamide gel
(Invitrogen NuPageTM 4-12 % Bis-Tris Gels, 1 mm x 10, 12 or 17 wells) and run for
40 min at 200 V (1x MES buffer, Invitrogen NuPAGE MES SDS Running Buffer (for
Bis-Tris Gels only) (20X)). SDS-PAGE gels were then stained in a Coomassie blue
staining solution for approximately 10 min. For destaining, gels were then put into a
beaker containing hot water and boiled for about 10 min in a microwave. After this
procedure the gels were dried with the DryEASE Kit (Invitrogen). An overview of all
expression trials carried out is demonstrated in Table 16. The highest amount of
soluble AGME was observed when E. coli BL21 (DE3) [pET-30 Xa/LIC-hldD] and
[pET-30 Xa/LIX-hldD-Y140F] (Figure 53A, B) (pET-30 Xa/LIC-hldD-Y140F was
also provided by our collaborators in Canada) or E.coli BL21 (DE3) pLysS
[pEHISTEV-hldD] (Figure 53C), grown in LB media until an A600nm = 0.7, were
induced with 0.2 mM IPTG. Then the temperature was decreased to 25 ºC for soluble
protein expression overnight. The same conditions for soluble expression were
repeated in a large scale for purification.
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Table 16. Overview of performed expression trials. Conditions of best soluble AGME expression are highlighted.
E. coli strain temperature expression vector IPTG [mM]
heatshock (hs)
cold shock (cs)
no shock (ns)
solubility:
soluble (s)
insoluble (i)
BL21 (DE3) 37 ° C pEHISTEV 0.2 ns i
BL21 (DE3) 37 ° C pEHISTEV 0.5 ns i
BL21 (DE3) 37 ° C pEHISTEV 1 ns i
BL21 (DE3) 37 ° C pEHISTEV 2 ns i
BL21 (DE3) 25 ° C pEHISTEV 0.2 ns i
BL21 (DE3) 25 ° C pEHISTEV 0.5 ns i
BL21 (DE3) 25 ° C pEHISTEV 1 ns i
BL21 (DE3) 25 ° C pEHISTEV 2 ns i
BL21 (DE3) 25 ° C pEHISTEV 0.5 hs i
BL21 (DE3) 25 ° C pEHISTEV 0.5 cs i
BL21 (DE3) 16 ° C pEHISTEV 0.2 ns i
BL21 (DE3) 16 ° C pEHISTEV 0.5 ns i
BL21 (DE3) 16 ° C pEHISTEV 0.2 hs i
BL21 (DE3) 16 ° C pEHISTEV 0.2 cs i
BL21 (DE3) 16 ° C pEHISTEV 0.5 hs i
BL21 (DE3) 16 ° C pEHISTEV 0.5 cs i
BL21 (DE3) 37 ° C pET-30 Xa/LIC 0.2 ns s
BL21 (DE3) 37 ° C pET-30 Xa/LIC 0.5 ns s
BL21 (DE3) 25 ° C pET-30 Xa/LIC 0.2 ns s
BL21 (DE3) 16 ° C pET-30 Xa/LIC 0.2 ns s
C43 (DE3) 37 ° C pEHISTEV 0.2 ns i
C43 (DE3) 37 ° C pEHISTEV 0.5 ns i
C43 (DE3) 37 ° C pEHISTEV 1 ns i
C43 (DE3) 37 ° C pEHISTEV 2 ns i
C43 (DE3) 25 ° C pEHISTEV 0.2 ns i
C43 (DE3) 25 ° C pEHISTEV 0.5 ns i
C43 (DE3) 25 ° C pEHISTEV 1 ns i
C43 (DE3) 25 ° C pEHISTEV 2 ns i
C43 (DE3) 25 ° C pEHISTEV 0.5 ns i
C43 (DE3) 25 ° C pEHISTEV 0.5 ns i
Ros. (DE3) 37 ° C pEHISTEV 0.2 ns i
Ros. (DE3) 37 ° C pEHISTEV 0.5 ns i
Ros. (DE3) 37 ° C pEHISTEV 0.2 ns i
Ros. (DE3) 16 ° C pEHISTEV 0.5 ns i
Ros. (DE3) 16 ° C pEHISTEV 0.2 ns i
BL21 (DE3) pLysS 37 ° C pEHISTEV 0.5 ns s
BL21 (DE3) pLysS 37 ° C pEHISTEV 0.2 ns s
BL21 (DE3) pLysS 25 ° C pEHISTEV 0.2 ns s
BL21 (DE3) pLysS 16 ° C pEHISTEV 0.2 ns s
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2.6 Purification of recombinant AGME and AGME Y140F
About 30g of cell pellets, frozen at -80 ºC after expression, were resuspended in 30-35
ml sample buffer containing 20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 5 mM
Imidazole, 1 % Triton X-100 and one Complete EDTA free Protease Inhibitor
Cocktail Tablet (Roche). Then DNAse was added to this buffer which leads to a
degradation of the E. coli DNA. Lysis of the cells was performed by sonication (MSE
Soniprep 150). The lysate was then centrifuged at 7,000 rpm for 20 min at 4 ºC
(Beckman CoulterTM AvantiTM J-20 XP). About 30 ml of supernatant were transferred
to a 50 ml tube and kept on ice. Remaining pellets were resuspended in about 30 ml
sample buffer and again sonicated. After that procedure, centrifugation at 7,000 rpm
for 20 min at 4 ºC was also performed again. This time the fraction was discarded.
The supernatant and the previous supernatant fraction, kept on ice, were pooled and
spun at 22,000 rpm for 35 min. The supernatant obtained after this centrifugation step
was filtered (0.2 μM filter, Millipore) and loaded onto a 5 ml Ni2+ column (HisTrap
HPTM, Amersham Biosciences) pre-equilibrated with sample buffer. After the flow
through had been collected about 10 column volumes (50 ml) of washing buffer (20
mM Tris-HCl, pH 8.0, 500 mM NaCl, 20 mM Imidazole) were applied to the Ni2+
column. This step was performed to remove any proteins not bound to the column.
The next step was the elution of the hexa-histidine tagged AGME with about 50 ml of
elution buffer (20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 300 mM Imidazole). All the
fractions obtained during this first purification step were analysed by SDS-PAGE
(Figure 54).
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After the protein sample had been applied to the column elution of AGME over a
gradient during which the concentration of buffer B increased (0-30 % buffer B,
length: 5 column volumes; 30-100 % buffer B, length: 25 column volumes) was
performed. Eluted enzyme fractions were analysed by SDS-PAGE (Figure 55).
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2.6.1 Preparation and reconstitution of apo-AGME
2.6.1.1 Preparation of apo-AGME (based on Gomi et al., 1989)
Gomi and coworkers performed a treatment of rat liver S-adenosylhomocysteinase
with acidic (NH4)2SO4 to separate this enzyme from its cofactor NAD. The intention
of this experiment was to obtain the apoenzyme for further exploring the associations
of this protein with its cofactor (Gomi et al., 1989). Ni et al., 2001 also used the same
method to obtain apo-AGME. After reconstitution of AGME with either NAD+,
NADP+ or FAD they confirmed that AGME prefers NADP+ as cofactor. (Ni et al.,
2001) The same methods of apoenzyme preparation and reconstitution with cofactor
was also applied to my AGME sample to get the holoenzyme with homogeneous
cofactor (NADP+) content.
Firstly, after ADP-β-L-glycero-D-mannoheptose 6-epimerase in 20 mM Tris-HCl, pH 
7.0, 50 mM NaCl and 1 mM DTT, stored at -80 ºC, had been thawed on ice, saturated
acidic (NH4)2SO4 (adjusted to pH 3.0 with concentrated H2SO4 ) was added to the
sample in a ratio of 3:1. Then the mixture was stirred for about half an hour at 4 ºC.
After this procedure centrifugation at 22,000 rpm for 20 min at 4 ºC was performed.
Then the supernatant was discarded and the pellet carefully resuspended in 20 mM
Tris-HCl, pH 7.0, 50 mM NaCl and 5 mM DTT. After the enzyme had been mixed
with acidic (NH4)2SO4 for a second time, stirred and spun again, the pellet was gently
resuspended in neutral (NH4)2SO4 containing 5 mM DTT. This mixture was then
centrifuged at 25,000 rpm for 30 min at 4 ºC. The supernatant was discarded and the
precipitated protein kept on ice overnight. The following day the pellet was gently
dissolved in 20 mm Tris-HCl, pH 7.0, concentrated, filtered and applied to a HiPrepTM
26/10 Desalting column (Amersham Biosciences). This step, performed on the
ÄKTAxpress, (Amersham Biosciences) removes any traces of ammonium sulfate and
DTT.
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2.6.1.2 Reconstitution of apo-AGME (based on Ni et al., 2001)
The desalted apo-enzyme was then concentrated again. Incubation of 100 or 200 μM 
NADP+ (Sigma) at room temperature for one hour was then carried out. After that the
reconstituted protein was dialysed against 1 L of 20 mM Tris-HCl buffer pH 7.0
overnight at 4 ºC to remove any unbound cofactor. The next morning the dialysed
sample was concentrated to about 5 mg/ml, filtered and loaded onto a HiPrepTM 16/60
SephacrylTM S-200 size exclusion column. This step was carried out to ensure a
complete separation of holo- and apo-HldD. Finally the reconstituted AGME was
concentrated to about 4.1 mg/ml, aliquoted into PCR tubes, snap frozen in liquid
nitrogen and again stored at -80 ºC until further usage.
2.7 Crystallisation
Prior to crystallisation attempts, AGME samples at concentrations of 4.1mg/ml and/or
7 mg/ml which had been stored at -80 ºC were thawed on ice and spun for 5 min at 4
ºC. ADP-β-D-mannose was then added to final concentrations between 1 and 6.6 mM. 
The samples were then incubated for 16 hours on ice or 2 hours at room temperature.
After that they were centrifuged at either 4 ºC (MSE Micro Centaur) or room
temperature (Heraeus Biofuge Pico) before use.
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2.7.1 Crystallisation of wildtype AGME
The crystallisation experiments were carried out using “grid screens” based on the
condition (2 M ammonium sulfate, 0.1 M HEPES-Na pH 7.5, 2 % PEG 400) in which
well diffracting AGME crystals in complex with ADP-α-D-glucose had been obtained 
(Ding et al., 1999). The sitting-drop vapour diffusion method was applied using
Douglas Instruments 96-well crystallisation plates (Douglas Instruments) at room
temperature. Protein and mother liquor were mixed in a ratio of 1:1 (1 μl + 1 μl, 
reservoir volume 100 μl). After the plates had been sealed they were incubated at 20 
ºC. However, none of the conditions yielded any crystals. For that reason AGME was
screened for other crystallisation conditions against the commercially available
96-condition screens, JCSG+ and Classics (GE Healthcare), using a nanodrop
crystallisation robot (Cartesian Honeybee X8+1, Genomic Solutions) on sitting drop
plates (Hampton Research CrystalQuickTM 96 wells, 4 μl square drop well, 3 drop 
well). The 288 wells on those plates allowed screening of two different concentrations
(well # 1, 4.1 mg/ml; well # 2, 7 mg/ml) and also of a distinct drop size (well # 3, 4.1
mg/ml in a protein:mother liquor ratio of 2:1) per crystallisation condition. Initial
crystals which appeared within one week were obtained under various different
conditions. Staining of those crystals with Izit Crystal Dye (Hampton Research)
confirmed that they were protein. The most promising looking crystallisation
conditions (Figure 58) were used for further optimisation experiments based on
different concentrations and pH values of the components of the mother liquor (see
Appendix).
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Figure 58. Crystals of AGME grown in presence of ADP-β-mannose (5-6.6 mM). 1: condition # 46 from JCSG+ screen; 2:
condition # 74 from Classics screen; 3: condition # 2 from JCSG+ screen; 4: condition # 78 from JCSG+ screen; 5:
condition # 5 from Classics screen
Crystals large enough for an X-ray diffraction experiment were obtained from the
condition 0.2 M Ca-Acetate, 0.1 M Na-cacodylate pH 6.5 and 35 % PEG 300 (starting
condition: JCSG+, condition # 46, see Appendix) (Figure 59) after approximately two
weeks.
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AGME at a concentration of 4.1 mg/ml was incubated with 10 mM ADP-β-mannose 
on ice overnight. Drops were made up manually by mixing 1.5 μl protein solution 
with 0.75 μl mother liquor (ratio 2:1) and the crystallisation plates were then 
incubated at 20 ºC.
Figure 59. Optimised crystals of AGME grown in presence of 6.6 mM ADP-β-mannose under the condition 0.2 M 
Ca-Acetate, 0.1 M Na-cacodylate pH 6.5 and 35 % PEG 300.
Cryoprotection of these crystals was not necessary due to the presence of a
cryoprotectant at a relatively high concentration (35 % PEG 300) in the mother liquor.
These crystals diffracted to about 3 Å resolution in-house. The “grid screen” based on
the condition 0.2 M CaCl2, 0.1 M HEPES-Na, pH 7.5 and 28 % PEG 800 (Classics #
74) only yielded fragile, poorly diffracting crystals. No improvement of the crystal
quality could be achieved with the other “grid screens” (see Appendix) either. Only
small, needle-shaped crystals ( Figure 58, 3-5) which diffracted very poorly appeared
after 1-3 days.
150 m150 m
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2.7.2 Crystallisation of wildtype AGME reconstituted with NADP+
Based on the results obtained from the crystallisation experiments carried out with
non-reconstituted AGME a “grid screen” (see Appendix) around condition # 46 of the
JCSG+ screen was set up again The protein solution was incubated with 5 mM
ADP-β-mannose for about 2 hours at room temperature. Again, drops were made up 
manually by mixing 1.5 μl protein solution with 0.75 μl mother liquor (ratio 2:1). 
Crystallisation plates were then incubated at 20 ºC. The largest crystals were again
obtained under the condition 0.2 M Ca-Acetate, 0.1 M Na-cacodylate pH 6.5 and
35 % PEG 300 (Figure 60) after 1-2 weeks.
Figure 60. Optimised crystals of reconsituted AGME grown in presence of 2.5 mM ADP-β-mannose under the condition 
0.2 M Ca-Acetate, 0.1 M Na-cacodylate pH 6.5 and 35 % PEG 300.
2.7.3 Crystallisation of AGME Y140F
The same “grid screen” (see Appendix) around condition # 46 of the JCSG+ screen
was set up to grow crystals of the mutant protein. AGME Y140F at a concentration of
4.1 mg/ml was incubated with 2 or 5 mM ADP-β-mannose for about 2 hours at room 
temperature.
150 m
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Drops were made up again manually by mixing protein solution with mother liquor in
a ratio of 2:1. Crystallisation plates were then incubated at 20 ºC. The best crystals
were grown again from 0.2 M Ca-Acetate, 0.1 M Na-cacodylate pH 6.5 and 35 %
PEG 300 (Figure 61) and appeared after around 3 weeks.
Figure 61. Optimised crystals of AGME Y140F grown in the presence of 2.5 mM ADP-β-mannose under the 
condition 0.2 M Ca-Acetate, 0.1 M Na-cacodylate pH 6.5 and 35 % PEG 300.
Additionally the mutant was also screened for new crystallisation conditions against
the commercially available 96-condition screens, JCSG+, Classics, PEGs and pH clear
(GE Healthcare), using the nanodrop crystallisation robot (Cartesian Dispensing
Robot Honeybee 963, Genomic Solutions) on sitting drop plates (Innovaplate™ SD-2
Crystallography Plate, Innovadyne Technologies, Inc.). The 192 wells on those plates
allowed screening of two different concentrations (well # 1, 4.1 mg/ml; well # 2, 7
mg/ml) per crystallisation condition. Initial crystals which appeared in a time range
between 2 days and 2 weeks were obtained under lots of different conditions. The
most promising looking crystallisation conditions (Figure 62) were again used for
further optimization experiments based on different concentrations and pH values of
the components of the mother liquor (see Appendix).
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Figure 62. Crystals of AGME Y140F grown in presence of ADP-β-mannose (2.5 mM). 1: condition # 67 from PEGs screen;
2: condition # 54 from PEGs screen; 3: condition # 76 from PEGs screen; 4: condition # 82 from Classics screen
5: condition # 73 from Classics screen
Good quality crystals were only grown from conditions of the “grid screen” around
condition # 73 of the Classics screen. The best diffracting crystals appeared over the
course of 1-2 weeks in drops containing 2 M (NH4)2SO4, 0.1 M HEPES-Na, pH 7.1,
2 % PEG 400 (Figure 63A) and 2 M (NH4)2SO4, 0.1 M HEPES-Na, pH 7.5, 2 % PEG
400, 10 mM Spermidine (Figure 63B). AGME Y140F at a concentration of 4.1 mg/ml
was incubated with 2 mM ADP-β-mannose at room temperature for about 2 hours. 
Drops were made up manually by mixing 1.5 μl protein solution with 1.5 μl mother 
liquor (ratio 1:1) and the crystallisation plates were then incubated at 20 ºC.
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Figure 63. Optimised crystals of AGME Y140F grown in presence of 1 mM ADP-β-mannose under the condition 2 M 
(NH4)2SO4, 0.1 M HEPES-Na, pH 7.1, 2 % PEG 400 (A) and 2 M (NH4)2SO4, 0.1 M HEPES-Na, pH 7.5, 2 % PEG 400, 10
mM Spermidine (B).
Cryoprotection of these crystals was performed in mother liquor containing 2 mM
ADP-β-mannose and 15 % glycerol before being flash frozen in liquid nitrogen.The 
“grid screens” around the other initial hits (crystallisation conditions PEGs # 67, # 54
and # 76 and Classics condition # 82), however, only yielded crystals which diffracted
poorly.
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2.8 Isothermal Titration Calorimetry (ITC) of AGME and
AGME Y140F with ADP-β-mannose 
2.8.1 Preparation of samples
2 ml of ADP-β-L-glycero-D-mannoheptose 6-epimerase at a concentration of 77 μM 
or ADP-β-L-glycero-D-mannoheptose 6-epimerase Y140F at a concentration of 100 
μM were dialysed in Thermo Scientific Slide-A-Lyzer Dialysis Cassettes (7 K 
MWCO or 10 K MWCO) for about 5 hours in 1 L buffer containing 20 mM Tris-HCl,
pH 7.0 and 50 mM NaCl buffer at 4 ºC. Then another dialysis step was carried out in
exchanged, fresh buffer overnight at 4 ºC. ADP-β-mannose was dissolved in the same 
buffer to a final concentration of 2 mM, which equates to 26 times higher than that of
the wildtype and 20 times higher than that of the mutant enzyme. Adjustment of the
pHs of the compound and the protein to the exactly same value of that of the dialysis
buffer and filtering of all the solutions were performed to decrease the noise from the
heat of dilution in the following ITC experiments.
2.8.2 ITC experiments
ITC was performed at 25 ºC using the MicroCalTM VP-ITC system. ADP-β-mannose 
solution was titrated into the enzyme solution. 35 injections each with a volume of 6
μl were carried out. As a control the same number of titrations into buffer was 
performed as well. When the titrant is added to the protein solution energy in form of
heat is absorbed or released. Absorption of energy occurs when the reaction is
endothermic and release of energy takes place in an exothermic reaction (Pierce et al.,
1999). In both ITC experiments, determination of entropy (ΔS), enthalpy (ΔH), the 
binding constant (Ka) and stoichiometry (n) was carried out (Pierce et al., 1999).
Analysis of the raw data was performed with the OriginTM ITC (Version 5.1 –
MicrocalTM) software. Substraction of the blank titrations was carried out to correct
this data and the integrated binding isotherm was adjusted to a one site binding model.
The isothermal titration calorimetric analysis of the AGME/ADP-β-mannose and 
AGME Y140F/ADP-β-mannose interactions are shown in Figure 64A and B. 
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The enthalpy (ΔH) (Table 17) is negative which means that heat was released upon 
titration of the compound into the protein solution (exothermic reaction). The
additional heat absorption (endothermic reaction) during the first four titrations of
ADP-β-mannose into AGME Y140F (Figure 64, B, top panel) is hard to explain. It 
could be possible that there was a slight difference in the pH values of ligand and
protein. The stoichiometry (n) is, as expected, close to 1.0 in both cases (Table 17). A
reaction stoichiometry of 1.0 means that one molecule of ligand binds to one active
site of a protein’s subunit. Both values are slightly below 1.0 which means that the
concentrations of either the enzymes or the compound have not been accurate.
Table 17. ITC results of AGME and AGME Y140F with ADP-β-mannose 
Protein interaction Stoichiometry Kd (μM) ΔH (kCal/mole) 
AGME/ADP-β-mannose  0.97 2.7 -1.369
AGME Y140F/ADP-β-mannose 0.78 2.7 -1.497
Discussion
The hldD gene from E. coli K-12 W3110 was cloned into pEHISTEV. Soluble
expression was obtained when E. coli BL21 (DE3)pLysS cells were transformed with
pEHISTEV-hldD. E. coli BL21 (DE3)pLysS is normally used to express a gene of
interest efficiently in the presence of a T7 promotor. This E. coli strain has a plasmid
named pLysS. The open reading frame which encodes the T7 lysozyme is located on
this plasmid. Any low level expression of the gene of interest controlled by the T7
promotor is inhibited by T7 lysozyme.
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Upon addition of IPTG, however, T7 lysozyme does not have any effect on higher
expression levels any more (description after http://www.promega.com/catalog/
products.aspx?categoryname=productleaf_1005). Expression trials with other E. coli
strains such as BL21 (DE3), C43 (DE3) or Rosetta (DE3) (see Table 16) were
unsuccessful. pEHISTEV is a pET based vector, contains a tobacco etch virus (TEV)
protease cleavage site and expresses an aminoterminal hexahistidine tagged protein.
This His-tag can be cleaved when TEV protease is added. The hexahistidine sequence
at a protein’s aminoterminus can facilitate its purification (Liu and Naismith, 2009).
Both vectors pEHISTEV and pET-30 Xa/LIC contain such a tag. Unlike the tobacco
etch virus protease recognition site in pEHISTEV, a factor Xa cleavage site is present
in pET-30 Xa/LIC. Our collaborators were unable to cleave the tag. In our case, the
idea was to perform a simple three step purification of AGME cloned into pEHISTEV
(two times Ni-NTA column and gelfiltration as the third purification step). First the
His-tagged enzyme was loaded onto a Ni-NTA column. Only His-tagged AGME
would bind, other E. coli proteins would get through the column. After elution of the
bound protein with a buffer containing a high concentration of imidazole (300-400
mM) and subsequent dialysis in an imidazole free buffer, TEV protease was added to
remove the His-tag from the protein. However, the TEV digest of hexahistidine
tagged AGME performed over 2 days under optimal conditions (dialysis in 20 mM
Tris-HCl, 300 mM NaCl, 0.5 mM EDTA and 1 mM DTT, pH 7.5 at room temperature)
was not successful. The most plausible explanation for that could be a buried cleavage
site (Figure 65). Another protein expressed in the same construct was used as a control
and was successfully cleaved when incubated with the same batch of TEV protease.
Consequently, AGME was not further purified.
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Figure 65. Stereo view of the buried N-terminus of AGME (monomer A is shown) (Pdb accession code 1eq2). The
aminoterminal β-sheet (β1) is shown in red. The other secondary structure elements are shown in green. α-helices and 
β-strands surrounding β1 are labelled.   
Next, expression of the pET-30 Xa/LIC-HldD construct in E. coli BL21 (DE3) was
tested as well. The level of soluble AGME expression from pET-30 Xa/LIC was much
higher than that expressed from pEHISTEV in E. coli BL21 (DE3) pLysS (Figure 53).
As a consequence a different purification protocol without any TEV cleavage
involved was designed (see Section 2.6). The first attempt to co-crystallise AGME
with ADP-β-mannose was a “grid screen” around the already published condition, 2 
M ammonium sulfate, 0.1 M HEPES-Na, pH 7.5 and 2 % PEG 400 which yielded
high quality crystals of AGME complexed with ADP-α-glucose (Ding et al., 1999;
Deacon et al., 2000). However, this screen did not yield any crystals. Reasons for that
could be differences in the AGME constructs and the purification protocols. Whereas
our AGME sample contains an aminoterminal His-tag, AGME which gave crystals in
complex with ADP-α-glucose (Ding et al., 1999; Deacon et al., 2000) was untagged.
In our case, AGME was purified using a Ni-NTA affinity column, followed by
hydrophobic interaction chromatography and finally gel filtration. Ding and
coworkers, however, performed hydrophobic interaction chromatography, affinity
chromatography (blue Sepharose CL-6B column) (Ding et al., 1994) and ion
exchange chromatography as last step to obtain pure protein (Ding et al., 1999).
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Furthermore, the protein sample was desalted against H2O (Ding et al., 1999) whereas
in our case AGME was in 20 mM Tris-HCl, pH 7.0, 50 mM NaCl and 1mM DTT
before applied to crystallisation trials (see Section 2.6). As a consequence AGME was
screened against a range of commercially available crystallisation screens. Initial
crystals were obtained in many conditions. The most promising ones were used to
design further “grid screens”. Crystals suitable for reasonable diffraction studies were
grown in 0.2 M Ca-acetate, 0.1 M Na-cacodylate, pH 6.5 and 35 % PEG 300. Larger
and thicker crystals than in the initial condition (0.2 M Ca-acetate, 0.1 M
Na-cacodylate, pH 6.5 and 40 % PEG 300) were obtained. In this case a decrease of
the number of nucleation events in the drop could be achieved by a lower
concentration of the precipitant, PEG 300. A dataset of one crystal grown from this
optimised condition and in the presence of 6.6 mM ADP-β-mannose was collected at 
IO2 at the Diamond synchrotron, Oxford (see next section). The structure was solved
and there was clear density for NADP+ in the electron density map, however, no
nucleotide sugar was observed in this structure. This was a very surprising result as
ITC data of AGME with ADP-β-mannose showed tight binding of the ligand to the 
protein (Kd = 2.7 μM). Additional soaking of AGME co-crystals with 20 mM of 
compound in a time course from 10 min to 6 hours did not turn out to be successful
either. The next approach was to denature AGME and to reconstitute it with NADP+.
Usually a mixture of NADP+ and NADPH is present in AGME after its purification.
(Morrison and Tanner, 2007) Therefore a homogeneous cofactor content in the
enzyme could support growth of AGME crystals complexed with ADP-β-mannose. 
Crystals were obtained in the same condition as the unreconstituted enzyme had been
crystallised in. The structure of one such crystal was solved, but again, there was no
sign of a bound nucleotide sugar. A plausible explanation for this negative result
could be that the compound had been turned over during the crystallisation process.
However, it is not clear why at least ADP is not bound in the structure, as the adenine
has strong van der Waals interactions with the enzyme (Deacon et al., 2000).
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An explanation that binding of ADP-β-mannose to AGME was observed in the ITC 
experiment but not in the crystal structures could be the fact that titration of a ligand
into an enzyme solution, as performed in ITC (Pierce et al., 1999), is a very fast
process and binding is only detected by absorption or release of heat (Pierce et al.,
1999). Crystallisation, however, is a much slower process. Consequently, a substrate
has already been turned over by the active enzyme before crystallisation has even
taken place. For that reason only an empty active site could then be observed in a
crystal structure. To exclude a possible turnover of the nucleotide sugar,
co-crystallisation of the AGME mutant Y140F which only displays 0.08 % epimerase
activity compared to the wildtype enzyme (Morrison and Tanner, 2007) with
ADP-β-mannose was attempted next. ITC was also performed which confirmed a 
tight interaction of the mutant with the compound, similar to the wildtype enzyme (Kd
=2.7 μM). Crystals (Figure 61) were again obtained under the condition 0.2 M 
Ca-acetate, 0.1 M Na-cacodylate, pH 6.5 and 35 % PEG 300. However, problems
appeared during data collection of these crystals. Many spots were overlapped
because of the very high mosaic spread (Figure 66).
Figure 66. Diffraction pattern of one of the AGME Y140F crystals grown from 0.2 M Ca-acetate, 0.1 M Na-cacodylate, pH
6.5 and 35 % PEG 300.
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Collecting data at even 0.1º oscillations did not show any improvement. Capillary
mounting of those crystals at room temperature and also de- and rehydration
experiments which can help to decrease the mosaicity were not successful. Collecting
data at lower resolutions which could also aid to reduce overlaps did not work either.
In the worst cases even autoindexing of the data failed. To screen for a new
crystallisation condition AGME Y140F was rescreened. Fortunately, optimisation of
one of many different conditions obtained proved to be successful. Two of the datasets,
one collected in-house on the RA-Μicro 7 HFM Table Top Rotating Anode X-Ray 
Generator (Rigaku), and the other one at BM14 at the ESRF, Grenoble, are discussed
in the following section. Interestingly, the initial condition this “grid screen” was
based on is exactly the same one from which well diffracting AGME crystals in
complex with ADP-α-glucose were obtained (Ding et al., 1999; Deacon et al., 2000)
No wildtype protein crystals with ADP-β-mannose could be grown from this 
condition.
Bioinformatics studies
Sequence alignments between AGME and other short chain dehydrogenases were
performed using the programme ClustalW (Chenna et al., 2003). Sequence identities
between the aligned proteins were calculated using the sequence alignment
programme BLAST (Altschul et al., 1990).
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Data collection, Processing, Molecular
Replacement of AGME and AGME Y140F and
Refinement of AGME Y140F
Summary
One complete X-ray dataset of AGME was collected to 2.9 Å at the Diamond
synchrotron, Oxford. Two complete datasets of AGME Y140F co-crystals were
collected as well, one in-house on the RA-Μicro 7 HFM Table Top Rotating Anode 
X-Ray Generator (Rigaku) to 2.8 Å, and the other one at BM14 at the ESRF,
Grenoble to 2.4 Å. The diffraction data were processed using Denzo and Scalepack in
the integrated package HKL2000 (Minor et al., 2002). The structure of AGME in
complex with ADP-α-glucose has already been solved (Deacon et al., 2000). For that
reason it was decided to use this structure as a model to calculate a set of initial phase
estimates using the technique of Molecular Replacement (MR). After the structures
had been solved using PHASER (McCoy et al., 2005; Storoni et al., 2004) or Molrep
(Vagin and Teplyakov, 1997), incorrect amino acid rotamers were manually modified
in COOT (Emsley and Cowtan, 2004) and additionally the Tyr at position 140 in the
mutant was changed to Phe. Isotropic refinement, TLS parameters and Non
crystallographic symmetry (NCS) restraints were carried out in all steps of refinement
using the programme REFMAC5 (Murshudov et al., 1999). The final model was
checked and validated using MOLPROBITY (Davis et al., 2004).
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2.9 Data collection, processing and structure solution of
AGME (IO2, Diamond, Oxford)
2.9.1 Data collection and processing
Diffraction data from one AGME crystal to 2.9 Å were collected at -173.15 ºC at a
wavelength of 1.06 Å on IO2 at the Diamond synchrotron, Oxford. Images in 0.25º
oscillations (Figure 67) with a 2s exposure were collected. Indexing and merging of
the data were performed using Denzo and Scalepack in the integrated package
HKL2000 (Minor et al., 2002). The crystal belonged to the spacegroup C2 with unit
cell parameters a = 160 Å, b =115.6 Å, c = 218.6 Å, α = 90º, β = 101.9º, γ = 90º. The 
data have an overall completeness of 95.7 %. Data collection and processing statistics
are presented in Table 18.
* Rmerge = ∑ │I (k) - <I>│ / ∑
intensity of a reflection, <I> is
summation is over all measureme
A
Figure 67. 0.25° oscillation X-ray images of th
collected data (B).
Data collection
λ (Å) 
Resolution (Å)
Spacegroup
Cell (Å,º)
Unique reflection
Average redundan
I/σ 
Completeness (%
Rmerge*
Table 18. Data c117
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2.9.2 Structure solution
The structure of AGME was solved by molecular replacement using PHASER
(McCoy et al., 2005; Storoni et al., 2004). A pentamer of AGME (Pdb accession code
1eq2) was used as a search unit. A solution was found for 2 pentamers in the
asymmetric unit consistent with the Matthews coefficient calculation (Table 19)
(Matthews, 1968) and a resolution range between 19.9 and 2.9 Å.
Table 19. Matthews coefficient and solvent content calculated from the unit cell and the molecular weight of the molecules
in the unit cell. Nmol/asym = number of molecules in the asymmetric unit, %solvent = % solvent content, P(2.93) =
probability at 2.93 Å resolution, P(tot) = probability across all resolution ranges. A Matthews coefficient of 2.75 Å3 Da-1,
corresponding to a 55.26 % solvent content at a probability of 0.16 at 2.93 Å and a total probability of 0.14 (shown in
orange), suggested 10 molecules of AGME in the asymmetric unit.
Nmol/asym Matthews Coeff. %solvent P(2.93) P(tot)
_________________________________________
1 27.47 95.53 0.00 0.00
2 13.74 91.05 0.00 0.00
3 9.16 86.58 0.00 0.00
4 6.87 82.10 0.00 0.00
5 5.49 77.63 0.00 0.00
6 4.58 73.16 0.01 0.00
7 3.92 68.68 0.02 0.01
8 3.43 64.21 0.04 0.03
9 3.05 59.73 0.09 0.08
10 2.75 55.26 0.16 0.14
11 2.50 50.78 0.22 0.21
12 2.29 46.31 0.22 0.23
13 2.11 41.84 0.15 0.18
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Clear rotation and translation solutions were found for each of the two pentamers. The
top solution from PHASER is shown in Table 20.
Table 20. The top solution from PHASER. RFZ = Z-score after fast rotation function, TFZ = Z-score after fast
translation function, PAK = number of clashes (unfavourable molecular contacts in crystal packing)
Pentamer 1 Pentamer 2
2.10 Data collection, processing, structure solution and
refinement of the AGME Y140F complex (in-house)
2.10.1 Data collection and processing
Before data collection crystals were cryoprotected in a solution containing 2 M
ammonium sulfate, 0.1 M HEPES-Na, pH 7.5, 2 % PEG 400, 10 mM Spermidine, 2
mM ADP-β-mannose and 15 % glycerol. Diffraction data were collected at -173.15 ºC 
at a wavelength of 1.542 Å in-house on the RA-Μicro 7 HFM Table Top Rotating 
Anode X-Ray Generator (Rigaku). Data from one crystal to 2.8 Å resolution were
collected in 0.1º oscillations (Figure 68) with a 60s exposure. Indexing and merging
of the data were performed using Denzo and Scalepack in the integrated package
HKL2000 (Minor et al., 2002).The crystal belonged to the space group P21 with unit
cell parameters a = 138 Å, b = 162 Å, c = 185 Å, α = 90º, β =101º, γ = 90º.  
Solution RFZ TFZ PAK RFZ TFZ PAK
1 36.9 37.1 0 47.8 78.5 0
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The data have an overall completeness of 99 % and 100 % in the highest resolution
shell from 2.85 – 2.8 Å resolution. Data collection and processing statistics are shown
in Table 21.
Table 21. Data collection statistics for the AGME Y140F crystal. Data for the highest
resolution shell are shown in brackets.
* Rmerge = ∑ │I (k) - <I>│ / ∑ I (k), where I (k) is the value of the kth measurement of the
intensity of a reflection, <I> is the mean value of the intensity of that reflection and the
summation is over all measurements.
Data collection AGME Y140F
λ (Å) 1.542 Å 
Resolution
Last shell (Å)
35 – 2.8
(2.85-2.8)
Spacegroup P21
Cell (Å, º) a = 138, b = 162, c = 185
α = 90, β =101, γ = 90  
Unique reflections 197672
Average redundancy 3.6 (3.5)
I/σ  15.3 (1.8) 
Completeness (%) 99 (100)
Rmerge* 0.092 (0.808)
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Figure 68. 0.1° oscillation X-ray image of the crystal of AGME Y140F collected in-house to 2.8 Å resolution.
2.10.2 Structure solution
The structure of AGME Y140F was solved by molecular replacement using PHASER
(McCoy et al., 2005; Storoni et al., 2004). A pentamer of AGME (Pdb accession code
1eq2) was used as a search unit. A solution was found for 4 pentamers in the
asymmetric unit consistent with the Matthews coefficient calculation (Table 22)
(Matthews, 1968) and a resolution range between 35 and 2.8 Å.
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Table 22. Matthews coefficient and solvent content calculated from the unit cell and the molecular weight of the molecules
in the unit cell. Nmol/asym = number of molecules in the asymmetric unit, %solvent = % solvent content, P(2.80) =
probability at 2.8 Å resolution, P(tot) = probability across all resolution ranges. A Matthews coefficient of 2.82 Å3 Da-1,
corresponding to a 56.48 % solvent content at a probability of 0.06 at 2.8 Å and a total probability of 0.06 (shown in
orange), suggested 20 molecules of AGME in the asymmetric unit.
Nmol/asym Matthews Coeff. %solvent P(2.80) P(tot)
_________________________________________
15 3.77 67.36 0.01 0.01
16 3.53 65.19 0.01 0.01
17 3.32 63.01 0.02 0.02
18 3.14 60.84 0.03 0.03
19 2.97 58.66 0.05 0.04
20 2.82 56.48 0.06 0.06
21 2.69 54.31 0.08 0.08
22 2.57 52.13 0.10 0.09
23 2.46 49.96 0.11 0.11
24 2.35 47.78 0.11 0.11
25 2.26 45.61 0.11 0.11
26 2.17 43.43 0.10 0.10
27 2.09 41.25 0.08 0.08
Clear rotation and translation solutions were found for each of the four pentamers
(Table 23). Only one unfavourable molecular contact was observed for the final
solution in the crystal packing. The Molecular Replacement solution was then applied
to the coordinates of the search model to work as the starting model in the refinement
described in section 2.10.3.
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Table 23. The top solution from PHASER. RFZ = Z-score after fast rotation function, TFZ = Z-score after fast
translation function, PAK = number of clashes (unfavourable molecular contacts in crystal packing)
Pentamer 1 Pentamer 2 Pentamer 3 Pentamer 4
2.10.3 Refinement
REFMAC 5 (Murshudov et al., 1999) was used to refine the structure of AGME
Y140F in complex with ADP-β-mannose. Data in the range from 182.6– 2.8 Å were 
used. Incorrect rotamers and the mutation at position 140 of the enzyme were
modified manually in COOT (Emsley and Cowtan, 2004). TLS parameters (Table 24),
isotropic B-thermal factors and NCS restraints were employed in all cycles of
refinement. Water, cofactor (NADP+) and ligand (ADP-β-mannose) molecules were 
also added in COOT (Emsley and Cowtan, 2004).
Table 24. TLS groups employed throughout the refinement of AGME Y140F. “Residues” 400 and 401 are referred to
NADP and ADP-β-mannose, respectively.  
TLS A-T chain1
RANGE 'A 1.' 'A 106.' ALL
RANGE 'A 400.' 'A 400.' ALL
TLS A-T chain2
RANGE 'A 107.' 'A 197.' ALL
TLS A-T chain3
RANGE 'A 198.' 'A 307.' ALL
RANGE 'A 401.' 'A 401.' ALL
The Rwork and Rfree after the last round of refinement were 24.5 % and 27.3 %
respectively (Table 25).
Solution RFZ TFZ PAK RFZ TFZ PAK RFZ TFZ PAK RFZ TFZ PAK
1 41.3 54.7 0 29.1 61.3 0 31.4 83.6 0 24.1 67.0 1
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Table 25. Refinement statistics of AGME Y140F. Rwork and Rfree in the highest resolution shell are shown in brackets
* Rwork = ∑hkl ││Fobs - │Fcalc││ / ∑hkl │Fobs│ 
* For Rfree the same calculation applies, but for only 5-10 % of reflections which are not included in the
refinement.
The quality of the structure was judged using MOLPROBITY (Table 26) (Davis et al.,
2004).
Refinement AGME Y140F
Rwork* % 24.5 (45.9)
Rfree* % 27.3 (52.1)
Number of atoms (average B value (Å2))
protein (overall)
protein (chain A) protein (chain K)
protein (chain B) protein (chain L)
protein (chain C) protein (chain M)
protein (chain D) protein (chain N)
protein (chain E) protein (chain O)
protein (chain F) protein (chain P)
protein (chain G) protein (chain Q)
protein (chain H) protein (chain R)
protein (chain I) protein (chain S)
protein (chain J) protein (chain T)
water (overall)
NADP+
ADP-β-mannose 
NCS deviations (rmsd (Å))
(chain A - chain B) (chain A - chain I) (chain A - chain P)
(chain A - chain C) (chain A -chain J) (chain A - chain Q)
(chain A - chain D) (chain A - chain K) (chain A - chain R)
(chain A - chain E) (chain A - chain L) (chain A - chain S)
(chain A - chain F) (chain A - chain M) (chain A - chain T)
(chain A - chain G) (chain A – chain N)
(chain A - chain H) (chain A - chain O)
48800 (35.7)
2440 (35.7) 2440 (35.7)
2440 (35.7) 2440 (35.7)
2440 (35.7) 2440 (35.7)
2440 (35.7) 2440 (35.7)
2440 (35.7) 2440 (35.7)
2440 (35.7) 2440 (35.7)
2440 (35.7) 2440 (35.7)
2440 (35.7) 2440 (35.7)
2440 (35.7) 2440 (35.7)
2440 (35.7) 2440 (35.7)
958 (27.8)
960 (36.1)
722 (37.6)
0.06 0.09 0.07
0.08 0.05 0.09
0.08 0.09 0.06
0.07 0.11 0.09
0.05 0.06 0.12
0.05 0.05
0.09 0.08
rmsd bonds (Å) / angles (°) 0.009 / 1.191
Ramachandran favoured (%) 96.4
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Table 26. Output from MOLPROBITY (Davis et al., 2007)
* 100th percentile is the best among structures of comparable resolution; 0th percentile is the
worst.
* Ramachandran outliers: Phe168 (chains I, J, K, M, R), Arg174 (chains A-T)
2.11 Data collection, processing, structure solution and
refinement of the AGME Y140F complex (BM14, ESRF,
Grenoble)
2.11.1 Data collection and processing
Before data collection crystals were cryoprotected in a solution containing 2 M
ammonium sulfate, 0.1 M HEPES-Na, pH 7.1, 2 % PEG 400, 2 mM ADP-β-mannose 
and 15 % glycerol.
Goal: <0.5%0.00%Residues with badangles:
Goal: <1%0.00%Residues with badbonds:
99th percentile* (N=4482,
2.55Å - 3.05Å)1.91MolProbity score
Goal: 00C deviations >0.25Å
Goal: >98%96.44%Ramachandran favored
Goal: <0.2%0.41%Ramachandranoutliers*
Goal: <1%2.08%Rotamer outliers
Protein
Geometry
Clashscore is the number of serious steric overlaps (> 0.4 Å) per 1000 atoms.
99th percentile* (N=141,
2.55Å - 3.05Å)
8.03Clashscore, all atoms:All-Atom
Contacts
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Diffraction data were collected at -173.15 ºC at a wavelength of 0.954 Å on BM14 at
the ESRF. Data from one crystal to 2.4 Å resolution were collected in 0.5º oscillations
(Figure 69) with a 10s exposure. Indexing and merging of the data were performed
using Denzo and Scalepack in the integrated package HKL2000 (Minor et al., 2002).
The crystal belonged to the space group C2 with unit cell parameters a = 342 Å, b =
61 Å, c = 192 Å, α = 105.7º, β = 105.0º, γ = 105.1º. The data have an overall 
completeness of 100 % and 98 % in the highest resolution shell from 2.39 – 2.35 Å
resolution. Data collection and processing statistics are shown in Table 27.
Table 27. Data collection statistics for the AGME Y140F crystal. Data for the highest resolution shell
are shown in brackets.
* Rmerge = ∑ │I (k) - <I>│ / ∑ I (k), where I (k) is the value of the kth measurement of the
intensity of a reflection, <I> is the mean value of the intensity of that reflection and the
summation is over all measurements.
Data collection AGME Y140F
λ (Å) 0.954 
Resolution
Last shell (Å)
50 – 2.35
(2.39 -2.35)
Spacegroup C2
Cell (Å, º) a = 342, b = 61, c = 192
α = 105.7, β = 105.0, γ = 105.1 
Unique reflections 162824
Average redundancy 1.9 (1.7)
I/σ 27 (5.2) 
Completeness (%) 100 (98)
Rmerge* 0.044 (0.192)
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Figure 69. 0.5° oscillation X-ray image of the crystal of AGME Y140F collected to 2.4 Å resolution at BM14, ESRF.
2.11.2 Structure solution
The structure of AGME Y140F complexed with ADP-β-mannose was solved by 
molecular replacement using Molrep (Vagin and Teplyakov, 1997). A monomer of
AGME (Pdb accession code 1eq2) was used as a search unit. A solution was found for
10 monomers in the asymmetric unit consistent with the Matthews coefficient
calculation (Table 28) (Matthews, 1968) and a resolution range between 39 and 2.5 Å.
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Table 28. Matthews coefficient and solvent content calculated from the unit cell and the molecular weight of the molecules
in the unit cell. Nmol/asym = number of molecules in the asymmetric unit, %solvent = % solvent content, P(2.36) =
probability at 2.36 Å resolution, P(tot) = probability across all resolution ranges. A Matthews coefficient of 2.77 Å3 Da-1,
corresponding to a 55.59 % solvent content at a probability of 0.13 at 2.36 Å and a total probability of 0.13 (shown in
orange), suggested 10 molecules of AGME Y140F in the asymmetric unit.
Nmol/asym Matthews Coeff. %solvent P(2.36) P(tot)
_________________________________________
1 27.68 95.56 0.00 0.00
2 13.84 91.12 0.00 0.00
3 9.23 86.68 0.00 0.00
4 6.92 82.24 0.00 0.00
5 5.54 77.80 0.00 0.00
6 4.61 73.35 0.00 0.00
7 3.95 68.91 0.01 0.01
8 3.46 64.47 0.03 0.03
9 3.08 60.03 0.07 0.07
10 2.77 55.59 0.13 0.13
11 2.52 51.15 0.20 0.20
12 2.31 46.71 0.24 0.23
13 2.13 42.27 0.19 0.19
Clear rotation and translation solutions were found for each of the 10 monomers
(Table 29). No unfavourable molecular contacts were observed for the final solution
in the crystal packing. The Molecular Replacement solution was then applied to the
coordinates of the search model to work as the starting model in the refinement
described in section 2.11.3.
129
Table 29. The top solutions from Molrep.
Rf/sig = Z-score after fast rotation function, Tf/sig = Z-score after fast translation function
Monomer 1 Monomer 2 Monomer 3 Monomer 4 Monomer 5
Monomer 6 Monomer 7 Monomer 8 Monomer 9 Monomer 10
2.11.3 Refinement
REFMAC 5 (Murshudov et al., 1999) was used to refine the structure of AGME
Y140F in complex with ADP-β-mannose. Data in the range from 38.7 – 2.36 Å were 
used. Incorrect rotamers and the mutation at position 140 of the enzyme were
modified manually in COOT (Emsley and Cowtan, 2004). TLS parameters (Table 30),
isotropic B-thermal factors and NCS restraints were employed in all cycles of
refinement. Water, cofactor (NADP+) and ligand (ADP-β-mannose) molecules were 
also added in COOT (Emsley and Cowtan, 2004).
Rf/sig Tf/sig Rf/sig Tf/sig Rf/sig Tf/sig Rf/sig Tf/sig Rf/sig Tf/sig
11 5.8 8.5 8.7 9.2 11 9.1 14.5 9.8 17.7
Rf/sig Tf/sig Rf/sig Tf/sig Rf/sig Tf/sig Rf/sig Tf/sig Rf/sig Tf/sig
8.6 17.5 9.5 36.2 8.4 30.6 6.8 40.3 7.3 56.8
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Table 30. TLS groups employed throughout the refinement of AGME Y140F. “Residues” 400 and 401 are
referred to NADP and ADP-β-mannose, respectively.  
TLS A-J chain1
RANGE 'A 1.' 'A 106.' ALL
RANGE 'A 400.' 'A 400.' ALL
TLS A-J chain2
RANGE 'A 107.' 'A 197.' ALL
TLS A-J chain3
RANGE 'A 198.' 'A 307.' ALL
RANGE 'A 401.' 'A 401.' ALL
One molecule of glycerol was also included in the final model in each of the 10
subunits. An additional chloride ion was also fitted in. The Rwork and Rfree after the last
round of refinement were 18.9 % and 20.9 %, respectively (Table 31).
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Table 31. Refinement statistics of AGME Y140F. Rwork and Rfree in the highest resolution shell are shown in brackets.
* Rwork = ∑hkl ││Fobs - │Fcalc││ / ∑hkl │Fobs│ 
* For Rfree the same calculation applies, but for only 5-10 % of reflections which are not included in the
refinement.
The quality of the structure was judged using MOLPROBITY (Table 32) (Davis et al.,
2004).
Refinement AGME Y140F
Rwork * % 18.9 (23.4)
Rfree* % 20.9 (27.1)
Number of atoms (average B value (Å2))
protein (overall)
protein (chain A)
protein (chain B)
protein (chain C)
protein (chain D)
protein (chain E)
protein (chain F)
protein (chain G)
protein (chain H)
protein (chain I)
protein (chain J)
water (overall)
NADP+ glycerol
ADP-β-mannose   chloride 
NCS deviations (rmsd (Å))
(chain A - chain B) (chain A - chain I)
(chain A - chain C) (chain A - chain J)
(chain A - chain D)
(chain A - chain E)
(chain A - chain F)
(chain A -chain G)
(chain A - chain H)
24411 (33)
2440 (33)
2440 (33)
2440 (33)
2440 (33)
2440 (33)
2440 (33)
2451(33)
2440 (33)
2440 (33)
2440 (33)
1549 (40)
480 (34.8) 60 (51.3)
380 (36.3) 1 (44.4)
0.06 0.05
0.10 0.08
0.07
0.09
0.05
0.05
0.07
rmsd bonds (Å) / angles (°) 0.005 / 0.956
Ramachandran favoured (%) 97.5
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Table 32. Output from MOLPROBITY (Davis et al., 2007)
* 100th percentile is the best among structures of comparable resolution; 0th percentile is the
worst.
* Ramachandran outliers: Phe168 and Arg174 (chains A-J)
Goal: <0.5%0.00%Residues with bad angles:
Goal: <1%0.00%Residues with bad bonds:
98th percentile* (N=8043, 2.11Å - 2.61Å)1.68MolProbity score
Goal: 00C deviations >0.25Å
Goal: >98%97.48%Ramachandran favored
Goal: <0.2%0.66%Ramachandran outliers
Goal: <1%1.10%Rotamer outliers
Protein
Geometry
Clashscore is the number of serious steric overlaps (> 0.4 Å) per 1000 atoms.
93rd percentile* (N=336, 2.11Å - 2.61Å)10.5Clashscore, all atoms:All-Atom
Contacts
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Discussion
AGME (IO2, Diamond, Oxford)
A complete data set from a crystal of AGME was collected to a resolution of 2.9 Å at
the Diamond beamline IO2. After an appropriate starting orientation had been given
enough data were collected to get a completeness of 95.7 % for the space group C2.
The presence of lots of overlapping reflections (Figure 67B) caused problems in
indexing the data. However, structure solution was straightforward.
Figure 70. The asymmetric unit of AGME showing two pentamers. Cα traces of the ten monomers (A-J) are shown in 
different colours.
The Rwork and Rfree after only one run of restrained refinement in REFMAC5 were
25.7 % and 29.7 %, respectively. These values represent a reasonably good agreement
between Fobs and Fcalc at a resolution of 2.9 Å, and are strong evidence for a correct
solution.
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In the electron density maps clear densities for NADP+ could be observed in each of
the 10 monomers. However, there was no sign of any bound nucleotide sugar. After
the cofactor molecules had been fitted into the appropriate electron densities and an
additional run of refinement had been carried out, Rwork and Rfree decreased to 24.4 %
and 28. 4 %, respectively. The structure was not further refined because of the missing
ADP-β-mannose in each of the monomers. A plausible explanation for that could be 
that the compound was turned over by the active enzyme during crystallisation.
Another reason could be that the quality of the data was not very good. Data quality
assessment by phenix.xtriage (Zwart et al., 2005) revealed possible twinning of the
data. However, the good Rfactor values and also the clear densities of the tightly bound
coenzyme in all ten monomers (Figure 71) support the former assumption.A134
Figure 71. (continues on next page)
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Figure 89. (continues on next page)
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Figure 71. Unbiased Fo-Fc at 2.5σ (green) and final 2Fo-Fc at 1σ (blue) maps around the NADP+ of monomers A-J of
AGME. The NADP+-molecule is modelled in the 2Fo-Fc density. Both electron densities for the cofactor are shown in
stereo view in monomer A. Both maps were calculated after one run of restrained refinement. The weak electron density
at the the nicotinamide part of NADP+ (Fo-Fc maps) shows that this moiety of the molecule is flexible. This figure has been
produced using PyMol (DeLano, 2007).
.
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AGME Y140F (in-house and at BM14, ESRF)
Data of crystals of AGME Y140F complexed with ADP-β-mannose were collected to 
resolutions of 2.4 and 2.8 Å at BM14, ESRF, and in-house on the RA-Μicro 7 HFM 
Table Top Rotating Anode X-Ray Generator (Rigaku), respectively. The crystal which
diffracted to 2.4 Å resolution belonged to the space group C2, whereas the crystal
which diffracted to lower resolution belonged to the space group P21. AGME in
complex with ADP-α-glucose also crystallised in space group P21. This is not
surprising, as the crystallisation condition is the same, except variations in the
concentration of the additive spermidine. However, the unit cell parameters were
different. (Ding et al., 1999; Deacon et al., 2000). Structure solution (Tables 23 and
29) and refinement of both structures were straightforward. The clashscores and the
MOLPROBITY scores (Tables 26 and 32) indicate the good quality of both structures.
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2.12 Sequence alignment between AGME and closely related
short chain dehydrogenases/reductases
An alignment between AGME and the structurally most closely related short chain
dehydrogenases/reductases UGE, DGD and GMER (Deacon et al., 2000) is shown in
Figure 72. AGME shares 24% and 22% sequence identity to E. coli and human UGE,
respectively. There are 21% identical amino acids between AGME and GMER, and
22% identical residues between AGME and the classical SDR enzym
3α,20β-hydroxysteroid dehydrogenase. This numbers agree very well with the 
identities published on pair-wise alignments of various short-chain
dehydrogenases/reductases which usually show 15-30 % identity (Oppermann et al.,
2003; Persson et al., 2003; Kallberg et al., 2002; Jörnvall et al., 1995). There is higher
sequence identity between AGME and dTDP-D-glucose 4,6 dehydratase though
(36%).
β1 + α1      
1EQ2 ------MIIVTGGAGFIGSNIVKALNDKGITDILVVDNLKDGTK------
1NAH -----MRVLVTGGSGYIGSHTCVQLLQNGHDVIILDNLCNSKRS------
Q14376 --MAEKVLVTGGAGYIGSHTVLELLEAGYLPVVIDNFHNAFRGGGSLPE
1BXK ----MRKILITGGAGFIGSALVRYIINETSDAVVVVDKLTYAGN------
1BWS --MSKQRVFIAGHRGMVGSAIRRQLEQRGDVELVLR--------------
2HSD NDLSGKTVIITGGARGLGAEAARQAVAAG---------------------
* * *33
β3 + α3             β4
1EQ2 --------FVNLVDLNIADYMDKEDFLIQIMAGEEFGDVEAIFHEGACSS
1NAH VLPVIERLGGKHPTFVEGDIRNEALMTEILHDHAIDTVIHFAGLK-AVGE
Q14376 SLRRVQELTGRSVEFEEMDILDQGALQRLFKKYSFMAVIHFAGLK-AVGE
1BXK LMSLAPVAQSERFAFEKVDICDRAELARVFTEHQPDCVMHLAAES-HVDR
1BWS -------------TRDELNLLDSRAVHDFFASERIDQVYLAAAKVGGIVA
2HSD ------------ARVVLADVLDEEGAATARELGDAARYQHLDVTIEEDWQ
*36 β3
Figure 72. (continues on next page)
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α4 β5 *116
1EQ2 TTEWDGKYMMDNNYQYSKELLHYCLEREIPFLYASSAATYG-GRTSDFIE
1NAH SVQKPLEYYDNNVNGTLRLISAMRAANVKNFIFSSSATVYGDNPKIPYVE
Q14376 SVQKPLDYYRVNLTGTIQLLEIMKAHGVKNLVFSSSATVYGNPQYLPLDE
1BXK SIDGPAAFIETNIVGTYTLLEAARAYWNALTEDKKSAFRFHHISTDEVYG
1BWS NNTYPADFIYQNMMIESNIIHAAHQNDVNKLLFLGSSCIYPKLAKQPMAE
2HSD RVVAYAREEFG------------SVDGLVNNAGISTGMFLETESVERFRK
β4
α5
*140 *144           β6
1EQ2 SREYEKPLNVYGYSKFLFDEYVRQILPEAN-SQIVGFRYFNVYGPREGHK
1NAH SFPTGTPQSPYGKSKLMVEQILTDLQKAQPDWSIALLRYFNPVGAHPSGD
Q14376 AHPTGGCTNPYGKSKFFIEEMIRDLCQADKTWNAVLLRYFNPTGAHASGC
1BXK DLHS-TDDFFTETTPYAPSSPYSASKASSDHLVRAWLRTYGLPTLITNCS
1BWS SELLQGTLEPTNEPYAIAKIAGIKLCESYNRQYGRDYRSVMPTNLYGPHD
2HSD VVEINLTGVFIGMKTVIPAMKDAGGGSIVNISSAAGLMGLALTSSYGASK
α4                   β5               α5
1EQ2 GSMAS-------VAFHLNTQLNNGESPKLFEGSENFKRDFVYVGDVADVNLWFL
1NAH MGEDP-QGIPNNLMPYIAQVAVGRRDSLAIFGNDYPTEDGTGVRDYIHVMDLAD
Q14376 IGEDP-QGIPNNLMPYVSQVAIGRREALNVFGNDYDTEDGTGVRDYIHVVDLAK
1BXK NNYGP-YHFPEKLIPLMILNALAG-KSLPVYGNGQQIRDWLYVEDHARALYCVA
1BWS NFHPSNSHVIPALLRRFHEATAQNAPDVVVWGSGTPMREFLHVDDMAAASIHVM
2HSD WGVRG----------------------LSKLAAVELGTDRIRVNSVHPGMTYTP
* β6 
Figure 72. Structural sequence alignment of AGME from E. coli K-12 (Pdb accession code 1eq2) with the structurally
most related enzymes, UDP-galactose 4-epimerase from E. coli (Pdb accession code 1nah) and Homo sapiens
(UniProtKB/TrEMBL entry Q14376), dTDP-D-glucose 4,6 dehydratase from E. coli (Pdb accession code 1bxk) and
GDP-4-keto-6-deoxy-D-mannose epimerase/reductase from E. coli (Deacon et al., 2000) (Pdb accession code 1bws).
3α,20β-hydroxysteroid dehydrogenase (Pdb accession code 2hsd) as a member of the classical SDR family is also shown as 
comparison to the five enzymes (Kallberg et al., 2002). Conserved sequence motifs (see Table 10) in AGME are highlighted
in yellow, the corresponding motifs in the two UDP-galactose 4-epimerases, in dTDP-D-glucose 4,6 dehydratase and in
GDP-4-keto-6-deoxy-D-mannose epimerase/reductase are highlighted in green. Motifs in 3α,20β-hydroxysteroid 
dehydrogenase are highlighted in turquoise. Residues conserved in all six SDR enzymes are marked with an asterisk. The
positions of secondary structural elements in the five extended SDR enzymes are marked on top of each motif, positions of
α-helices and β-strands, as they occur in 3α,20β-hydroxysteroid dehydrogenase a are shown in red at the bottom of each 
motif. The crucial residues (Ser116, Tyr140 and Lys144) in the catalytic region of AGME (Deacon et al., 2000) are labelled
as well. Residues at “key positions” based on coenzyme specificity are highlighted in magenta. The Asp residue at the end
of β2 in AGME (Kallberg et al., 2002) is highlighted in grey. Numbers (*36) refer to 3α,20β-hydroxysteroid dehydrogenase 
and human UDP-galactose 4-epimerase(*33) (Persson et al., 2003). This sequence alignment was carried out using the
programme ClustalW (Chenna et al., 2003).
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The sequence alignment demonstrated above shows that AGME is a member of the
extended family of short chain dehydrogenases/reductases (Kallberg et al., 2002).
It is 310 residues long (Deacon et al., 2000) and contains the fingerprint sequence
Thr-Gly-X-X-Gly-a-h-Gly (Table 10) which is typical for members of the extended
family of short-chain dehydrogenases/reductases (Kallberg et al., 2002). The motif
Asp-h-x-Asp in β3 (Table 10) (Persson et al., 2003), which is said to be involved in
the association of the adenine base of the NADP (Kallberg et al., 2002 and references
therein) is also very conserved in AGME, the only difference is that instead of a
hydrophobic amino acid after the first Asp, one can find a polar, aromatic residue (Tyr)
in AGME (Figure 72). The cluster Asp/Glu-X-h-h-His-X-Ala-Ala (Table 10) which
comprises β4 in the extended SDR family (Persson et al., 2003), also displays high
conservation in ADP-β-L-glycero-D-mannoheptose6-epimerase (Figure 72). The 
motif h-Asn-h-h-Gly-Thr-X-X-h-h-c (Table 10) (Kallberg et al., 2002), which is
referred to be part of the catalytic region in extended SDRs (Kallberg et al., 2002 and
references therein) does not appear in AGME. However the Asn, which has been
reported to create the tetrad Asn-Ser-Tyr-Lys in the majority of short chain
dehydrogenases/reductases (Filling et al., 2002; Oppermann et al., 2003), is conserved
(Figure 72) and one can suggest that apparently there is a catalytic tetrad in AGME as
well. The conserved motif h-h-h-X-Ser-Ser-X-X-h-a-Gly (Table 10) of β5 of members 
of the extended SDR-family (Persson et al., 2003) is also present in AGME. Only the
hydrophobic residue at position 3 in this cluster is replaced by an aromatic, polar
amino acid (Tyr), and another polar residue (Thr) replaces the hydrophobic residue at
position 8 in this motif (Figure 72). AGME also contains the highly conserved
sequence arrangement Pro-Tyr-X-X-Ala/Ser-Lys-X-X-h-Asp/Glu of α5 (Table 10), 
typical for members of the extended family of SDRs (Persson et al., 2003) with the
exception that the first residue (Pro) is missing (Figure 72). The motif
h-Lys/Arg/X-X-Asn-Gly-Pro of β6 (Table 10) (Kallberg et al., 2002) is absent in each
of the five extended SDRs (Figure 72).
141
Unsurprisingly, because of its high degree of homology to human UGE, UGE from E.
coli belongs to the same subfamily of extended SDRs (eD1) (Kallberg et al., 2002)
(Table 11). The sequence alignment shown in Figure 72 also identifies bacterial, such
as human dTDP-D-glucose 4,6 dehydratase (Persson et al., 2003), as a member of the
eD1 subfamily of extended short chain dehydrogenases/reductases (Kallberg et al.,
2002; Persson et al., 2003) (Table 11). It contains an acidic residue (Asp) right after
the end of β2 and is NAD(H)-dependent (Kallberg et al., 2002; Gross et al., 2001).
AGME represents a special case. The last amino acid of β2 is an aspartic acid (Figure 
72) (Kallberg et al., 2002) which is specific for SDRs interacting with NAD(H)
(Kallberg et al., 2002). However, AGME is an NADP(H)-specific member (Deacon et
al., 2000; Ni et al., 2001; Kallberg et al., 2002) of the extended SDR-family (Kallberg
et al., 2002). However, it can be seen from the X-ray structure of AGME in complex
with ADP-α-glucose (Deacon et al., 2000) that the aspartic acid occurs, unlike in other
enzymes which are NAD(H) specific, in a “more open conformation” (Kallberg et al.,
2002) and for that reason there is more space to allow nicotinamide adenine
dinucleotide phosphate to bind (Kallberg et al., 2002; Deacon et al., 2000; Ni et al.,
2001). Apart from that there is also a basic residue, a lysine (Figure 72) in the vicinity
of β2 (in the short three amino acids long loop between β2 and α2) which would 
classify it as a member of the cP1 subfamily of extended SDRs (Table 11) (Persson et
al., 2003). However, this residue occurs at key position 37 of UGE from Homo
sapiens instead of 34 (Kallberg et al., 2002) and for that reason a strict classification
of this epimerase is not possible. GDP-4-keto-6-deoxy-D-mannose
epimerase/reductase from E. coli is similar, it is also a NADP(H)-binding member
(Rizzi et al., 1998) of extended SDRs (Persson et al., 2003) and has a basic residue
(Arg) (Figure 72) in the proximity of the second -sheet of its structure, but this
amino acid is located at key position 33 (Table 11) (Kallberg et al., 2002) of UGE.
Human GDP-4-keto-6-deoxy-D-mannose epimerase/reductase has not been classified
into one of the subfamilies either (Persson et al., 2003).
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Structures of AGME Y140F in complex with
ADP-β-mannose 
Summary
This section describes the two solved structures of AGME Y140F complexed with
ADP-β-mannose. First an analysis of both overall structures, bound cofactors and 
ligands is performed. Then a more detailed description of the active site is carried out
based on the higher resolution structure. Differences and common features to the
already solved wildtype structure in complex with ADP-α-glucose are also discussed. 
Finally it is attempted to elucidate the exact roles of Tyr140 and Lys178 in the
epimerisation process of this enzyme as the nucleotide sugar in the structure is not
disordered and only one bound conformation is observed.
2.13 Overall structures
Unsurprisingly, because of their essentially identical sequence, the mutant protein
shares the same fold as wildtype AGME. The asymmetric unit of the 2.4 Å resolution
AGME Y140F structure is composed of 10 monomers (Figure 73A), the one of the
2.8 Å resolution mutant structure consists of 20 subunits. (Figure 73B)
Figure 73. (A) Cα traces of the monomers (A-J) forming two
traces of the monomers (A-T) forming four pentamers (gree
Y140F. This figure has been produced using PyMol (DeLano,
In the 2.4 Å resolution structure the
Superposition of monomers B-J to A (Figu
(see Table 31). In the 2.8 Å resolution struc
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 pentamers in the 2.4 Å structure of AGME Y140F. (B) Cα 
n, blue, red and magenta) in the 2.8 Å structure of AGME
2007).
ten monomers are essentially identical.
re 74A) shows an average Rmsd of 0.06 Å
ture the Rmsd values are also very low.
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If one superimposes subunits B-T to A (Figure 74B), the average Rmsd is 0.07 Å (see
Table 25) In the structure of AGME complexed to ADP-α-glucose (Deacon et al.,
2000) the Rmsd values from superposition of the same nine monomers to A are
slightly higher. They lie in a range between 0.12 Å and 0.21 Å.
Figure 74. Stereo view of the Cα tracing of the ten monomers of the 2.4 Å (A) and the twenty monomers of the 2.8 Å (B) 
AGME Y140F structures after their superposition. This figure has been produced using PyMol (DeLano, 2007).
The ten subunits of the higher resolution AGME Y140F structure essentially contain
all amino acids. In one monomer only two residues are missing at the
carboxyterminus (amino acids 309 and 310), whereas the other nine subunits lack
three residues (amino acids 308-310).
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No disordered regions have been observed in this structure unlike in Deacon and
coworkers’ structure in which most of the monomers lack additional residues (amino
acids 265-271 are missing in three monomers, one subunit lacks residues 262-271,
residues 195-207 and 251-271 are completely disordered in another monomer, and
one subunit lacks amino acids 194-206 and 249-271) (Deacon et al., 2000). Most of
the twenty monomers of the lower resolution mutant structure have several amino
acids such as Arg, Lys and Glu with disordered side chains. In general there is
sufficient electron density for the main chain in those regions. Only in two chains
several parts of the carboxyterminal main chain (amino acids 194-196, 199-201, 205,
251, 253-255, 257, 262 and 271 in chain G, and residues 194-195, 201, 204, 206, 254,
256-257, 262 and 272 in chain O) are disordered. In all twenty subunits the last three
amino acids (308-310) are missing as well.
2.14 Active site of AGME Y140F
2.14.1 NADP+ and ADP-β-mannose molecules in both mutant 
structures
There is clear electron density for one molecule of cofactor and one of nucleotide
sugar in each of the ten monomers of the 2.4 Å structure (Figures 75 and 76).
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Figure 75. (continues on next page)
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igure 75. Unbiased Fo-Fc at 3σ (green) and final 2Fo-Fc at 1σ (blue) maps around the NADP+ of monomers A-J of the 2.4
structure of AGME Y140F. The NADP+-molecule is modelled in the 2Fo-Fc density. Both electron densities for the
ofactor of monomer A are shown in stereo view. Both maps were calculated at final stages of refinement before modelling
f the ligands. The weak electron density at the the nicotinamide part of NADP+ (Fo-Fc maps) shows that this moiety of the
olecule is flexible. This figure has been produced using PyMol (DeLano, 2007).
J
AB149
Figure 76. (continues on next page)
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76. Unbiased Fo-Fc at 3σ (green) and final 2Fo-Fc at 1σ (blue) maps around ADP-β-mannose of monomers A-J of 
Å structure of AGME Y140F. The sugar molecule is modelled in the 2Fo-Fc density. Both electron densities for the
tide sugar of monomer A are shown in stereo view. Both maps were calculated at final stages of refinement before
ling of the ligands. This figure has been produced using PyMol (DeLano, 2007).
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There is clear electron density for one molecule of cofactor in each of the 20
monomers of the 2.8 Å structure (Figure 77). In 19 subunits enough electron density
was present to fit ADP-β-mannose. In one monomer (B) only ADP could be modelled 
in (Figure 78).
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Figure 77. Unbiased Fo-Fc at 3σ (green) and final 2Fo-Fc at 1σ (blue) maps around the NADP+ of monomers A-T of the 2.8
Å structure of AGME Y140F. The NADP+-molecule is modelled in the 2Fo-Fc density. Both electron densities for the
cofactor of monomer A are shown in stereo view. Both maps were calculated at final stages of refinement before modelling
of the ligands. The weak electron density at the the nicotinamide part of NADP+ (Fo-Fc maps) shows that this moiety of the
molecule is flexible. This figure has been produced using PyMol (DeLano, 2007).
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Figure 78. (continues on next page)
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Figure 78. Unbiased Fo-Fc at 3σ (green) and final 2Fo-Fc at 1σ (blue) maps around ADP-β-mannose of monomers A and 
C-T and ADP of monomer B of the 2.8 Å structure of AGME Y140F. The sugar molecule and ADP are modelled in the
2Fo-Fc density. Both electron densities for the nucleotide sugar of monomer A are shown in stereo view. Both maps were
calculated at final stages of refinement before modelling of the ligands. This figure has been produced using PyMol
(DeLano, 2007).
In the 2.4 Å resolution structure, cofactor and ADP-β-mannose molecules are 
essentially located at the same positions in all ten monomers (Figure 79). The Rmsd
values for the superimposed NADP molecules are in the range between 0.014-0.022 Å
and for the nucleotide sugars they vary between 0.084 and 0.121 Å. However, these
Rmsd values are lower than the estimated overall coordinate error (see Murshudov
and Dodson, 1997) The ESU (Estimated Standard Uncertainties) based on maximum
likelihood are 0.14 Å which means that these root mean square deviations are within
structural error.
T
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Figure 79. Stereo view of the ten superimposed NADP and ADP-β-mannose molecules of 2.4 Å AGME Y140F. This figure
has been produced using PyMol (DeLano, 2007).
In each of the twenty subunits of the lower resolution structure the ligands are
essentially positioned in the same locations as well (Figure 80). The Rmsd values for
the twenty superimposed coenzyme molecules differ in a range between 0.023-0.049
Å. The Rmsds for the nineteen superimposed nucleotide sugars (monomer B with
only ADP-fitted has not been considered) are slightly higher (between 0.201 and
0.319 Å).
Figure 80. Stereo view of the twenty superimposed NADP and nineteen ADP-β-mannose molecules of 2.8 Å AGME Y140F.
This figure has been produced using PyMol (DeLano, 2007).
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Superposition of the ligand molecules from one subunit of the higher resolution and
one monomer of the lower resolution structure (Figure 81) also shows that the
positions of the coenzymes and nucleotide sugars in the active site are essentially the
same in both structures. The Rmsd values for the aligned coenzymes and nucleotide
sugars are 0.11 Å and 0.23 Å, respectively. However, these Rmsd values are lower
than the estimated overall coordinate error of the structure (see Murshudov and
Dodson, 1997). The ESU (Estimated Standard Uncertainties) based on maximum
likelihood are 0.31 Å .
Figure 81. Stereo view of one superimposed NADP and ADP-β-mannose molecule from monomer A of the 2.4 Å (both
molecules in green) and 2.8 Å structure (both molecules in magenta) of AGME Y140F. This figure has been produced
using PyMol (DeLano, 2007).
2.14.2 NADP-binding site
As in the ten subunits of the AGME crystal structure in complex with ADP-α-glucose 
(Deacon et al., 2000), the NADP-molecules are essentially located at the same
positions in all ten or twenty monomers of AGME Y140F (Figures 79 and 80).
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If one superimposes the cofactor molecules from one subunit of the mutant enzyme on
one from that of the ADP-α-glucose bound structure (Figure 82) one can see very 
clearly that the ligands in both monomers also share more or less the same position.
Figure 82. Stereo view of the superimposed NADP-molecules from monomer A of 2.4 Å AGME Y140F and monomer A of
wildtype AGME (Deacon et al., 2000). This figure has been produced using PyMol (DeLano, 2007).
Contacts of the cofactor with the epimerase are discussed in detail by Deacon et al.,
2000. However, there are some notable distinctions between the mutant and Deacon
and coworkers’ structure. Closer inspection of the nicotinic acid amide moiety
revealed that the N7 and the O7 atoms of the carboxamide group are positioned
differently. Comparison to the NAD-molecules of the structurally most related
SDR-enzymes UDP-galactose 4-epimerase (Pdb accession code 1ek6) (Thoden et al.,
2000) and dTDP-D-glucose 4,6 dehydratase (Pdb accession code 1bxk) (Thoden et al.,
unpublished) (Deacon et al., 2000) shows that both atoms of the niacinamide are in
exactly the same positions as in AGME Y140F.
It has been reported that in UGE (Thoden et al., 2000; Thoden et al., 1996), DGD
(RmlB) (Allard et al., 2001a; Allard et al., 2004) and also RmlD (Blankenfeldt et al.,
2002), the nicotinic acid amide of the nicotinamide adenine dinucleotide phosphate
builds up an intramolecular H-bond between the amide and the α-PO4
3- of the adjacent
ribose (Thoden et al., 2000; Thoden et al., 1996; Allard et al., 2001a; Allard et al.,
2004 ; Blankenfeldt et al., 2002) to occur in a syn conformation with the B face being
orientated to the sugar (Thoden et al., 2000; Thoden et al., 1996; Blankenfeldt et al.,
2002; Deacon et al., 2000). For that reason it can be assumed that the same
intramolecular H-bond occurs in the nicotinamide of AGME Y140F as well. However,
one explanation for the different orientation of the carboxamide in Deacon and
coworkers’ structure could be that in most of the ten monomers of their structure the
carbonyl is in H-bonding distance to Lys178. Due to the fact that the C=O represents a
proton acceptor and the lysine usually carries a positive charge (NH3+) (Blankenfeldt
et al., 2002) a hydrogen bond could be formed between both groups and the amide
could become protonated. That is why it can be concluded that both orientations of the
carboxamide of the nicotinamide are acceptable. Figure 83 shows a superposition of
the nicotinamide moieties in all four structures.
Figure 83. Close up view of the superimposed nicotinamide moieties from monomer A
of wildtype AGME (Pdb accession code 1eq2) (Deacon et al., 2000), monomer A of UG
monomer A of DGD (Pdb accession code 1bxk). This figure has been produced using PUGE
DGD
AGME
AGME Y140F164
of 2.4 Å AGME Y140F, monomer A
E (1ek6) (Thoden et al., 2000) and
yMol (DeLano, 2007).
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There is no clear evidence that Cys78, which occurs in an oxidised state in the ten
monomers of the AGME structure (Deacon et al., 2000) is also oxidised in the ten or
twenty subunits of AGME Y140F. In the wildtype structure a direct coordination
occurs in a few subunits whereas in the other monomers Cys78 coordinates via H2O
(Deacon et al., 2000). The average B factors of the atoms in the cofactor molecules of
the 2.4 Å and 2.8 Å mutant structures are 34.8 Å2 and 36.1 Å2. These values are
slightly higher than the average atomic B factor of the NADP-molecules in Deacon
and coworkers’ structure which is 28.2 Å2. In the structure of AGME complexed to
ADP-α-glucose, the average B factor of the atoms of the niacinamide moiety (33.2 Å2)
is significantly higher than that of adenine (24.2 Å2) which has strong interactions
with residues of the enzyme indicating that the nicotinamide is more flexible (Deacon
et al., 2000).
The average atomic temperature factors of the nicotinic acid amide and adenine
moieties in both mutant structures, however, do not differ much (Table 33).
Furthermore, whereas the average B factors of the nicotinic acid amide part differ
between the monomers in Deacon and coworkers’ structure (Deacon et al., 2000),
essentially no differences between these values are observed in the ten subunits of the
2.4 Å and twenty monomers of the 2.8 Å mutant structure (Table 33).
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Table 33. Overview of average B values (Å2) of protein, ligands, diverse ligand moieties and H2O in the mutant
structures and the already published AGME structure. Differences over the monomers are given in brackets.
average B value (Å2) 2.4 Å mutant
structure
2.8 Å mutant
structure
AGME structure
(Deacon)
protein (mainchain) 32.8 35.6 29.1
protein (sidechain) 33.3 35.8 30.5
NADP 34.8 (-) 36.1 (-) 28.2 (26-34.8)
nicotinamide ring 35.4 (-) 36.7 (36.7-36.8) 33.2 (35.5-53.5)
adenine base 33.2 (-) 35.8 (35.7-35.8) 24.2 (16.9-26.2)
ADP-β(α)-mannose (glucose) 36-37 37.6 (37.4-37.9) 55.4 (45.4-61.8)
mannose (glucose) 41-42 41-43 72 (62.5-80.1)
adenine base 32.6 (32.1-32.9) 35.2 (34.4-35.4) 45 (26 -51)
water 40 28 34
2.14.3 Substrate-binding site
In all monomers of the 2.4 Å and in nineteen subunits of the 2.8 Å resolution mutant
structure, ADP-β-mannose is bound to the active site in one single conformation 
(Figures 79-81). In the subunits of AGME structure complexed to ADP-α-glucose 
(Deacon et al., 2000), however, the sugar moiety is disordered. For that reason it was
only possible to fit the whole nucleotide sugar into three of the ten monomers of the
asymmetric unit. Moreover, two completely distinct orientations of the glucose part
can also be observed in these three subunits (Deacon et al., 2000) (Figure 84).
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Figure 84. Stereo view of the superposition of NADP and ADP-β-mannose molecules from monomer A of the 2.4 Å
resolution AGME mutant (carbons in green) with the NADP and ADP-α-glucose-moieties from monomers B (C-atoms in
cyan) and D (carbons in magenta) of AGME (Pdb accession code 1eq2) (Deacon et al., 2000). This figure has been
produced using PyMol (DeLano, 2007).
The average B-factor of ADP-α-glucose (55.4 Å2) is significantly higher than that of
the coenzyme (28.2 Å2) and these values also show a great difference between the ten
subunits (Table 33). In the three ADP-α-glucose molecules the average B-factors of 
the sugar moieties are much higher than those of the adenine parts, 71.6 Å2 and 45.2
Å2, respectively (Deacon et al., 2000). The high average temperature factor of 72 Å2
at the hexose position indicates that this part is very flexible due to the disordered
electron density and the two different conformations. In both mutant structures,
however, the average atomic temperature factors of ADP-β-mannose are only slightly 
higher than those for the cofactor (Table 33). There, the B-factors of the nucleotide
sugar only vary slightly from subunit to subunit (Table 33). Unlike in the AGME
structure complexed with ADP-α-glucose (Deacon et al., 2000), the difference
between the average temperature factors of the mannose and adenine moieties of the
nucleotide sugar in both mutant structures is small (Table 33).
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The relatively low average B-factors of the mannose moiety in the mutants compared
to the high temperature factor of the glucose part in Deacon and coworkers’ structure
can be explained by the fact that the electron density for the mannose is well defined.
Given the similarity between the two mutant structures and within each monomer, the
A subunit of the 2.4 Å resolution structure is discussed. Any significant differences
amongst subunits or between the 2.4 and 2.8 Å structures are noted.
The adenine moiety of ADP-β-mannose interacts, like the base of ADP-α-glucose in 
Deacon and coworkers’ structure, particularly with hydrophobic residues such as
Val184, Leu200, Phe201 and Phe243 (Deacon et al., 2000) (Figure 85).
Figure 85. Stereo view of the adenine binding site in AGME Y140F. Hydrogen bonds are shown as dashed lines. This
figure has been produced using PyMol (DeLano, 2007).
In general the ribose part of ADP-β-mannose also shows the same associations with 
the protein as the pentose moiety of the adenosine diphosphate part of ADP-α-glucose 
(see Figure 5 (b), Deacon et al., 2000) (Figure 86).
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Figure 86. Stereo view of the ribose binding site in AGME Y140F. H-bonds between atoms of the pentose and amino acids
Ser180, Ala182 and His187 are shown as dotted lines. This figure has been produced using PyMol (DeLano, 2007).
The distances of amino acids of AGME Y140F which are in close contact to the
pyrophosphate moiety of ADP-β-mannose are also essentially identical to those 
responsible for the binding of the PPi of ADP-α-glucose (see Figure 5 (b), Deacon et
al., 2000) (Figure 87)
Figure 87. Close up view of the pyrophosphate binding site in AGME Y140F. Hydrogen bonds between atoms of the PPi
and amino acids Thr81, Arg209 and Asn169 are shown as dotted lines. This figure has been produced using PyMol
(DeLano, 2007).
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The most significant differences between the bound nucleotide sugars in the mutant
and Deacon and coworkers’ structures lie in the sugar moieties. Whereas two different
orientations of the glucose can be observed in AGME (Deacon et al., 2000), only one
conformation of the mannose part occurs in AGME Y140F. The oxygen at position 6
of mannose is in close contact with three residues, Ser116, Ala118 and 140Phe (Figure
88). The distances between O6 of mannose and CZ of 140Phe differ from 4.2 to 4.4 Å
over nine monomers. Only in subunit F the contact is not so close (4.8 Å). The oxygen
at position 6 of the hexose moiety is in hydrogen bonding distance to OG of Ser116.
The distances differ from 2.5 to 2.7 Å among the ten subunits. CB of Ala118 is the
third residue which is located in the vicinity of O6 of mannose. The distances from
monomer to monomer vary also only slightly (3.8-4.2 Å). Two residues are located
close to O2 of mannose, Lys178 and Met181 (Figure 88). Distances between O2 and
NZ of Lys178 range between 3.2 and 3.4 Å over the ten subunits, and O of Met181 is
positioned 3.2-3.3 Å from O2. The oxygen at position 3 of the hexose moiety is
hydrogen bonded to Ser79 and NZ of Lys178. O of Met181 is also closely located to
O3 of the mannose moiety (Figure 88). The distances from monomer to monomer
vary only slightly between 3.8 and 4.0 Å. O of Ser79 is also in H-bonding distance to
O4 of the sugar. The second amino acid closely located to this oxygen is 140Phe
(Figure 88). Distances between O4 and CZ of 140Phe range from 3.5 to 3.7 Å over
the ten monomers.
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Figure 88. Stereo view of the interactions of O2, O3, O4 and O6 of the mannose moiety of ADP-β-mannose (carbons in
cyan) in AGME Y140F with closely positioned residues (C-atoms in green). H-bonds are shown as dotted lines. This figure
has been produced using PyMol (DeLano, 2007).
If one compares the positions of mannose from AGME Y140F and glucose from
monomer D of Deacon and coworkers’ structure in the active sites, similarities and
also differences between both moieties can be observed (Figure 89).
Figure 89. Stereo view of superimposed ADP-β-mannose (carbon atoms in green) of AGME Y140F and ADP-α-glucose 
(carbons in cyan) from monomer D of AGME (Pdb accession code 1eq2). Residues close to the hexose moieties of both
molecules, and also the highly conserved Lys144 (Deacon et al., 2000) are also shown (C-atoms of residues of AGME
Y140F are shown in green and carbons of AGME in cyan). The exactly same positions of the active site residues (Ser116,
140Phe/Try140 and Lys144 (Deacon et al., 2000)) in both structures indicate that the mutation does not perturb the
catalytic region of AGME. This figure has been produced using PyMol (DeLano, 2007).
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The distance of 3.8 Å between the oxygen at position 6 of glucose and CZ of Tyr140
hardly differs from that of O6 of mannose to CZ of 140Phe (4.2-4.4 Å). The same
oxygen is positioned 3.3 Å from the hydroxyl group of the Tyr140 side chain. OG of
Ser116 is also located within H-bonding distance (3.0 Å) to O6 of the glucose moiety.
The distance of 4.4 Å to CB of Ala118 is also similar to the distance between O6 of
mannose and CB of Ala118 in the mutant structure (3.8-4.2 Å). O5 is also located at
almost the same position in both hexoses (Figure 89). However, due to the fact that
ADP-α-glucose and ADP-β-mannose display a diverse stereochemistry at C-1″ and 
C-2″ (Morrison and Tanner, 2007 Morrison et al., 2005), the other atoms of both
sugars occupy different positions (Figure 89). Whereas the glucose moiety in
monomer D of AGME is located at a relatively similar position as the mannose part in
AGME Y140F, the orientation of glucose in monomers B and F of AGME is
somewhat different (Deacon et al., 2000) (see Figure 84).
Investigation of the contact between C-6″ of the mannose/glucose moieties and C-4″ 
of NADP also revealed that the distances between the carbons at positions 6 of the
two completely different orientated Glc molecules and 4 of the cofactor are longer
(around 4 Å in monomer B, 4.1 Å in monomer F) (Deacon et al., 2000) (Figure 90A
and B) than that between C-6″ of mannose and C-4″ of the coenzyme in the mutant 
structure (2.9-3 Å over the ten subunits) (Figure 90C).
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Figure 90. Stereo view of the distances between C6 of the glucose moiety of ADP-α-glucose and C4 of NADP in
monomers B (4 Å) (A) and D (3.4 Å) (B) of AGME (Pdb accession code 1eq2) and between C6 of the mannose part of
ADP-β-mannose and C4 of NADP (2.9 Å) (C) of 2.4 Å AGME Y140F. This figure has been produced using PyMol
(DeLano, 2007).
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Discussion
The structure of AGME in complex with ADP-β-mannose displays significant 
differences to the wildtype enzyme when bound to ADP-α-glucose (Deacon et al.,
2000). In the mutant only one orientation of the sugar moiety is observed whereas the
hexose moiety of ADP-α-glucose in Deacon and coworkers’ structure has two 
completely different orientations. For that reason it has been difficult to propose a
mechanism for AGME based on structural data and biochemical analysis. It has been
suggested that Tyr140 and Lys178 could act as the catalytic bases (Morrison and
Tanner, 2007). However, the structure of AGME Y140F complexed with a substrate in
the β-manno configuration clearly shows that Lys178 is located too far (7.7 Å) from 
O6 of mannose, the position at which H+-abstraction and -addition takes place (Figure
91A) (Morrison and Tanner, 2007). If one rotates the C-5″-C-6″ bond by 120º so that
O6 is orientated in the same way as it would be in the other epimer, the distance
would still be too long (6.2 Å) for Lys178 to deprotonate the hydroxyl group (Figure
91B). This indicates that this Lys residue does not operate directly as a catalytic base.
The fact that the K178M mutant only displays 0.1% epimerase activity compared to
the wildtype protein (Morrison and Tanner, 2007) suggests that it plays some other
important role in the catalytic process.
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91. Stereo view of the distance between O6 of the mannose moiety of ADP-β-mannose and NZ of Lys178 of
E (7.7 Å) (A) and after a 120º rotation about the C-5″-C-6″ bond (6.2 Å) (B). Tyr140 has been modelled based on the 
n of 140Phe. This figure has been produced using PyMol (DeLano, 2007).
s been proposed that the Tyr residue of the catalytic triad always functions as the
lytic base which abstracts the H+ of the OH-group to oxidise an alcohol (or
ces the C=O group) (Morrison and Tanner, 2007). It has been suggested that, in
directly abstracts H+ from the substrate (Naismith, 2006; Morrison and Tanner,
).
Lys178 Lys178
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However, it has also been proposed, that H+-shuttling, in which the catalytic Ser plays
a role, may take place (Liu et al., 1997; Berger et al., 2001; Morrison and Tanner,
2007).
A one base mechanism has been proposed for dTDP-6-deoxy-L-lyxo-4-hexulose
reductase (RmlD) from Salmonella enterica serovar Typhimurium. This member of
the family of short chain dehydrogenases/reductases is essentially the best example to
study the reaction mechanism of SDR-enzymes. Unlike the majority of other
representatives of sugar metabolising enzymes which accomplish reactions in addition
to simply transferring H- to or from the coenzyme (Blankenfeldt et al., 2002), RmlD
just performs H--addition to position 4 (Blankenfeldt et al., 2002) of the substrate
dTDP-6-deoxy-L-lyxo-4-hexulose (Schnaitman and Klena, 1993; Reeves, 1994;
Graninger et al., 1999; Blankenfeldt et al., 2002). Amino acids which play a crucial
role in H--transfer are Tyr128, Lys132 and Thr104 (which is often replaced by Ser in
other SDRs) (Blankenfeldt et al., 2002). Thr104, Tyr128 and Lys132 represent the
catalytic triad (Jörnvall et al., 1995; Oppermann et al., 2003; Filling et al., 2002;
Blankenfeldt et al., 2002) in RmlD (Blankenfeldt et al., 2002). The catalytic acid/base
residue is Tyr128. The pKa value of the oxygen of the tyrosine’s phenolic side chain
has been decreased to <7 due to NH3+ of Lys132 (Blankenfeldt et al., 2002) and the
positively charged nitrogen of the niacinamide (Liu et al., 1997; Thoden et al., 2000;
Blankenfeldt et al., 2002) (3.6 Å between OH of Tyr128 and N1N of NADPH). This
lysine is not in H-bonding distance with Tyr128 (5.3 Å between OH of Tyr128 and
NZ of Lys132), however, it forms two H-bonds with O2D and O3D of the ribose
moiety of the coenzyme. The distances are 3.2 and 3.1 Å, respectively. Oη of Tyr128
also forms a H-bond with O2D (3.1 Å) of the pentose. The nicotinic acid amide of the
nicotinamide adenine dinucleotide phosphate also builds up an intramolecular H-bond
between the amide and the α-PO4
3- (2.7 Å between N7N of the
pyridine-3-carboxamide and O2N of the α-phosphate) to occur in a syn conformation
with the B face being orientated to the sugar (Blankenfeldt et al., 2002).
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In AGME complexed with ADP-β-mannose it is proposed that Tyr140 functions as the 
direct catalytic acid/base residue. Like in the structure of RmlD in complex with the
product dTDP-L-rhamnose (Blankenfeldt et al., 2002) the positively charged groups,
NH3+ of Lys144 and N1N of the cofactors moiety could also contribute to a decrease
of the pKa value of Oη of the conserved Tyr. The distance between OH of Tyr140 and
N1N of the nicotinamide is 3.9 Å. NZ of Lys144 and the hydroxyl group of Tyr140
are not located in hydrogen bond distance either (5 Å), but the side chain nitrogen of
Lys144 is also in close contact with the 2'OH and 3'OH of the cofactor’s ribose (3.9
and 2.9 Å, respectively) (Figure 92). Another parallel to the RmlD complex structure
is the presence of an H-bond between the conserved Tyr (Tyr140) and 2'OH of the
pentose moiety of the coenzyme (2.8 Å) (Figure 92). The orientation of the nicotinic
acid amide part is also in a syn conformation forming a short intramolecular H-bond
(Blankenfeldt et al., 2002) (Figure 92).
Figure 92. Stereo view of the distances between Tyr140 and Lys 144 and the 2'OH and 3'OH of the ribose of NADP (red
dotted lines), the distances between Tyr140 and Lys144 and Tyr140 and N1N of the nicotinamide (black dashed lines), and
the intramolecular H-bond of the cofactor (blue dotted line). Amino acids, NADP and ADP-β-mannose are shown as 
sticks .This figure has been produced using PyMol (DeLano, 2007).
Tyr140
Lys144 Lys144
Tyr140
H--transfer between C-6″ of the sugar moiety and C-4″ of the niacinamide ring 
requires that the C-6″-H of the hexose points directly to the carbon at position 4 of the 
nicotinamide (Morrison et al., 2005; Morrison and Tanner, 2007). Both structures,
RmlD in complex with dTDP-L-rhamnose, and AGME with ADP-β-mannose bound 
fulfil this requirement (Figure 93A and B).
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ure 93. Stereo views showing the orientation of the hydrogens of C-6″ of the mannose moiety in AGME (A) and C-4″ 
the rhamnose moiety in RmlD (Pdb accession code 1kc3) (B) in respect to C-4″ of the nicotinamide ring of the 
nzymes. Sugar moieties, cofactors (with hydrogens) and the conserved Tyr are shown as sticks. Distances between
″(mannose) / C-4″ (rhamnose) and C-4″ of the niacinamides are 2.9 Å and 3.1 Å, respectively. This figure has been
duced using PyMol (DeLano, 2007).
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The Ser or Thr residue of the catalytic triad of short chain dehydrogenases (Jörnvall et
al., 1995; Blankenfeldt et al., 2002) plays a role in short H-connections with the C=O
or OH of the substrate in SDR/substrate/cofactor complexes, however its specific
function is the subject of debate (Blankenfeldt et al., 2002). Firstly, it was proposed
that this amino acid functions as H+-shuttle (Naismith, 2006; Liu et al., 1997;
Blankenfeldt et al., 2002) because in abortive complexes it was observed that the Tyr
and the sugar moiety are not located closely enough to carry out H+-transfer without
the assistance of Ser (Thoden et al., 1996a, Blankenfeldt et al., 2002).
In the ternary AGME complex, the OH-group of Tyr140 is located more closely to O6
of the mannose moiety (3.3 Å) (Figure 94). The distance between OG of Ser116 and
O6 of the hexose is 2.5 Å (Figure 94), similar to that between the corresponding
atoms of the threonine and rhamnose in Blankenfeldt and coworkers’ structure. The
most significant difference between both complex structures lies in the distances
between the Tyr and Thr/Ser. In AGME OH of Tyr140 and OG of Ser116 are only
located 3.2 Å from each other (Figure 94) which would permit H+-shuttling. However,
due to the close distance between Tyr140 and O6 of mannose a proton shuttling
mechanism, involving another residue, would not be necessary. In non-abortive
complexes, for instance in the structure of RmlB from Streptococcus suis in complex
with dTDP-xylose (Allard et al., 2002; Blankenfeldt et al., 2002) or Arabidopsis
thaliana SQD1 with UDP-glucose bound (Mulichak et al., 1999), a closer contact
between Tyr and the sugar (about 2.5 Å) takes place. In both cases it is very possible
that a low-barrier H-bond (LBHB) between Tyr and the sugar is part of the
mechanism. In such a LBHB, one H+ is split between the oxygens of the Tyr and the
sugar (Blankenfeldt et al., 2002).
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Figure 94. Stereo view showing the distances (dashed lines) between Tyr140 and Ser116 and between both residues and O6
of the sugar moiety of ADP-β-mannose in AGME. This figure has been produced using PyMol (DeLano, 2007).  
No energy is needed then to move H+ from one oxygen to the other (Cleland et al.,
1998; Blankenfeldt et al., 2002). A LBHB connection between Tyr and the sugar
would be very advantageous because it abolishes the barrier for H+-addition to a C=O
connection or H+-abstraction from an OH-group (Blankenfeldt et al., 2002). It is
possible that in AGME Ser116 fulfils the role of “fine-tuning” (Blankenfeldt et al.,
2002) the transition state pKa.
We propose there is only one base, Tyr140. An inspection of the crystal structure of
AGME Y140F in complex with ADP-β-mannose reveals that the oxygen at position 6 
of the mannose moiety displays an orientation similar to the natural product
ADP-L-glycero-D-mannoheptose (Figure 95).
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Figure 95. Stereoview of ADP-β-mannose and Tyr140 from AGME. ADP-L,D-Hep is shown as comparison. The C-6”-OH
in all molecules is boxed. This figure has been produced using PyMol (DeLano, 2007).
If one rotates the C-5″-C-6″ bond of ADP-β-mannose by 120º, the orientation of O6 
would mimic that seen in the natural substrate ADP-D-glycero-D-mannoheptose
(Figure 96).
Figure 96. Stereo view of ADP-β-mannose after a 120º rotation about the C-5″-C-6″ bond and Tyr140 of AGME. 
ADP-D,D-Hep is shown as comparison. The C-6”-OH in all molecules is boxed This figure has been produced using
PyMol (DeLano, 2007).
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First, a transient oxidation of ADP-D,D-Hep at C-6″ takes place to form the 6″-ketone 
(Morrison and Tanner, 2007). Tyr140 (as tyrosinate) abstracts H+ from C-6-OH″ of 
ADP-D,D-Hep which occurs together with H- removal and transfer to NADP+ (Figure
97) to give NADPH and the keto-intermediate (Morrison and Tanner, 2007). The
distance between OH of the phenolic side chain of Tyr 140 and O6 of the mannose
moiety of ADP-β-mannose is only 2.1 Å (Figure 97) indicating that the tyrosine 
residue is propriately located to perform oxidation of the substrate.
Figure 97. Stereo view of the contacts between C-6″ of the sugar moiety of ADP-β-mannose (after a 120º rotation about 
the C-5″-C-6″ bond) and C-4″ of NADP+ and O6 of mannose and O of Tyr140 (2.1 Å). Hydrogens are shown in white,
directions of proton and hydride transfers as arrows, and distances as dashed lines This figure has been produced using
PyMol (DeLano, 2007).
Next, the C-5″-C-6″ connection of the 6″-ketone is rotated and the opposite face of 
the C=O is shown to NADPH. At this point the Tyr would not be located in an
appropriate way to add H+ to C=O (Morrison and Tanner, 2007) (Figure 98) and
would therefore be required to change its position.
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The catalytic region is large enough to allow this required movement of Tyr140
(Figure 99).
Figure 98. Stereo view of the same site as demonstrated in Figure 97. Hydrogens are shown in white. The required little
movement of Tyr140 (only 8.3º) to accommodate a proper position for adding H+ to the C=O group of the intermediate
(Morrison and Tanner, 2007) is shown as an arrow. This figure has been produced using PyMol (DeLano, 2007).
Figure 99. Stereo view of the active site of AGME. Tyr140 and atoms of the mannose moiety of ADP-β-mannose are shown 
as sticks. The required movement of the tyrosine residue into the other pocket of the catalytic region to be in an
appropriate position to add H+ the C=O group at position 6 of the rotated keto-intermediate (Morrison and Tanner, 2007)
is shown as arrow. This movement would not cause any clashes of Tyr140 with any amino acids of the protein. Ser116,
as most closely located residue, is now 2.4 Å from Tyr140. This figure has been produced using PyMol (DeLano, 2007).
Now, Tyr140 is properly located to protonate C=O which occurs together with H-
transfer from NADPH to C-6″ to generate NADP+ and ADP-L,D-Hep (Figure 100)
(Morrison and Tanner, 2007).
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Figure 100. Stereo view of contacts between C-6″ of the sugar moiety of ADP-β-mannose and C-4″ of NADPH and the 
location of the rotated intermediate in respect to the moved Tyr140. Hydrogens are shown in white, directions of proton
and hydride transfers as arrows. This figure has been produced using PyMol (DeLano, 2007)
The active site of AGME would also be large enough to accommodate the C-7″-OH of 
the substrate ADP-D,D-Hep (Figure 101A). C-7″-OH of ADP-D,D-Hep would not 
clash with any residues of the enzyme. The most closely located residue is Ser116
(Figure 101A) (2.6 Å between O7 of the substrate and OG of Ser116). However, in
the case of ADP-L,D-Hep, O7 would be located too closely to Ser116 (2.2 Å), C-6″ of 
the nicotinamide ring (2.1 Å) and also Tyr140 (2 Å) (Figure 101B). For that reason
small movements of either residues, niacinamide, or substrate would be required. A
movement of the tyrosine of about 35º would be required to increase the distance to
O7 of ADP-L,D-Hep (3.2 Å) (Figure 101B). However, Tyr140 would then clash with
Ser116 and Ala118 (distances of 2 Å ). For that reason a conformational change of the
active site would be necessary.
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Figure 101. Stereo views of the interactions of ADP-D,D-Hep (A) and ADP-L,D-Hep (B) with residues of AGME. The
nucleotide sugars, NADP and amino acids are shown as sticks. The 35º movement of Tyr140 is shown as an arrow. This
figure has been produced using PyMol (DeLano, 2007)
An overview of the whole reaction is shown in Figure 102.
Figure 102. Proposed one-base mechanism for the reaction catalysed by AGME. Tyr140 is the catalytic site acid/base
amino acid.
O
HO
OH
HO
OADP
O
HO
OH
HO
OADP
O
O
HO
OH
HO
OADP
O
HO
OH
HO
OADP
OH
OHH
HO
N ADP+
OH
A DP-D,D-Hep 6"-keto intermediate
rotation
HO
O
NADPH
H
HO
NAD P+
ADP-L,D-Hep
Tyr140- Tyr140H
HTyr140-Tyr140
NADPH
nicotinamide nicotinamide
B
186
Future aims
The structure of AGME Y140F in complex with a substrate in a β-manno 
configuration, ADP-β-mannose, has been solved allowing us to propose a one-base 
mechanism for the epimerisation reaction catalysed by AGME. The role of Lys178
has not been elucidated yet. It could be involved in substrate binding. It could be
attempted to crystallise the AGME K178M mutant in presence of ADP-β-mannose 
and/or ADP-D,D-Hep and/or the product ADP-L,D-Hep. A structure with one of those
nucleotide sugars bound to the active site would indicate that Lys 178 is not important
for sugar binding, whereas an empty active site would indicate that this lysine residue
plays a crucial role in substrate binding. Further work could also include the design of
inhibitors against AGME, to measure their inhibitory potencies and to try to get
crystal structures of AGME/inhibitor complexes to study interactions of the inhibitors
with this SDR enzyme.
CHAPTER 3
STRUCTURES OF THE
CATALYTIC DOMAIN OF
STROMELYSIN-1 (SCD) IN
COMPLEX WITH NONPEPTIDE
INHIBITORS
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Introduction
3.1 Matrix metalloproteinases
Gross and Lapiere (Gross and Lapiere, 1962) discovered the first matrix
metalloproteinase (MMP), collagenase, in the early 1960s (reviewed in Page-McCaw
et al., 2007). They discovered that there was a protein in tadpole tails during
disambiguation which was able to degrade collagen in fibrils (Gross and Lapiere,
1962). Later, a collagenase of the interstitium, collagenase-1, was discovered
(Birkedal-Hansen et al., 1993). In vitro, collagenase-1 is involved in the degradation
of collagens in fibrils, which are essential parts of the extracellular matrix (ECM) in
vertebrates. This enzyme cuts amide bonds in collagens (Welgus et al., 1983). After
further studies had been performed the family of enzymes was found, named matrix
metalloproteinases. The fact that high levels of matrix metalloproteinases were
observed in various diseases in humans such as tumours and rheumatoid arthritis
drove the interest in this protein family (see review Page-McCaw et al., 2007). The
fact that a higher level of matrix metalloproteinase activity can favour or block cancer
development shows that the relationship between matrix metalloproteinases and
disease is complex (reviewed in Page-McCaw et al., 2007). Initially, it was assumed
that matrix metalloproteinases are only involved in degradation of parts of the
extracellular matrix but they also participate in other processes (reviewed in
Page-McCaw et al., 2007). They can play a role in cell movement, in the generation
of “specific substrate-cleavage fragments” and in the control of tissue composition
(Page-McCaw et al., 2007). Moreover, they are also involved in the activation,
deactivation or modification of signalling molecules (Figure 103) (Page-McCaw et al.,
2007).
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Because of proteolysis of substrates of the extracellular matrix, carried out by matrix
metalloproteinase, fragments which act distinctively compared to their precursor
molecules are yielded. Examples for substrates of matrix metalloproteinases represent
cell-adhesion molecules, tyrosine kinase receptors, chemokines, peptide growth
factors, cytokines, other matrix metalloproteinases and proteolytic proteins (reviewed
in Page-McCaw et al., 2007).
Figure 103. (taken from Page-McCaw et al., 2007) Possible modes of matrix metalloproteinase action. Members of this
enzyme family have the ability to cut parts of the extracullar matrix, which leads to more space for cells or tissues to
migrate (a). Specific autocrine or paracrine signalling molecules can also be produced by cleavage carried out by matrix
metalloproteinases (b). Matrix metalloproteinases are also able to directly control the composition of the tissue of the
epithelium by cutting junctions between cells or the basement membrane (c). The action of cryptic signalling molecules
can also be activated or altered by this family of proteinases which leads to various processes in cells (d). Deactivation or
change of the function of signalling compounds which leads to modifications in cell death, proliferation, cell motility or
differentation can also be accomplished by matrix metalloproteinases (Page-McCaw et al., 2007).
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3.1.1 Structure of matrix metalloproteinases
Matrix metalloproteinases are referred to as “the matrixin subfamily of zinc
metalloprotease family M10 in the MEROPS database (http://www.merops.
sanger.ac.uk/)” (Nagase et al., 2006). In general matrix metalloproteinases contain a
prosegment of approximately 80 residues, a region of around 170 residues,
responsible for catalysis, a linker or “hinge region” and a haemopexin (Hpx) region
which is around 200 residues long. Highly conserved motifs in matrixins are the
His-Glu-X-X-His-X-X-Gly-X-X-His cluster which interacts with Zn2+ and can be
found the catalytic region, and the “Cys-switch” fingerprint
Pro-Arg-Cys-Gly-X-Pro-Asp which is part of the prosegment (Figure 104). The
three His of the His-Glu-X-X-His-X-X-Gly-X-X-His cluster and the Cys of the
“Cys-switch” sequence ligate the Zn2+ which is involved in catalysis. Because of the
cysteine-zinc interaction pro-matrix metalloproteinases do not display any activity, as
the H2O is unable to interact with the catalytic Zn2+ (Nagase et al., 2006). A
“Met-turn” is present eight amino acids after the Zn2+ interacting region (Figure 104),
which stabilises the structure surrounding this Zn2+ (Bode et al., 1993; Nagase et al.,
2006).
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MMP1_HUMAN PDAETLKVMKQPRCGVPDVA---------QFVLTEGNPRWEQTHLTYRIENYTP--DLPRADVDHAIEKAFQLWSNVTPLTFTKVS----
MMP2_HUMAN LDQNTIETMRKPRCGNPDVA---------NYNFFPRKPKWDKNQITYRIIGYTP--DLDPETVDDAFARAFQVWSDVTPLRFSRIH----
MMP3_HUMAN LDSDTLEVMRKPRCGVPDVG---------HFRTFPGIPKWRKTHLTYRIVNYTP--DLPKDAVDSAVEKALKVWEEVTPLTFSRLY----
MMP7_HUMAN LNSRVIEIMQKPRCGVPDVA---------EYSLFPNSPKWTSKVVTYRIVSYTR--DLPHITVDRLVSKALNMWGKEIPLHFRKVV----
MMP9_HUMAN LDSATLKAMRTPRCGVPDLG---------RFQTFEGDLKWHHHNITYWIQNYSE--DLPRAVIDDAFARAFALWSAVTPLTFTRVY----
MMP10_HUMAN LDTDTLEVMRKPRCGVPDVG---------HFSSFPGMPKWRKTHLTYRIVNYTP--DLPRDAVDSAIEKALKVWEEVTPLTFSRLY----
MMP11_HUMAN --------LRPPRCGVPDPS-DGLSARNRQKRFVLSGGRWEKTDLTYRILRFP--WQLVQEQVRQTMAEALKVWSDVTPLTFTEV-----
MMP12_HUMAN LDTSTLEMMHAPRCGVPDVH---------HFREMPGGPVWRKHYITYRINNYTP--DMNREDVDYAIRKAFQVWSNVTPLKFSKIN----
MMP14_HUMAN ADADTMKAMRRPRCGVPDKFGAEIKANVRRKRYAIQGLKWQHNEITFCIQNYTP--KVGEYATYEAIRKAFRVWESATPLRFREVPYAYI
*** * * * * ** *
MMP1_HUMAN ----EGQADIMISFVRGDHRDNSPFDGPGGNLAHAFQPGP-GIGGDAHFDEDERWTNN--------------------------
MMP2_HUMAN ----DGEADIMINFGRWEHGDGYPFDGKDGLLAHAFAPGT-GVGGDSHFDDDELWTLGEGRSDGKMWCATTANYDDDRKWGFCP
MMP3_HUMAN ----EGEADIMISFAVREHGDFYPFDGPGNVLAHAYAPGP-GINGDAHFDDDEQWTKD—------------------------
MMP7_HUMAN ----WGTADIMIGFARGAHGDSYPFDGPGNTLAHAFAPGT-GLGGDAHFDEDERWTDGS-------------------------
MMP9_HUMAN ----SRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGP-GIQGDAHFDDDELWSLGKGRGDGRLWCATTSNFDSDKKWGFCP
MMP10_HUMAN ----EGEADIMISFAVKEHGDFYSFDGPGHSLAHAYPPGP-GLYGDIHFDDDEKWTED--------------------------
MMP11_HUMAN ---HEGRADIMIDFARYWHGDDLPFDGPGGILAHAFFPKTHR-EGDVHFDYDETWTIG—------------------------
MMP12_HUMAN ----TGMADILVVFARGAHGDFHAFDGKGGILAHAFGPGS-GIGGDAHFDEDEFWTTH--------------------------
MMP14_HUMAN REGHEKQADIMIFFAEGFHGDSTPFDGEGGFLAHAYFPGPN-IGGDTHFDSAEPWTVRNE------------------------
** * * * *** *** * ** *** * *
MMP1_HUMAN FREYNLHRVAAHELGHSLGLSHSTDIGALMYPSY--TFSG--DVQLAQDDIDGIQAIYG---------RSQNPVQP
MMP2_HUMAN DQGYSLFLVAAHEFGHAMGLEHSQDPGALMAPIY----TYTKNFRLSQDDIKGIQELYGASPDIDLGTGPTPTLGP
MMP3_HUMAN TTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLYH-SLTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVP
MMP7_HUMAN SLGINFLYAATHELGHSLGMGHSSDPNAVMYPTY--GNGDPQNFKLSQDDIKGIQKLYGKRSNSRKK---------
MMP9_HUMAN DQGYSLFLVAAHEFGHALGLDHSSVPEALMYPMY----RFTEGPPLHKDDVNGIRHLYGPRPEPEPRPPTTTTPQP
MMP10_HUMAN ASGTNLFLVAAHELGHSLGLFHSANTEALMYPLYN-SFTELAQFRLSQDDVNGIQSLYGPPPASTEEPLVPTKSVP
MMP11_HUMAN DQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYT----FRYPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQA
MMP12_HUMAN SGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTY--KYVDINTFRLSADDIRGIQSLYG-------DPKENQRLPN
MMP14_HUMAN LNGNDIFLVAVHELGHALGLEHSSDPSAIMAPFYQ—WMDTENFVLPDDDRRGIQQLYGGESGFPTKMPPQPRTTS
* ** ** * * * * * **
Figure 104. Structural sequence alignment of various MMPs (MMP-1, UniProtKB/TrEMBL entry P03956; MMP-2,
UniProtKB/TrEMBL entry P08253; MMP-3, UniProtKB/TrEMBL entry P08254; MMP-7, UniProtKB/TrEMBL entry
P09237; MMP-9, UniProtKB/TrEMBL entry P14780; MMP-10, UniProtKB/TrEMBL entry P09238; MMP-11,
UniProtKB/TrEMBL entry P24347; MMP-12, UniProtKB/TrEMBL entry P39900; MMP-14, UniProtKB/TrEMBL entry
P50281) from Homo sapiens. The conserved “Cys switch” fingerprint (Nagase et al., 2006) sequence is highlighted in
yellow, the Zn2+ associating motif in green, and the Met residue, 8 amino acids after the Zn2+ interacting cluster (Nagase et
al., 2006) in turquoise. Residues conserved in all nine matrix metalloproteinases are highlighted in magenta and marked
with asterisks. This sequence alignment was carried out using the programme ClustalW (Chenna et al., 2003).
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The His-Glu-X-X-His-X-X-Gly-X-X-His cluster and the “Met-turn” also occur in
other protein families such as ADAM (a disintegrin and metalloproteinase),
ADAMTS (ADAM with thrombospondin fingerprint sequences), the astacins and
serralysins (Nagase et al., 2006). For that reason they are all named “metzincins”
(Bode et al., 1993).
The structures of the catalytic regions of matrixins are essentially identical. The
secondary structural elements of this region are three α-helices and five β-strands 
which are linked by loops. One catalytic and one structural Zn2+, and usually three
Ca2+ which are responsible for the stabilisation of the protein are present in this
domain. The prosegment of MMPs is composed of three α-helices and loops. The 
“Cys switch” is located in the region responsible for substrate interaction, however,
the propeptide binds in a reverse way with respect to a peptide substrate (Nagase et al.,
2006). Cleavage of the prosegment allows the catalytic region to digest diverse
substrates. The haemopexin region which occurs in the majority of matrixins consists
of a “four-bladed β-propeller structure” that plays a role in associations between 
proteins and possibly substrate recognition (reviewed in Page-McCaw et al., 2007).
The haemopexin region also has an influence on protease activity and is involved in
protease degradation as well (Overall, 2002).
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3.1.2 Domains of matrix metalloproteinases
Due to different occurrence and arrangement of the domains (Figure 105) and the fact
that matrix metalloproteinases favour distinct substrates, they can be divided into
stromelysins, matrilysins, gelatinases, membrane-type (MT)-matrixins, collagenases
and others (Visse and Nagase, 2003; Nagase et al., 2006; Catania et al., 2007). A
detailed description of members of these families and their functions can be found in
Nagase et al., 2006.
Figure 105. (taken from Nagase et al., 2006) Organisation of the various domains of matrix metalloproteinases. sp: signal
sequence; pro: prosegment; cat: region responsible for catalysis; FNII: fibronectin type II motif; L1: linker or
“hinge-region”; Hpx: hemopexin region; CysR: cysteine rich; Ig: immunoglobulin part; L2: second connection; Mb:
plasma membrane;TM: transmembrane domain; GPI: glycosylphosphtidylinositol anchor; Cy: tail located in the
cytoplasm.
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3.1.3 Stromelysin-1 (MMP-3)
Initially it was thought that MMP-3 participates in the synovitis cascade (Marcy et al.,
1991). The molecular weight of MMP-3 containing all domains is 52 kDa, and it
needs zinc to be active (Chen et al., 1999). Glycoproteins, several parts of the ECM
such as fibronectin and laminin and also collagens and procollagens are targets of this
matrixin (Welgus, 1991; Chen et al., 1999). Furthermore MMP-3 can undergo
autocatalysis and is also able to cleave a range of other members of the matrixin
family (Nagase et al., 1991; Chen et al., 1999).
3.1.3.1 Structure of pro-stromelysin-1
Matrixins containing all their domains are flexible in their nature and for that reason it
is not easy to obtain crystals of them (Dhanaraj et al., 1996). Initially it has been
reported that only entire MMP-1s from Sus scrofa (mature form) gave crystals of an
appropriate stability to perform crystallographic studies. (Dhanaraj et al., 1996; Li et
al., 1995). However, ten years later, the structure proMMP-1 from Homo sapiens was
solved comprising the prosegment, catalytic region, hinge peptide and haemopexin
region (Jozic et al., 2005). However, most X-ray structures of MMPs such as
stromelysin-1 (Kohno et al., 2006; Pikul et al., 2001; Dunten et al., 2001; Cheng et al.,
2000; Steele et al., 2000; Pavlovsky et al., 1999; Chen et al., 1999; Dhanaraj et al.,
1996; Becker et al., 1995) are only of the catalytic domain. In the case of MMP-3 all
published structures are those of the catalytic domain only except the one published
by Becker et al., 1995 which contains the propeptide.
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A structure of stromelysin-1 including the Hpx domain has not been published yet. In
prostromelysin-1, the structure of the segment, responsible for catalysis is almost
identical to the catalytic region of the mature enzyme (Becker et al., 1995). The
prosegment of pro-stromelysin-1 is, as in other proMMPs (Nagase et al., 2006), such
as pro-MMP-1 (Jozic et al., 2005) composed of three α-helices and a prosegment 
(Becker et al., 1995) (Figures 107 and 108A and B).
In proMMP-3 this region contains amino acids 16-82. The first 15 amino acids and
amino acids 31-39 are disordered (Becker et al., 1995).
Figure 107. Stereo ribbon diagram of the prosegment of pro-MMP-3 (Pdb accession code 1slm). This figure has been
produced using PyMol (DeLano, 2007).
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 108. (A) Stereo view of Cα tracing of the prodomains of pro-MMP-3 from Homo sapiens (in green, Pdb accession
slm) and human pro-MMP-1 (in magenta, Pdb accession code 1su3) after their superposition. (B) Stereo ribbon
ms of both structures after their superposition. This figure has been produced using PyMol (DeLano, 2007).
rms deviation between both prosegments is 0.65 Å for 52 Cα positions. The 
egment occupies the catalytic region of pro-stromelysin-1, and there is an
ciation between Cys75 and the Zn2+ crucial for catalysis (Figure 109) (Becker et
995).
estingly, the propeptide interacts in an opposite way to propeptide-derived
kers bound to stromelysin and collagenase (Becker et al., 1995). The interactions
eptide-based blockers will be discussed in detail in section 3.1.3.3. The
82-Phe83 connection is cut and processed stromelysin-1 generated (Cameron et
995; Becker et al., 1995).
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Figure 109. Stereo view of the region around the catalytic Zn2+ in pro-stromelysin-1 (Pdb accession code 1slm). Secondary
structural elements of the prosegment and the catalytic domain are coloured in green and cyan, respectively. Residues
from each of the two domains ligated with Zn2+ (grey sphere) are shown as sticks. This figure has been produced using
PyMol (DeLano, 2007).
3.1.3.2 Structure of the catalytic domain of stromelysin-1
“Recombinant human truncated stromelysin (RHTS)” (Chen et al., 1999) comprises
the catalytic region of MMP-3. It comprises the region from Phe83 to Thr255 and its
molecular weight is about 20 kDa (Chen et al., 1999). RHTS displays similarity to
stromelysin-1 containing all domains in regard to enzymatic activity, preference and
susceptibility to blocking compounds (Marcy et al., 1991; Ye et al., 1992; Chen et al.,
1999).
The catalytic domain of stromelysin-1 displays “an α/β-type” (Chen et al., 1999)
fold common to all members of the matrixin family (Figure 110) (Chen et al., 1999).
Cys75
His201
His205
His211
Cys75
is
His205
is211
Cys75
His211
His201
His205
Fig
sho
L))
por
str
figu
NC C N
L
1
2
3
12
3 4
5
N
C
L
12
3 4
5
1
2
3 N
C
L
AB
N
C
N
Cure
wn
. (B
cin
uct
re197
110. (A) Stereo view of the structure of RHTS (Pdb accession code 1cqr) (based on Chen et al., 1999). α-helices are 
 in cyan, β-sheets in red and loops in magenta (flexible loop from amino acids 210-234 (Chen et al., 1999) labelled as
) C-α tracing of the catalytic domain of stromelysin-1 from Homo sapiens (in cyan, Pdb accession code 1cqr) and
e MMP-1 (in magenta, Pdb accession code 1fbl) after their superposition. The rms deviation between both
ures is 0.49 Å for 141 Cα positions. (C) Ribbon stereo diagrams of both structures after their superposition. This
has been produced using PyMol (DeLano, 2007).
C
198
3.1.3.2.1 Location of metal ion sites
The catalytic domain of stromelysin-1 contains two zinc ions. One is involved in
catalysis and the second one is the structural Zn2+ (Dhanaraj et al., 1996) The catalytic
Zn2+ is ligated with NE2 of His201, His205 and His211 (Dhanaraj et al., 1996). The
distances between those nitrogens and Zn2+ vary between 2.1-2.2 Å (Figure 111). It is
also possible that additionally to the interactions with the three histidines this zinc ion
can also bind to one or two other atoms. These atoms can be part of either another
protein or H2O, or groups accomplished by a substrate or inhibitor (Chen et al., 1999).
Figure 111. Close up view of the interactions between NE2 of His201, His205 and His211 and the catalytic Zn2+ in RHTS
(Chen et al., 1999) (Pdb accession code 1cqr). The three histidines are shown as sticks, and the catalytic zinc as grey
sphere and distances as dotted lines. This figure has been produced using PyMol (DeLano, 2007).
The structural Zn2+ is situated between the third and fourth β-helix and is ligated by 
NE2 of His 151 and His 166, ND1 of His179 and OD2 of Asp153 (Figure 112)
(Dhanaraj et al., 1996).
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Figure 112. Close up view of the interactions of NE2 of His151 and His166, ND1 of His179 and OD2 of Asp153 with the
structural Zn2+ in RHTS (Pdb accession code 1cqr) (Chen et al., 1999). The three histidines and the aspartic acid are
shown as sticks, the catalytic zinc as grey sphere and distances as dashed lines. This figure has been produced using
PyMol (DeLano, 2007).
Matrixins need Ca2+ to be active (Marcy et al., 1991) and the majority contain three
Ca2+ in their catalytic region (Nagase et al., 2006; Chen et al., 1999). In MMP-3, Ca1
is ligated by OD1 of Asp158, the oxygens of Gly159, Gly161 and Val163, OD2 of
Asp181 and OE2 of Glu184 (Chen et al., 1999; Dhanaraj et al., 1996). Ca2 is ligated
by OD1 of Asp107 and Asp182, O of Asp182 and Glu184 and two H2O (Figure 113B)
(Chen et al., 1999). Ca3 is in close contact with O-atoms provided by Asp141, Gly173,
Asn175 and Asp177 (Figure 113C) (Chen et al., 1999).
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3.1.3.2.2 The active site and subsites of the catalytic domain of MMP-3
The catalytic region of MMP-3 including Zn2+ is situated in a big crevice (Figure
110A) surrounded by α2, β5 and a loop which shows flexibility (amino acids 
210-234). His201 and His205 which coordinate the Zn2+ belong to α2. β5 can 
participate in the interaction with an inhibitor. The subsite S1' is formed by the loop.
(Chen et al., 1999). The S1' subsite is in general non-polar but its size is different
depending on the particular matrixin. It has a great influence on the substrate
preference. When a substrate interacts with the protein, the H2O bound to Zn2+ moves.
COO- of Glu in the catalytic region enables the cleavage of the amide bond. It takes
H+ from the shifted H2O and consequently, the polarized H2O can perform a
nucleophilic attack on the C of C=O of the amide bond (Nagase et al., 2006).
Inhibitors interact with Zn2+ and have other regions denoted P1, P2, P1΄, P2΄ which 
match sites S1, S2, S1΄, S2΄ on the protein (Chen et al., 1999).
In stromelysin-1 the S1' subsite is bulky and broad (Figure 114). It is built up by
nonpolar amino acids such as Leu164, Leu197, Val198, Leu218, Met219, Pro221 and
Leu222. Other residues which contribute to the formation of this pocket are His201
and Tyr223. Consequently, the P1' moiety of an inhibitor should not display any
polarity and because of the large size of this cavity it can also be quite long. Crucial
amino acids which bind to a P1' moiety are Leu164, Leu197, Val198, His201, Pro221,
Leu222 and Tyr223. The S2' subsite of MMP-3 is also hydrophobic. Amino acids
involved in the formation of this substrate binding site are Asn162, Val163 and
Leu164. P2' and also P3' moieties can be comparatively hydrophilic because they
point to the solvent. The P3' moity is normally quite bulky in molecules which block
matrixin 1, however, the same group does not need this feature in stromelysin-1
inhibitors (Chen et al., 1999).
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The S1 and S3 substrate binding sites (Figure 114) which belong to the “unprimed
side” (Finzel et al., 1998) (S1-S4) essentially create “one large open space” (Finzel et
al., 1998) which is made up by amino acids Tyr155, His166, Ala167 and Tyr168
(Finzel et al., 1998). One wall of the S1 subsite is formed by the Phe residues at
positions 86 and 210, His205, His211 and Zn2+. Tyr155 and Tyr168 form the other
wall. The bottom of this substrate binding site is built up by amino acids
Ala165-Tyr168 (Pavlovsky et al., 1999). The S2 subsite (Figure 114), a “shallow
depression” (Finzel et al., 1998) is built up by His205, Phe210 and Phe86. Phe86,
Pro87, Pro90 and Ala169 form the substrate binding site S4 (Finzel et al., 1998).
Figure 114. (based on Finzel et al., 1998) A surface diagram to show the location of the subsites S1, S2, S3, S4, S1', S2' and
S3' in the catalytic domain of stromelysin-1 (Pdb accession code 1usn) (shown as surface). Carbons are shown in green,
oxygens in red and nitrogen sin blue. The catalytic zinc ion is shown as grey sphere. This figure has been produced using
PyMol (DeLano, 2007).
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3.1.3.3 Inhibitors of stromelysin-1
Insights into the blocking mechanism of endogenous tissue inhibitors of
metalloproteinases (TIMPs) have been provided by several X-ray structures of
matrixins in complex with them. These blockers are usually “wedge-shaped (Figure
115A) (Gomis-Rüth et al., 1997; Fernandez-Catalan et al., 1998). In the structure of
the catalytic domain of MMP-3 complexed with TIMP-1 (Gomis-Rüth et al., 1997),
the first four amino acids of the protein (Cys1-Val4) and the amino acids
Glu67-Cys70 are connected by a S-S bridge from an adjacent backbone which plugs
into the catalytic region of the matrixin (Nagase et al., 2006; Gomis-Rüth et al., 1997).
The α-NH2- and the C=O group of Cys1 interact with the catalytic Zn2+ (Gomis-Rüth
et al., 1997). Additionally, H-bonds could also be generated between this
α-NH2-group and O of C=O of Ser 68 and O of COO- of Glu202 of stromelysin-1
(Gomis-Rüth et al., 1997) (Figure 115B) The side chain of Thr2 points into the S1'
subsite (Gomis-Rüth et al., 1997). If this amino acid is substituted, binding of the
inhibitor to a matrixin will be altered, for instance, mutation to Gly at this position
leads to an inactive inhibitor (Meng et al., 1999).
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ure 115. (A) (based on Nagase et al., 2006; Gomis-Rüth et al., 1997) Stereo ribbon diagram of the catalytic region of
trixin 3 (cyan) complexed with TIMP-1 (magenta) (Pdb accession code 1uea). Amino acids Cys1-Val4 and Glu67-Cys70
the inhibitor are shown as spheres (based on Gomis-Rüth et al., 1997 and Nagase et al., 2006). (B) (based on
mis-Rüth et al., 1997) Stereo ribbon diagram of the residues in the vicinity of the catalytic Zn2+. The three conserved
tidines of MMP-3 and N and O of Cys1 of the inhibitor interact with the catalytic Zn2+ (grey sphere) (Gomis-Rüth et al.,
7). Residues of the matrixin (carbons in green) and TIMP-1 (carbons in yellow) are shown as sticks. This figure has
n produced using PyMol (DeLano, 2007).
MPs are native blockers of matrixins (Steele et al., 2000) which bind their targets in
1:1 ratio (Willenbrock and Murphy, 1994; Gomis-Rüth et al., 1997; Steele et al.,
00).
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Because of their size (Steele et al., 2000) (184-194 amino acids) (Nagase et al., 2006)
and broad inhibitory spectrum (Gomis-Rüth et al., 1997) their use in therapy is
restricted (Steele et al., 2000). That is why the design of inhibitors of MMP-3 and
other matrixins which are small and more specific is desirable (Steele et al., 2000).
The first synthetic inhibitors displayed a structure derived from the prodomain of
matrixins (Fotouhi et al., 1994; Steele et al., 2000). It has been shown that this kind of
inhibitors interact with the catalytic site of a particular MMP in an opposite direction
with respect to the prosegment (Becker et al., 1995; Dhanaraj et al., 1996; Steele et al.,
2000). The inhibitors normally have a moiety such as OP(OR)R2, OP(OR)2R COO- or
R-CO-NH-O-, which coordinates the catalytic Zn2+ (Morphy et al., 1995; Pavlovsky et
al., 1999).
An example for a complex structure of the catalytic domain of MMP-3 and a
propeptide derived inhibitor was reported by Steele et al., 2000. The bound inhibitor
is named Ro-26-2812, contains a diphenyl group and the prosegment derived
tripeptide Cys-Gly-Val, and has a half maximal inhibitory concentration of 1.6 μM. It 
interacts with the S1'- S3' subsites of the enzyme (Steele et al., 2000) (Figure 116).
Figure 116. Surface representation of the interactions of Ro-26-2812 with subsites of the catalytic domain of stromelysin-1
(Pdb accession code 1c3i) The inhibitor is shown as sticks and the catalytic zinc ion as grey sphere. This figure has been
produced using PyMol (DeLano, 2007).
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Zn2+ ligates with the S-atom of the Cys-group of Ro-26-2812 (Figures 116 and 117).
Its phenyl benzene moiety fills the S1' cavity (Figures 116 and 117). O of the COOH
group of the Cys group of Ro-26-2812 generates a H-bond with N of Leu164 (2.6 Å)
(Figure 117). O of the COOH group of the Gly of Ro-26-2812 forms a H-bond with N
of Tyr223 and the amide of the same group is in close contact with O of Pro221
(Figure 117). The amide of the Val of Ro-26-2812 generates a H-bond with O of the
COOH group of Asn162 (Steele et al., 2000) (Figure 117).
Figure 117. (based on Steele et al., 2000) Stereo view of close interactions of Ro-26-2812 with residues of the catalytic
domain of stromelysin-1 (Pdb accession code 1c3i). Amino acids (carbons in green) and the inhibitor (C-atoms in magenta)
are shown as sticks, the catalytic Zn2+ as grey sphere. This figure has been produced using PyMol (DeLano, 2007).
Unlike Ro-26-2812, the Cys-Gly-Val tripeptide of the prosegment (Becker et al., 1995)
interacts with different subsites of MMP-3 (Steele et al., 2000). Gly and Val bind to
the S1 and S2 substrate binding sites (Steele et al., 2000) whereas the S1' substrate
binding site is not occupied (Becker et al., 1995). Unlike in the Ro-26-2812/MMP-3
complex, there are no H-bonds between O-atoms of any COOH group in the
tripeptide and the enzyme. The amide of Val does not generate any H-bonds either
(Steele et al., 2000) (Figure 118).
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Figure 118. Stereo view showing the binding mode of the Cys-Gly-Val sequence of the propeptide to the catalytic domain
stromelysin-1 (Pdb accession code 1slm). Amino acids (carbons in green) and the tripeptide (C-atoms in magenta) are
shown as sticks, the catalytic Zn2+ as grey sphere. This figure has been produced using PyMol (DeLano, 2007).
If one compares the orientation and interactions of Ro-26-2812 to other peptide based
inhibitors of the catalytic domain of stromelysin-1 (Becker et al., 1995; Dhanaraj et
al., 1996; Esser et al., 1997) they all bind in a similar fashion. In the structure of
MMP-3 in complex with the hydroxamate inhibitor PD-140798, the subsites S1'-S3'
are also occupied by the various moieties of the inhibitor. The substrate binding sites
S1' and S2' are filled by leucine groups whereas a phenylalanine moiety points into
the S3' subsite. Two O-atoms of the hydroxamic acid moity of PD-140798 coordinate
with the catalytic Zn2+ (Dhanaraj et al., 1996). Becker and coworkers determined the
crystal structure of the catalytic domain of stromelysin-1 complexed with the
N-carboxyalkyl peptide inhibitor I (Figure 118) (Ki = 0.23 μM) (Becker et al., 1995;
Chapman et al., 1993). The S1' substrate binding site is occupied by a
homophenylalanine moiety (Becker et al., 1995). The P2' group of this inhibitor is an
Arg, the side chain of which is exposed to the solvent, the P3' moiety is an anilide
(Gooley et al., 1994). The COOH group of N-carboxyalkyl peptide inhibitor I
interacts with the catalytic Zn2+ (Becker et al., 1995). Based on this complex a series
of more potent carboxyalkylpeptides was synthesized (Esser et al., 1997).
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An X-ray structure complexed with one of those inhibitors, L-764,004
(stromelysin-1-Ki = 2 nM) (Figure 119) was determined. It contains a
4-fluorodiphenylethyl moiety as P1', an iso-butyl moiety as P2' (Esser et al., 1997)
and the same anilide moiety as P3' group (Gooley et al., 1994). Additionally a CnH2n+1
chain with a benzolactam functions as P1 group (Esser et al., 1997).
Figure 119. (after Becker et al., 1995; Esser et al., 1997) Chemical structures of the N-carb
al., 1995; Chapman et al., 1993) (left) and L-764,004 (Esser et al., 1997 (right).
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Figure 120. (after Esser et al., 1997) Overview of the structure-activity relationship for P1'-lemonene-ethyl carboxylate
blockers of stromelysin-1.
In general, many peptide based inhibitors are only very potent in vitro, block a range
of matrixins (Pavlovsky et al., 1999; Finzel et al., 1998) and do not display high
bioavailability (Pavlovsky et al., 1999) or good solubility or long serum half life, thus
are unsuitable for therapeutical applications (Finzel et al., 1998). For that reason
various so called “nonpeptide inhibitors” have been designed (Pavlovsky et al., 1999;
Finzel et al., 1998). The design of most of these compounds is based on interactions
with the S1' substrate binding site (Finzel et al., 1998). Pavlovsky and coworkers
determined four X-ray structures of stromelysin-1/nonpeptide inhibitor complexes
(Pavlovsky et al., 1999). All four inhibitors display specificity for MMP-3 (Ortwine et
al., 1997; White et al., 1997; Pavlovsky et al., 1999).
They all have a diphenyl piperidine moiety as P1' group. In the structures solved with
the sulfonamide inhibitors I-III (Figure 121) bound, one O of the C=O group ligates
with the catalytic Zn2+. In the fourth structure with the hydroxamic acid based
inhibitor IV (Figure 121) two O-atoms chelate with this zinc ion. Unlike inhibitors I
and IV, inhibitors II and III contain an additional indole ring as P1 group. The
interactions of a 1-benzazole ring with the S1 substrate binding site, however, do not
appear to have a positive effect on Ki (Pavlovsky et al., 1999) (Figure 121).
Figure 121. (after Pavlovsky et al., 1999) Nonpeptide inhibitors I-IV co-crystallised w
Ki –values for stromelysin-1 are also shown (Pavlovsky et al., 1999).
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Figure 122. Surface representation of the interactions of inhibitor II with subsites of the catalytic domain of stromelysin-1
(Pdb accession code 1caq). The inhibitor is shown as sticks and the catalytic zinc ion as grey sphere. This figure has been
produced using PyMol (DeLano, 2007).
As already discussed in the previous examples of stromelysin-1 inhibitors almost all
of these compounds contain hydrophobic P1' moieties (Kohno et al., 2006). Often the
group of choice is a methoxyphenyl (Figure 123A) (Pikul et al., 2001; Almstead et al.,
1999; Cheng et al., 1999; Cheng et al., 2000; ). Other inhibitors have a phenyl (Figure
123B) (Chen et al., 1999) or a 4-phenoxyphenyl group (Figure123C) (Dunten et al.,
2001).
Figure 123. Chemical structures of methoxyphe
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Particularly interesting is the structure of the catalytic domain of stromelysin-1 from
Homo sapiens complexed with the inhibitor SM-25453 (Ki = 5.6 μM for 
collagenase-1, 0.02 μM for stromelysin-1, 0.007 μM for collagenase-3) because the 
inhibitor’s P1' moiety is a large aliphatic chain which has a polar guanidinomethyl
group attached. The associations of this hydrophilic group with residues at the bottom
of the S1' substrate site are very specific. The fact that there are four H-bonds between
the guanodinomethyl group and amino acids in collagenase-3 and only three H-bonds
of the same moiety with MMP-3 explains the higher Ki value of SM-25453 for
MMP-13. Apart from this moiety SM-25453 also contains a hydroxamic acid as the
Zn2+ chelating group and a D-lysine (Figure 124) (Kohno et al., 2006).
Figure 124. (after Kohno et al., 2006) Chemical structure of SM-25453.
Other research groups focused their design on inhibitors to explore interactions with
the S2' subsites of stromelysin-1 and other members of the MMP family (Cheng et al.,
1999; Cheng et al., 2000; Pikul et al., 2001). Pikul and coworkers solved the structure
of the catalytic domain of stromelysin-1 in complex with an inhibitor which they
called 4e. This compound contains a hydroxamic acid moiety, a
6-oxohexahydropyrimidine ring connected with a sulfonamide group and a
methoxyphenyl group.
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Additionally a CH2Ph group is attached to the hexahydropyrimidine ring (Figure 125)
which points to the S2' substrate binding site. Compounds having CnH2n+1 or like 4e a
benzylic C6H5-group at their hexahydropyrimidine rings proved to be more potent and
specific for MMPs (Pikul et al., 2001).
Figure 125. (after Pikul et al., 2001) Chemical structure of 4e.
Cheng and coworkers synthesized a series of inhibitors containing a hydroxamic acid,
a sulfonamide, a methoxyphenyl and a remodelled proline ring moiety. Their studies
revealed that an “sp2 centre” (Cheng et al., 1999) at carbon number 4 of this ring lead
to a dramatic increase in the potency of those compounds. In particular, inhibitors
with oxime or exomethylene groups at this position showed this feature. The X-ray
structure of the catalytic domain of MMP-3 with one of those inhibitors, called 14
(Figure 126), was solved showing that the oxime group points to the S2' subsite
(Cheng et al., 1999).
Figure 126. (after Cheng et al., 1999) Chemical structure of compound 14.
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Further nonpeptide inhibitors against stromelysin-1 and other MMPs have been
designed such as piperazine derived inhibitors (Figure 127A) (Cheng et al., 2000),
2,4,6-pyrimidine triones (Figure 127B) (Dunten et al., 2001) and thiadiazole
inhibitors (Figure 127C and D) (Finzel et al., 1998).
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In the structure of the catalytic domain of stromelysin-1 complexed to a pyrimidine
trione inhibitor named “compound 2” (Dunten et al., 2001), the interactions of this
inhibitor with the catalytic Zn2+ are quite unique compared to the previously discussed
inhibitors. Here, apart from the three His residues, three atoms of this
2,4,6-pyrimidine trione are in close distances to the catalytic Zn2+, N3, O2 and O4
(Figure 128) (Dunten et al., 2001).
Figure 128. (based on Dunten et al., 2001) Stereo view of the interactions of N3, O2 and O4 of compound 2 with the
catalytic Zn2+ of the catalytic domain of stromelysin-1 (Dunten et al., 2001) (Pdb accession code 1g4k). The three histidines
ligating with Zn2+ (carbons in green) and the inhibitor (C-atoms in magenta) are shown as sticks, the catalytic Zn2+ as
orange sphere and distances as dashed lines. This figure has been produced using PyMol (DeLano, 2007).
.
The interesting feature of the structures with two thiadiazole inhibitors bound is that
they exploit the unprimed subsites of stromelysin-1 (S1-S4) (Figure 129). Compound
PN-142372 (Figure 127D) contains a carbamide and a penta-fluorophenylalanine
moiety. The latter group is responsible for the high Ki value for MMP-3 compared to
PNU-141803. PNU-141803 has amide, β-phenylalanine and O-benzylcarbamate 
groups (Figure 127C). The latter moiety can even extend to the S4 substrate binding
site (Figure 129). In both inhibitors S2 of the thiadiazole ligates with the catalytic
Zn2+ (Figure 129) (Finzel et al., 1998).
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Figure 129. (after Finzel et al., 1998) Surface representation of the interactions of inhibitors PNU-142372 (carbons in
green) and PNU-141803 (C-atoms in magenta) with subsites of the catalytic domain of stromelysin-1 (Pdb accession codes
1usn and 2usn). The inhibitors are shown as sticks and the catalytic zinc ion as grey sphere. This figure has been
produced using PyMol (DeLano, 2007).
Another series of nonpeptide inhibitors against MMP-3 characterised by hydroxamic
acid and sulfonamide moieties has been synthesized (MacPherson et al., 1997)
(Figure 130).
Figure 130. Chemical structure of inhibitor 3 and functions of its diverse moieties (after MacPherson et al., 1997).
It was aimed to design compounds which could efficiently inhibit the decomposition
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Initial studies in optimising those compounds revealed that the hydroxamic acid
moiety is crucial for their activities. Changing the benzol moiety of the
para-methoxybenzenesulfonamide group to heterocycles (azabenzene,
dimethylthiazole, thiofuran) eliminated activity. The RSO2NH2 group was shown to
be essential because its substitution by an amide connection resulted in an inactive
compound. In general, addition of various different groups, especially non-polar ones,
to N of RSO2NH2 lead to potent compounds. Reduced activity was only detected with
(CH2)5NH, branching, or no groups attached. Most groups added to the position next
to R-CO-NH-OH were accepted. Additionally it was also observed that the preferred
chirality centre at this position was R. The S-isomer or racemic mixture displayed less
potency. Further studies were carried out to optimise “oral activity and duration of
action” (MacPherson et al., 1997) in an “in vivo” (MacPherson et al., 1997) rabbit
model (MacPherson et al., 1997). The compound, named 70 or CGS 27023A was
identified (Figure 131). The 1-methylethyl moiety attached at the position next to
R-CO-NH-OH proved to be crucial for long action of this inhibitor after oral
administration. Its function is very probably to prevent R-CO-NH-OH becoming
metabolically inactivated (MacPherson et al., 1997).
Figure 131. Chemical structure of inhibitor 70 (CGS 27023A) (MacPherson
Ki values for various matrixins are also shown (after MacPherson et al., 1997enzyme assay Ki (nM)
MMP-3 43 (13; Li et al., 1998)
MMP-1 33
MMP-2 20217
and Parker, 1995; MacPherson et al., 1997).
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3.3 Project aims
The objective of this project is the determination of X-ray structures of the catalytic
domain of MMP-3 in complex with a series of inhibitors based on CGS 27023A
(Figure 132), provided by our collaborators Erin Wilfong and Eric Toone from Duke
University, Durham, USA.
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An NMR structure of the catalytic domain of stromelysin-1 in complex with CGS
27023A has already been published (Gonnella et al., 1997; Li et al., 1998). The
interactions of the diverse moieties of inhibitors 1-8 with subsites of stromelysin-1
and close contacts to residues of this enzyme are aimed to be studied with crystals
structures of those complexes. Comparisons to the available NMR structure and other
X-ray structures of stromelysin-1/inhibitor complexes will also be discussed.
Purification and crystallisation of the catalytic
domain of human stromelysin-1 (SCD)
Summary
This section describes the purification and crystallisation of the catalytic domain of
MMP-3 from Homo sapiens.
3.3 Purification
Purified enzyme of the catalytic domain of human stromelysin-1 (SCD) (Pavlovsky et
al., 1999; Li et al., 1998) (amino acids 83-251) was provided by our collaborators
Erin Wilfong and Eric Toone from Duke University, Durham, USA. After purification
the protein was lyophilised in 2 mM Tris-HCl, pH 7.5, 10 mM CaCl2 and 1 μM Zn 
(OAc)2 and shipped to St. Andrews to perform crystallisation trials.
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Initial crystallisation attempts failed, it was therefore decided to check the purity of
the enzyme. About 5 mg of the lyophilised powder were dissolved in H2O and loaded
onto an SDS-PAGE gel (Figure 133)
Figure 133. SDS-PAGE showing lyophilised SCD dissolved in H2O. Lane 1: Mark12TM Protein Standard; lanes 2-4: SCD
in H2O in increasing dilutions.
One band at around 20 kDa corresponding to the catalytic domain of MMP-3 was
observed. Additionally two other bands at around 6 kDa were present. Those two
bands probably represent autolysis products of the full length enzyme. Consequently,
it was decided to purify the protein further.
3.3.1 Size exclusion chromatography
About 14 mg of lyophilised enzyme powder were dissolved in 5 ml buffer containing
2 mM Tris-HCl, pH 7.5, 10 mM CaCl2 and 1 μM Zn (OAc)2.
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Then the sample was filtered and loaded onto a HiPrepTM 16/60 SephacrylTM S-200
size exclusion column (Amersham Biosciences). This purification step was performed
on the ÄKTAxpress (Amersham Biosciences). SCD fractions eluted in 2 mM
Tris-HCl, pH 7.5, 10 mM CaCl2 and 1 μM Zn (OAc)2 were then checked for their
purity by SDS-PAGE (Figure 134).
Figure 134. (A) SDS-PAGE showing the fractions of SCD e
exclusion column. Lane 1: Mark12TM Protein Standard; lane 2: S
SCD fractions; (B) Size exclusion chromatogram of SCD.
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Fractions containing pure SCD (about 13 ml) were pooled and concentrated
(VIVASPIN 20, 3,000 MWCO PES, Sartorius Stedim Biotech GmbH (SSB)) to 11.5
mg/ml (Figure 135).
Figure 135. SDS-PAGE showing concentrated SCD. Lane 1: Mark12TM Protein Standard; lane 2: SCD at 11.5 mg/ml
3.4 Crystallisation
Prior to crystallisation SCD at a concentration of 11.5 mg/ml was spun for 5 min at
4ºC. Then inhibitors 1-8, dissolved in 100 % dimethyl sulfoxide (DMSO) (Sigma®)
were added to final concentration of 4 mM. The eight samples were then incubated for
1-2 hours at room temperature. After that they were centrifuged at room temperature
(Heraeus Biofuge Pico) and applied to crystallisation trials. Crystallisation
experiments were carried out using the conditions 0.1 M ammonium sulfate, 0.1 M
Na-cacodylate, pH 6.5, 20-30 % PEG 8000 in which well diffracting crystals
complexed with four different nonpeptide inhibitors had been obtained (Pavlovsky et
al., 1999).
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The sitting-drop vapour diffusion method was applied using Douglas Instruments
96-well crystallisation plates (Douglas Instruments) at room temperature. Protein and
mother liquor were mixed in a ratio of 1:1 (2.5 μl + 2.5 μl, reservoir volume 100 μl ). 
Sealed plates were then incubated at 20ºC. Additionally the catalytic domain of
stromelysin-1 was screened for other crystallisation conditions against commercially
available 96-condition screens, JCSG+ and Classics (GE Healthcare), using the
nanodrop crystallisation robot (Cartesian Dispensing Robot Honeybee 963, Genomic
Solutions) on sitting drop plates (Innovaplate™ SD-2 Crystallography Plate,
Innovadyne Technologies, Inc.). The 192 wells on those plates allowed screening of
two different compounds (well # 1, compound 4; well # 2, compound 8) per
crystallisation condition. Crystals large enough for diffraction experiments appeared
after one to four weeks under the already published conditions (Pavlovsky et al.,
1999), but only when inhibitors 3 or 4 had been incubated with the protein solution
(Figure 136). Crystals grew neither in presence of the other compounds, nor under any
conditions of the two commercial screens.
A B
Figure 136. Crystals of SCD grown in presence of 2mM of compound 3 under the condition 0.1 M (NH4)2SO4, 0.1 M
Na-cacodylate, pH 6.5, 29% PEG 8000 (A) and in presence of 2mM of compound 4 under the condition 0.1 M (NH4)2SO4,
0.1 M Na-cacodylate, pH 6.5, 26% PEG 8000 (B).
100 m
100 m4
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These crystals were cryoprotected in a solution containing 0.15 M (NH4)2SO4, 0.1 M
Na-cacodylate, pH 6.5, 30 % PEG 8000, 10 % PEG 400 and 2 or 4 mM of inhibitors 3
or 4 before being flash frozen in liquid nitrogen.
Discussion
The purified catalytic domain of stromelysin-1 was sent by our collaborators in a
lyophilised form. Initial crystallisation and co-crystallisation trials with this sample
using already published conditions (Chen et al., 1999; Pavlovsky et al., 1999) and
also four different commercially available crystallisation screens (JCSG+, Classics,
PEGs, pH clear) only yielded salt crystals. Consequently, the purity of the sample was
checked by SDS-PAGE electrophoresis which revealed that additionally to full length
RHTS, two other bands at a molecular weight of about 6 kDa corresponding to
autolysis products were also present in the sample. The introduction of an additional
purification step (size exclusion chromatography) was carried out to remove those
contaminants. It was also very important to include CaCl2 in the gel filtration buffer.
If one withdraws calcium the protein becomes exceedingly unstable and degrades
completely within hours. It can tolerate not having zinc for a couple of days but Ca2+
seems to be required for any degree of stability (personal communication with Erin
Wilfong). Consequently, after the size exclusion step, the incubation time of SCD
with the compounds was also kept short (1-2 hours at room temperature) and after that
crystallisation trials were set up immediately. The fact that co-crystals could only be
obtained in the presence of two of the compounds (3 and 4) is hard to explain as all of
the inhibitors are very similar (see Figure 132). Perhaps, one could have tried more
variations in the crystallisation conditions (also changing the concentration of
ammonium sulfate and the pH of Na-cacodylate and/or using a wider concentration
range of PEG 8000) and/or in protein and/or inhibitor concentrations).
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Data collection, Processing, Molecular
Replacement and Refinement of the catalytic
domain of human MMP-3 complexed with
inhibitors 3 and 4
Summary
Two complete X-ray datasets of SCD co-crystals, one in complex with inhibitor 3 and
a second one complexed with compound 4, were collected on the in-house RA-Μicro 
7 HFM Table Top Rotating Anode X-Ray Generator (Rigaku) to 2.4 and 2.5 Å,
respectively. The diffraction data were processed using Denzo and Scalepack in the
integrated package HKL2000 (Minor et al., 2002). An already solved structure of the
catalytic domain of MMP-3 (Pdb accession code 1b8y) (Pavlovsky et al., 1999) was
decided to be used as a model to calculate a set of initial phase estimates using the
technique of Molecular Replacement (MR). After the structures had been solved using
PHASER (McCoy et al., 2005; Storoni et al., 2004), incorrect amino acid rotamers
were manually changed in COOT (Emsley and Cowtan, 2004). Isotropic refinement
and TLS parameters were carried out in all steps of refinement using the programme
REFMAC (Murshudov et al., 1999). The final models were checked and validated
using MOLPROBITY (Davis et al., 2004).
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3.6 Data collection, processing, structure solution and
refinement of SCD in complex with inhibitor 4
3.5.1 Data collection and processing
Before data collection crystals were cryoprotected in a solution containing 0.15 M
ammonium sulfate, 0.1 M Na-cacodylate, pH 6.5. 30 % PEG 8K, 4 mM compound 4
and 10 % PEG 400. Diffraction data were collected at -173.15 ºC at a wavelength of
1.542 Å in-house on the RA-Μicro 7 HFM Table Top Rotating Anode X-Ray 
Generator (Rigaku). Data from one crystal to 2.5 Å resolution were collected in 0.5º
oscillations (Figure 137) with 20s exposure. Indexing and merging of the data were
performed using Denzo and Scalepack in the integrated package HKL2000 (Minor et
al., 2002). Initially it was not sure if the crystal belonged to the space group C222 or
C2221. However, PHASER (McCoy et al., 2005; Storoni et al., 2004) could only find
a correct solution in C2221. Data quality assessment by phenix xtriage (Zwart et al.,
2005) revealed pseudo translational symmetry (Table 34).
Table 34. Output from phenix.xtriage (Zwart et al., 2005) showing pseudo translational symmetry and reindexing
parameters.
The full list of Patterson peaks is:
x y z height p-value(height)
( 0.000, 0.000, 0.500 ) : 77.422 (8.535e-07)
( 0.500, 0.000, 0.000 ) : 9.031 (2.276e-01)
If the observed pseudo translationals are crystallographic the following
spacegroups and unit cells are possible:
space group operator unit cell of reference setting
C 2 2 2 (a,b,2*c) x, y, z+1/2 (56.48, 121.04, 46.87, 90.00, 90.00, 90.00)
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As a consequence reindexing of the data using the CCP4 programme Reindex was
necessary. The data have an overall completeness of 99 % and 85.4 % in the highest
resolution shell from 2.54-2.5 Å resolution. Data collection and processing statistics
are shown in Table 35.
Table 35. Data collection statistics for the SCD complex crystal. Data for the highest resolution
shell are shown in brackets.
* Rmerge = ∑ │I (k) - <I>│ / ∑ I (k), where I (k) is the value of the kth measurement of the
intensity of a reflection, <I> is the mean value of the intensity of that reflection and the
summation is over all measurements.
Data collection SCD
λ (Å) 1.542 Å 
Resolution
Last shell (Å)
50 – 2.5
(2.54-2.5)
Spacegroup C2221
Cell (Å, º) a = 56.5, b = 121, c = 47
α = β = γ = 90  
Unique reflections 11540
Average redundancy 3.6 (3.0)
I/σ  26.6 (4.8) 
Completeness (%) 99 (85.4)
Rmerge* 0.065 (0.225)
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Figure 137. 0.5º oscillation X-ray image of the co-crystal of SCD collected in-house to 2.5 Å resolution.
3.5.2 Structure solution
The structure of SCD in complex with with inhibitor 4 was solved by molecular
replacement using PHASER (McCoy et al., 2005; Storoni et al., 2004). A monomer of
of the catalytic domain of stromelysin-1 (Pdb accession code 1b8y) was used as a
search unit. A solution was found for one monomer in the asymmetric unit consistent
with the Matthews coefficient calculation (Matthews, 1968) and a resolution range
between 60.5 and 2.5 Å. A clear rotation and translation solution (Z-scores of 15.1 and
21.4, respectively) for one monomer was found in the space group C2221. Only one
unfavourable molecular contact was observed for the final solution in crystal packing.
The Molecular Replacement solution was then applied to the coordinates of the search
model to work as the starting model in the refinement described in section 3.5.3
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3.5.3 Refinement
REFMAC 5 (Murshudov et al., 1999) was used to refine the structure of the catalytic
domain of MMP-3 in complex with inhibitor 4. Data in the range from 60.5-2.5 Å
were used. Incorrect rotamers of the enzyme were modified manually in COOT
(Emsley and Cowtan, 2004). TLS parameters (Table 36) and isotropic B-thermal
factors were employed in all cycles of refinement.
Table 36. TLS groups employed throughout the refinement of SCD. “Residues” 1-5 are referred to the metal ions Zn2+ and
Ca2+, “residue” 6 to compound 4.
TLS
RANGE 'A 80.' 'A 260.' ALL
RANGE 'B 1.' 'B 6.' ALL
Waters and ligands (compound 4, Zn2+, Ca2+, SO42-) were also added in COOT
(Emsley and Cowtan, 2004). The Rwork and Rfree after the last round of refinement
were 24 % and 25.5 %, respectively (Table 37). The quality of the structure was
judged using MOLPROBITY (Table 38) (Davis et al., 2004).
230
Table 37. Refinement statistics of SCD complexed with inhibitor 4. Rwork and Rfree in the highest resolution shell are
shown in brackets.
* Rwork = ∑hkl ││Fobs - │Fcalc││ / ∑hkl │Fobs│ 
* For Rfree the same calculation applies, but for only 5-10 % of reflections which are not included in the
refinement.
Refinement SCD
Rwork* % 24 (26.5)
Rfree* % 25.5 (21)
Number of atoms (average
B value (Å2)
protein (mainchain)
protein (sidechain)
water
Zn2+
Ca2+
Inhibitor 4
SO42-
636 (27.9)
636 (28.3)
15 (44.4)
2 (34.6)
3 (32.1)
17 (50.7)
5 (55.2)
rmsd bonds (Å) / angles (°) 0.006 / 0.929
Ramachandran favoured (%) 94.8
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Table 38. Output from MOLPROBITY (Davis et al., 2007)
* 100th percentile is the best among structures of comparable resolution; 0th percentile is the
worst.
* Ramachandran outliers: Leu245
Goal: <0.5%0.63%Residues with badangles:
Goal: <1%0.00%Residues with badbonds:
98th percentile*
(N=6960, 2.25Å -
2.75Å)
1.80MolProbity score
Goal: 01C deviations>0.25Å
Goal: >98%94.77%Ramachandranfavored
Goal: <0.2%0.65%Ramachandranoutliers*
Goal: <1%0.00%Rotamer outliers
Protein
Geometry
Clashscore is the number of serious steric overlaps (> 0.4 Å) per
1000 atoms.
98th percentile*
(N=271, 2.25Å -
2.75Å)
8.01Clashscore, allatoms:All-Atom
Contacts
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3.6 Data collection, processing, structure solution and
refinement of SCD in complex with inhibitor 3
3.6.1 Data collection and processing
Before data collection crystals were cryoprotected in a solution containing 0.15 M
ammonium sulfate, 0.1 M Na-cacodylate, pH 6.5. 30 % PEG 8K, 2 mM compound 3
and 10 % PEG 400. Diffraction data were collected at -173.15 ºC at a wavelength of
1.542 Å in-house on the RA-Μicro 7 HFM Table Top Rotating Anode X-Ray 
Generator (Rigaku). Data from one crystal to 2.4 Å resolution were collected in 0.5º
oscillations (Figure 138) with 20s exposure. Indexing and merging of the data were
performed using Denzo and Scalepack in the integrated package HKL2000 (Minor et
al., 2002). The crystal belonged to the space group C2221. The data have an overall
completeness of 99.3 % and 97.9 % in the highest resolution shell from 2.4-2.36 Å
resolution. Data collection and processing statistics are shown in Table 39.
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Table 39. Data collection statistics for the SCD complex crystal. Data for the highest resolution shell
are shown in brackets.
* Rmerge = ∑ │I (k) - <I>│ / ∑ I (k), where I (k) is the value of the kth measurement of the
intensity of a reflection, <I> is the mean value of the intensity of that reflection and the
summation is over all measurements.
Figure 138. 0.5º oscillation X-ray image of the co-crystal of SCD collected in-house to 2.4 Å resolution.
Data collection SCD
λ (Å) 1.542 Å 
Resolution
Last shell (Å)
50-2.36
(2.4-2.36)
Spacegroup C2221
Cell (Å, º) a = 57, b = 120.5, c = 47
α = β = γ = 90  
Unique reflections 6909
Average redundancy 2.3 (1.9)
I/σ 21.3 (5.1) 
Completeness (%) 99.3 (97.9)
Rmerge* 0.062 (0.196.)
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3.6.2 Structure solution
The structure of SCD in complex with with inhibitor 3 was solved by molecular
replacement using PHASER (McCoy et al., 2005; Storoni et al., 2004). A monomer of
of the catalytic domain of stromelysin-1 (Pdb accession code 1b8y) was used as a
search unit. A solution was found for one monomer in the asymmetric unit consistent
with the Matthews coefficient calculation (Matthews, 1968) and a resolution range
between 24.3 and 2.5 Å. A clear rotation and translation solution (Z-scores of 13.8 and
19.5, respectively) was found for one monomer. No unfavourable molecular contacts
were observed for the final solution in crystal packing. The Molecular Replacement
solution was then applied to the coordinates of the search model to work as the
starting model in the refinement described in section 3.6.3
3.6.3 Refinement
REFMAC 5 (Murshudov et al., 1999) was used to refine the structure SCD in
complex with inhibitor 3. Data in the range from 14-2.4 Å were used. Incorrect
rotamers of the enzyme were modified manually in COOT (Emsley and Cowtan,
2004). TLS parameters (Table 40) and isotropic B-thermal factors were employed in
all cycles of refinement. Waters and ligands (compound 3, Zn2+,Ca2+,SO42-) were also
added in COOT (Emsley and Cowtan, 2004). The Rwork and Rfree after the last round of
refinement were 25.2 % and 28.2 %, respectively (Table 41). The quality of the
structure was judged using MOLPROBITY (Table 42) (Davis et al., 2004).
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Table 40. TLS groups employed throughout the refinement of SCD. “Residues” 1-5 are referred to the metal ions Zn2+ and
Ca2+, “residue” 6 to compound 3.
TLS GROUP 1
RANGE 'A 80.' 'A 104.' ALL
TLS GROUP 2
RANGE 'A 105.' 'A 212.' ALL
RANGE 'B 1.' 'B 6.' ALL
TLS GROUP 3
RANGE 'A 212.' 'A 237.' ALL
Table 41. Refinement statistics of SCD complexed with inhibitor 3. Rwork and Rfree in the highest resolution shell are
shown in brackets.
* Rwork = ∑hkl ││Fobs - │Fcalc││ / ∑hkl │Fobs│ 
* For Rfree the same calculation applies, but for only 5-10 % of reflections which are not included in the
refinement.
Refinement SCD
Rwork* % 25.2 (27.1)
Rfree* % 28.2 (35.6)
Number of atoms (average
B value (Å2)
protein (mainchain)
protein (sidechain)
water
Zn2+
Ca2+
Inhibitor 3
SO42-
636 (54.9)
636 (55.4)
16 (66.2)
2 (55.1)
3 (50.8)
24 (60)
5 (50.6)
rmsd bonds (Å) / angles (°) 0.01 / 1.214
Ramachandran favoured (%) 89.5
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Table 42. Output from MOLPROBITY (Davis et al., 2007)
* 100th percentile is the best among structures of comparable resolution; 0th percentile is the
worst.
* Ramachandran outliers: Ser244
Goal: <0.5%1.25%Residues with badangles:
Goal: <1%0.00%Residues with badbonds:
54th percentile*
(N=8058, 2.15Å -
2.65Å)
2.69MolProbity score
Goal: 00C deviations>0.25Å
Goal: >98%89.54%Ramachandranfavored
Goal: <0.2%1.31%Ramachandranoutliers*
Goal: <1%2.26%Rotamer outliers
Protein
Geometry
Clashscore is the number of serious steric overlaps (> 0.4 Å) per
1000 atoms.
51st percentile*
(N=331, 2.15Å -
2.65Å)
23.15Clashscore, allatoms:All-Atom
Contacts
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Discussion
Both complexes crystallised in the same space group and the cell dimensions are also
identical (Tables 35 and 39). This is not surprising as the crystallisation condition is
the same. Only the concentrations of the precipitant, PEG 8K, vary slightly.
Furthermore, the two inhibitors are also very similar, compound 3 only has an
additional pyridine moiety (see Figure 132). In one case data had to be reindexed
because of pseudotranslational symmetry (see Table 34). Sometimes, problems
occurred with other datasets from crystals grown under the same conditions during
data processing. It was often quite difficult to mount a single crystal onto the
goniometer because they usually grew in clusters (see Figure 136). As a consequence
more than one lattice was frequently present in diffraction patterns. Structure solution
and refinement were straightforward. A clashscore of all atoms of 8.01 (98th percentile)
and a MOLPROBITY score of 1.8 (98th percentile) indicates the good quality of the
SCD structure complexed with inhibitor 4 (Table 38). The corresponding scores for
the SCD structure in complex with inhibitor 3 are much lower (Table 42) which
means that still further refinement will be required before submission to the Protein
Data Bank.
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Structures of SCD in complex with inhibitors 3
and 4
Summary
This section describes the two solved structures of SCD complexed with compounds 3
and 4. First an analysis of both overall structures and bound ligands is performed.
Than a more detailed desription of the active sites in both structures is carried out,
with focus on the interactions of the inhibitors with the enzyme. Differences and
common features between both complexes, other solved SCD X-ray structures and the
solution structure in complex with CGS 27023A (Inhibitor 1) (Li et al., 1998) are also
discussed.
3.7 Overall structures
Unsurprisingly, because of their essentially identical sequence, both structures of SCD
share the same fold as other structures of the catalytic domain of MMP-3 (Alcaraz et
al., 2007; Kohno et al., 2006; Pikul et al., 2001; Dunten et al., 2001; Cheng et al.,
2000; Steele et al., 2000; Pavlovsky et al., 1999; Chen et al., 1999; Dhanaraj et al.,
1996; Becker et al., 1995). If one superimposes the 2.4 Å resolution structure with
one of the already published SCD structures (Figure 139A) (Chen et al., 1999), the
rmsd is only 0.351 Å for 135 Cα positions. Superposition of the 2.4 Å and 2.5 Å 
resolution structures gives an rmsd of 0.163 Å for 133 Cα positions (Figure 139B). 
The asymmetric unit of both structures is composed of one monomer.
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39. (A) Stereo view of the Cα tracing of SCD complexed with inhibitor 3 (cyan) and chain A of the native catalytic 
of stromelysin-1 (green) (Chen et al., 1999) (Pdb accession code 1cqr). (B) Stereo view of the Cα tracing of SCDs 
ed with inhibitors 3 (cyan) and 4 (magenta). This figure has been produced using PyMol (DeLano, 2007).
onomers of both structures are essentially complete apart from some parts of
ong, flexible loop” (amino acids 210-234) (Chen et al., 1999). In the SCD
re complexed with inhibitor 3, the electron density for amino acids 212-214
48 is weak. Amino acids 215, 216 and 225-230 are completely missing.
ionally the last two carboxyterminal residues (250-251) are also disordered.
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In the lower resolution complex structure, the electron density for amino acids
213-216, 243 and 247 is not well-defined. As in the 2.4 Å resolution structure the
region displaying residues 225-231 is also completely disordered and the two terminal
amino acids are missing as well. Disordered amino acids in this flexible loop have
also been reported in other X-ray structures of the catalytic domain of MMP-3 (Chen
et al., 1999; Dhanaraj et al., 1996; Pavlovsky et al., 1999). In the remainder of both
structures electron density is only missing for a few side chains of amino acids such as
Arg, Lys and Glu.
3.8 Ion binding sites and coordination
The positions and interactions of the catalytic and structural Zn2+, as well as for the
three Ca2+, are essentially identical in both complexes and the same as in previously
published SCD structures (Figures 140 and 141) (Kohno et al., 2006; Pikul et al.,
2001; Dunten et al., 2001; Cheng et al., 2000; Steele et al., 2000; Pavlovsky et al.,
1999; Chen et al., 1999; Becker et al., 1995).
Figure 140. Interactions of both SCDs with the catalytic (left) and structural (right) zinc ions. Carbons of amino acids and
Zn2+ are shown in green for the SCD structure complexed with inhibitor 3 and in cyan for the SCD structure in complex
with inhibitor 4. This figure has been produced using PyMol (DeLano, 2007).
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Figure 141. Interactions of both SCDs with the first (A), second (B) and third (C) cal
and waters are shown in green for the SCD structure complexed with inhibitor 3 and
complex with inhibitor 4. Calcium ions are shown in magenta. This figure has been
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There is no electron density for the two H2O normally ligating with this Ca2+ (Chen et
al., 1999), and the B factor for this calcium ion is almost twice as high as the
temperature factors for Ca1 and Ca3 (Table 43). In the SCD structure complexed with
inhibitor 3 one water molecule is bound to Ca2 (Figure 141B). The B factors for each
of the three Ca2+ do not differ significantly (Table 43).
Table 43. Temperature factors (A2) of the first, second and third calcium ions (Ca1-Ca3) in both SCD complex structures
compared to two other inhibited structures of the catalytic domain of MMP-3.
Ca1 Ca2 Ca3
SCD + inhibitor 3 50 52 50
SCD + inhibitor 4 26 44 26
1b8y (Pavlovsky et
al., 1999)
14 40 14
1sln (Becker et al.,
1995)
8 30 13
One sulfate ion is also present in the SCD structures complexed with compounds 3
and 4 at exactly the same position as in the structures of the catalytic domain of
MMP-3 in complex with other nonpeptide inhibitors (Pavlovsky et al., 1999) (Figure
142). It is in close contact with Lys110, the first residue of α1 (amino acids 110-125) 
(Figure 142) (Pavlovsky et al., 1999). Interestingly this SO42- only occurs in the
crystals with the space group P41212 even though all complexes crystallised under the
same conditions. There is no electron density for this anion in the other crystal forms
(P6522, hexagonal and P21, monoclinic) (Pavlovsky et al., 1999).
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Figure 142. Stereo view of superimposed sulfate ion and α-helix 1 of SCD structures in complex with inhibitors 3 (green) 4 
(cyan) and inhibitor I (magenta) (Pdb accession code 1b8y) (Pavlovsky et al., 1999). Lys110 is shown as sticks and close
interactions (< 3.5 Å) between sulfate O-atoms of SCD complexed with inhibitor 3 and N of Lys110 as dashed lines. This
figure has been produced using PyMol (DeLano, 2007).
3.9 Interactions with inhibitors 3 and 4
There is clear electron density for one molecule of inhibitor 3 in the 2.4 Å resolution
(Figure 143A) and for one molecule of inhibitor 4 in the 2.5 Å resolution structure
(Figure 143B)
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143. Unbiased Fo-Fc at 3σ (green) and final 2Fo-Fc at 1σ (blue) maps around compound 3 of the 2.4 Å structure of
A) and unbiased Fo-Fc at 3σ (green) and final 2Fo-Fc at 1σ (blue) maps around compound 4 of the 2.5 Å structure of
(B). Both inhibitor molecules are modelled in the 2Fo-Fc density. Both maps were calculated at final stages of
ment before addition of the compounds. This figure has been produced using PyMol (DeLano, 2007).
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The methoxy group attached to the phenyl ring is flexible in both inhibitors as
indicated by the missing electron density in both 2Fo-Fc and Fo-Fc maps (Figure 143A
and B). The average B factor of the methoxy group of inhibitor 4 in the 2.5 Å
resolution structure is 53.6 Å2, whereas the tightly bound hydroxamic acid moiety has
an average temperature factor which is unsurprisingly lower (46.6 Å2). The average B
factors of the corresponding groups of inhibitor 3 in the 2.4 Å resolution structure are
61.7 Å2 and 57.9 Å2, respectively.
Because of the essentially same locations of the inhibitors, interacting residues and the
catalytic zinc ions in both SCD structures (Figure 144), only the binding mode of
inhibitor 3 will be discussed in detail due to its additional pyridine group.
Figure 144. Stereo view of superimposed inhibitors 3 (carbons in magenta) and 4 (C-atoms in yellow) and adjacent
residues (shown as green sticks in the 2.4 Å SCD structure and as cyan sticks in the 2.5 Å SCD structure). The zinc ions
located at the exactly same position in both structures are shown as sphere(s) in green (higher resolution structure) and
cyan (lower resolution structure). This figure has been produced using PyMol (DeLano, 2007).
The two O-atoms of the hydroxamic acid moiety of inhibitor 3, O and OAE interact
with the catalytic Zn2+ additionally to histidines 201, 205 and 211 (Figure 145) (Chen
et al., 1999; Pavlovsky et al., 1999; Li et al., 1998).
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The C=O oxygen (O) is also in close distance to NE2 of His211 (2.6 Å) (Figure 145).
Oxygen OAE shows interactions with more residues of SCD. It is in H-bonding
distance to OE2 (Li et al., 1998; Chen et al., 1999) (2.5 Å) and OE1 of Glu202 (3.2 Å)
(Pavlovsky et al., 1999) and the NE2 nitrogen of both His 201 and 205 (3.1 Å and 2.9
Å, respectively) (Figure 145). The nitrogen NAQ which establishes a covalent
connection with OAE (Chen et al., 1999) could also generate H-bonds with O of Ala
165 (3 Å) (Li et al., 1998; Chen et al., 1999) and OE2 of Glu202 (2.9 Å) (Li et al.,
1998) (Figure 145).
Figure 145. Close up view of the interactions of the hydroxamic acid moiety of inhibitor 3 (carbons in cyan) with the
catalytic zinc (grey sphere) and residues of SCD (shown as sticks with C-atoms in green). Distances are shown as dotted
lines. This figure has been produced using PyMol (DeLano, 2007).
Oxygen OAC of the sulfonamide moiety of the inhibitor generates three H-bonds with
the enzyme (Figure 146A), one with N of Leu164 (2.8 Å) (Li et al., 1998; Pavlovsky
et al., 1999), one with N of Ala165 and one with O of Ala165 (3.5 Å). The second
O-atom of the sulfonamide (OAD) is only in close contact with one amino acid of
SCD, Asn162. The distance between this oxygen and O of Asn162 is 3.6 Å.
Ala165
Glu202
His201
His205
His211
The methoxy phenyl moiety of inhibitor 3 (Figure 146) represents the P1' group
which inserts into the S1' subsite of SCD (Li et al., 1998) (Figure 147). There are only
two residues of the enzyme adjacent to this moiety. The oxygen (OAR) of the
methoxy group is located closely to ND1 of His201 (3.4 Å) and O of Leu197 (3.6 Å)
(Figure 146B). The azine ring which fills the S2' subsite of the catalytic domain of
MMP-3 (Figure 147) (Li et al., 1998) does not associate with any amino acids at all
and points to the solvent (Li et al., 1998).
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ure 146. Stereo views of the interactions of the sulfonamide moiety (A) and the methoxy group (B) of inhibitor 3 with
idues of SCD. Carbons of the inhibitor and residues of SCD are shown in cyan and green, respectively are The catalytic
c is shown as grey sphere, distances as dashed lines. This figure has been produced using PyMol (DeLano, 2007).
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Figure 147. Surface representation of the interactions of inhibitor 3 with subsites of the catalytic domain of the 2.4 Å SCD
structure. The inhibitor is shown as sticks and the catalytic zinc ion as grey sphere. This figure has been produced using
PyMol (DeLano, 2007).
However, isothermal titration calorimetry (ITC) studies, performed by our
collaborators (Wilfong, 2008), show that compound 3 binds thirteen times more
tightly to stromelysin-1 than compound 4 (Figure 148). Also, the Kd value for CGS
27023A is more than six times lower than for compound 2 (Figure 148) which
contains all the moieties of CGS 27023A except the pyridine ring. Consequently, it
can be concluded that the azine ring contributes significantly to the potency of these
inhibitors (MacPherson et al., 1997). It is conjectured that the azine ring displaces a
water molecule previously bound to the protein thereby increasing the entropy of the
system compared to the non-azine molecule and given the similar enthalpies the
binding stability increases.
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Inhibitor 3 Inhibitor 4
Kd = 22 nM Kd = 296 nM
              ΔG = -10.6 kcal/mol                           ΔG = -8.9 kcal/mol 
ΔH = -10.7 kcal/mol                           ΔH = -13.6 kcal/mol 
CGS 27023A Inhibitor 2
Kd = 7 nM Kd = 44 nM
              ΔG = -11.1 kcal/mol                           ΔG = -10.2 kcal/mol 
ΔH = -9.0 kcal/mol                            ΔH = -7.5 kcal/mol 
Figure 148. (after Wilfong, 2008) Isothermal titration calorimetry (ITC) data for CGS 27023A and inhibitors 2-4.
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3.10 Common features and differences in inhibitor binding
between the crystal structure of SCD in complex with
inhibitor 3 and the NMR structure of SCD complexed with
CGS 27023A (Inhibitor 1)
The binding mode of both inhibitors is essentially the same in both structures. The
two oxygens O and O1 of the hydroxamic acid moiety of CGS 27023A also function
as ligands of the catalytic zinc apart from the three conserved histidines (Figure 149)
(Chen et al., 1999; Pavlovsky et al., 1999; Li et al., 1998). Like in the SCD structure
complexed to inhibitor 3, the nitrogen is also in H-bonding distance to O of Ala165
(Li et al., 1998) (2.9 Å). Additionally the close distances of the hydroxylamine
oxygen to NE2 of His201 and His205 (2.5 Å in both cases) are also common in both
structures. However, there are also differences. Whereas only one atom of the
hydroxamate of inhibitor 3 is in hydrogen bonding distance to NE2 of His201 (OAE)
(Figure 145), both O-atoms and also the nitrogen of the same moiety are in very close
contact with NE2 of this histidine (2.5, 2.4 and 3.1 Å, respectively) (Figure 149).
His211 is positioned further away from the C=O oxygen of the hydroxamic acid in the
CGS 27023A complex structure (Figure 149) which leads to an increase of the
distance between this O-atom and NE of His211 (4.2 Å; 2.6 Å between the same
atoms in the inhibitor 3 complex). The most striking differences between both
structures lie in the interactions of the hydroxamate with Glu202. Li and coworkers
reported that there could be an H-bond (about 2.3 Å) between the O-atom of the
OH-group of the hydroxamate, which could carry H+, and OE2 of Glu202.
Additionally this H-bond could be underpinned by the presence of the protective
isopropyl moiety of this inhibitor which would obviate the fast replacement of H+ of
the OH with H2O (Li et al., 1998). However, the side chain of Glu202 is positioned
much too far away to make any interactions with the inhibitor at all (Figure 149).
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Figure 149. Stereo view of the interactions of the hydroxamic acid moiety of CGS 27023A (carbons in magenta) with
residues of SCD (shown as sticks with C-atoms in green) (Pdb accession code 1bm6). The catalytic zinc ion is shown as
grey sphere and distances are shown as dotted lines. This figure has been produced using PyMol (DeLano, 2007).
Only one sulfonamide oxygen of inhibitor 3 (OAC) is in H-bonding distance with
three atoms, provided by Leu164 and Ala165, (see Figure 146A) whereas both
O-atoms of the sulfonamide can generate hydrogen bonds with residues of SCD (Li et
al., 1998). This is mainly possible due to the different positions of Asn 162 and
Leu164 in the NMR structure complexed with CGS 27023A (Figure 150) compared to
the 2.4 Å resolution crystal structure. OB1 (OAD in inhibitor 3) is now located only
2.3 Å from O of Asn162 (3.6 Å in the SCD structure in complex with inhibitor 3).
Additionally it is in H-bonding distance to N of Leu164 (Li et al., 1998). OB2 (OAC
in inhibitor 3) could also form an H-bond with O of Asn162 (3.4 Å). As in the 2.4 Å
SCD complex structure, this O-atom of the sulfonamide is also in H-bonding distance
with N of Leu164 (Li et al., 1998) and Ala165 (2.4 and 2.7 Å, respectively). O of
Ala165, however, is positioned slightly further away (3.7 Å).
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Figure 150. Stereo view of the interactions of the sulfonamide moiety of CGS 27023A (carbons in magenta) with residues
of SCD (shown as sticks with C-atoms in green) (Pdb accession code 1bm6). The catalytic zinc ion is shown as grey sphere
and distances are shown as dotted lines. This figure has been produced using PyMol (DeLano, 2007).
There are also more interactions of the methoxy phenyl group of inhibitor 1 with
residues of the enzyme than the same moiety of inhibitor 3 with SCD. Whereas the
O-atom of the methoxy group of inhibitor 3 is only in H-bonding distance with ND1
of His201 (see Figure 146B), the corresponding O-atom of CGS 27023A could
generate hydrogen bonds with three atoms, provided by His 201 (ND1, 2.6 Å),
Leu218 (O, 2.6 Å) and Met219 (O, 3.2 Å) (Figure 151). The two latter amino acids
are located more closely to the methoxy oxygen in the NMR structure (Figure 151)
than the corresponding residues in the 2.4 Å X-ray structure. O of Leu197, however is
positioned further away in Li and coworkers’ structure due to the slightly different
orientation of the flexible methoxy group (Figure 151).
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Figure 151. Stereo view of the interactions of the methoxy phenyl moiety of CGS 27023A (carbons in magenta) with
residues of SCD (shown as sticks with C-atoms in green) (Pdb accession code 1bm6). The catalytic zinc ion is shown as
grey sphere and distances are shown as dotted lines. This figure has been produced using PyMol (DeLano, 2007).
The pyridine ring of CGS 27023A is rotated differently compared to the pyridine ring
of inhibitor 3 (Figure 152). Whereas in the 2.4 Å crystal structure no contacts between
this moiety of the latter compound and amino acids of SCD can be observed, two
carbons of this ring of CGS 27023A are located closely to atoms of Asn162. CD1 is
positioned 3.6 Å from O of Asn162 and CE1 is located 3.1 Å from CB of Asn162
(Figure 152).
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Figure 152. Close up view of the interactions of the pyridine ring of CGS 27023A (carbons in magenta) with residues of
SCD (shown as sticks with C-atoms in cyan) (Pdb accession code 1bm6). The superimposed residues and inhibitor 3 of the
2.4 Å resolution SCD structure are also shown as sticks (C-atoms in green and orange, respectively). Zinc ions in the
X-ray and NMR structure are shown as green and cyan spheres, respectively. This figure has been produced using PyMol
(DeLano, 2007).
CGS 27023A also contains, in contrast to inhibitor 3, an isopropyl moiety as P1 group
which mainly points to the solvent (Figure 153) (Li et al., 1998). This hydrophobic
group is only in contact with one nonpolar residue, Val163.
Figure 153. Surface representation of the interactions of inhibitors CGS 27023A (carbons in magenta) and 3 with subsites
of the catalytic domain of the SCD structure. The surface of the 2.4 Å SCD crystal structure is shown. This figure has
been produced using PyMol (DeLano, 2007).
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It was reported that in the NMR structure (Li et al., 1998) the part of the flexible S1'
loop (Gooley et al., 1996; Chen et al., 1999; Li et al., 1998) comprising amino acids
221-231 undergoes a remarkable modification in its conformation compared to other
reported SCD structures (Li et al., 1998). This distinct conformation (Figure 154)
leading to a “compact enzyme-inhibitor complex” (Li et al., 1998) could be
responsible for the higher potency of this nonpeptide inhibitor compared to peptidic
blockers which actually display more associations with the enzyme. Furthermore, this
change in conformation limits acess to the S1' subsite (Li et al., 1998). In the SCD
crystal structure complexed with inhibitor 3, however, there is absolutely no sign of
any similar conformation of the S1' loop (Figure 154). In addition, most of the
residues of this loop region (amino acids 221-231) are disordered. (Figure 154).
Figure 154. Ribbon diagram showing the 2.4 Å SCD structure complexed with inhibitor 3 (secondary structure elements
in green, C-atoms of the inhibitor in orange) superimposed with the NMR structure of SCD in complex with inhibitor 1
(NMR structure with the lowest energy of the ensemble of the twenty structures deposited is used) (secondary structure
elements in cyan, carbons of the inhibitor in magenta) (Pdb accession code 1bm6) (Li et al., 1998) (Rmsd = 1.55 Å for 139
Cα positions). Both loop regions, amino acids 221-231 in the NMR structure, and residues 221-224 in the crystal structure 
are shown in magenta and orange, respectively. Additionally disordered parts of the entire flexible loop (amino acids
210-234) (Chen et al., 1999) in the X-ray structure are boxed. This figure has been produced using PyMol (DeLano, 2007).
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It has been shown that in the crystal structure of the catalytic domain of MMP-3
complexed with the inhibitor PGV-25727 the conformation of the S1' loop between
amino acids 222 and 231 has been modified due to binding of this compound (Chen et
al., 1999). PGV-25727 (Figure 155) is similar to inhibitor 3 and CGS 27023A (Figure
132). In the uninhibited structure access to the S1' subsite is prevented by Tyr223. In
the inhibited enzyme, however, Tyr223 was moved by Ph of PGV-25727 (Chen et al.,
1999). It has been reported that this highly conserved tyrosine residue might function
as a “selective gatekeeper” (Dhanaraj et al., 1996; Chen et al., 1999) to the S1' pocket
(Dhanaraj et al., 1996; Chen et al., 1999).
Figure 155. (after Chen et al., 1999) Chemical structure of PGV-25727.
Comparison of the location of Tyr223 and the conformation of the flexible S1' loop
(Gooley et al., 1996; Chen et al., 1999; Li et al., 1998) between Chen and coworkers’
complex structure and the SCD structure with inhibitor 3 bound reveals that the
tyrosine is located at exactly the same position in both structures (Figure 156).
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Additionally, parts of the S1' loop which are not disordered in the SCD structure
complexed with inhibitor 3 are essentially at almost the same positions in both
complexes (Figure 157B). Consequently, it can be proposed that the binding mode of
inhibitors 3 and PGV-25727 and the resulting modification of the conformation of the
flexible loop which leads to an increase in size of the S1' subsite (Chen et al., 1999)
are identical in both SCD structures.
.
Figure 156. Stereo view of superimposed Tyr223 of SCD complexed with inhibitor 3 (carbons in green 2Fo-Fc density at 1
σ), SCD in complex with inhibitor PGV-25727 (C-atoms in cyan) (Pdb accession code 1b3d) (Chen et al., 1999), native
SCD (carbons in magenta) (Pdb accession code 1cqr) (Chen et al., 1999) and the NMR structure of SCD complexed with
CGS 27023A (C-atoms in yellow) (Pdb accession code 1bm6) (Li et al., 1998). This figure has been produced using PyMol
(DeLano, 2007).
Further comparisons between the 2.4 Å resolution SCD complex structure and other
structures of the catalytic domain of stromelysin-1 complexed with other nonpeptide
(Pavlovsky et al., 1999) (see Section 3.1.3.3 and peptidic inhibitors containing P1'
groups (Becker et al., 1995) (see Section 3.1.3.3) reveals that in all those structures
the location of Tyr223 is essentially identical and the S1' loop displays the same “open
conformation” (Li et al., 1998; Finzel et al., 1998) (Figure 157A and B).
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osition of Tyr223 residues and inhibitors of SCD structures complexed with the nonpeptide
green), PGV-25727 (C-atoms in cyan) (Pdb accession code 1b3d) (Chen et al., 1999) and I
ccession code 1b8y) (Pavlovsky et al., 1999) and the N-carboxyalkyl peptide inhibitor I (C-atoms
ion code1sln) (Becker et al., 1995). (B) Ribbon diagram of the same four superimposed SCD
scheme as in (A)). The part of the loop displaying amino acids Tyr223 to Arg231 (Chen et al., 1999)
been produced using PyMol (DeLano, 2007).
structures with inhibitors bound lacking a P1' group (see Section
t al., 1998), Tyr223 and also the loop from Leu222 to Arg231 adopt
and conformation (“S1'-closed conformation”) (Finzel et al., 1998)
in the native structure of the catalytic domain of MMP-3 (Finzel et
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Superposition of Tyr223 residues and inhibitors of SCD structures complexed with the nonpeptide
5727 (C-atoms in cyan) (Pdb accession code 1b3d) (Chen et al., 1999), PNU-142372 (carbons in green)
ode 1usn) (Finzel et al., 1998), PNU-141803 (C-atoms in magenta) (Pdb accession code 2usn) (Finzel et al.,
tive SDR structure (carbons in yellow) (Pdb accession code 1cqr) (Chen et al., 1999). (B) Ribbon diagram
superimposed SCD structures (same colour scheme as in (A)). The part of the loop displaying amino
rg231 (Chen et al., 1999) is boxed. This figure has been produced using PyMol (DeLano, 2007).
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The significant differences in the location of Tyr223 and the conformation of the S1'
loop between the 2.4 Å resolution X-ray structure of SCD complexed with inhibitor 3
and the NMR structure in complex with the similar inhibitor, CGS 27023A (only
contains an additional isopropyl group) (Li et al., 1998), is hard to explain as the
X-ray and NMR structures of the catalytic domain complexed with the same
N-carboxyalkyl peptide inhibitor (Becker et al., 1995; Gooley et al., 1994; Gooley et
al., 1996) do not display such dramatic distincions in this region (Figure 159 and B).
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(A) Superposition of Tyr223 residues and the same N-carboxyalkyl peptide inhibitor of the crystal (C-atoms
db accession code 1sln) (Becker et al., 1995) and NMR (C-atoms in cyan) (Pdb accession code 2srt) (Gooley et
tructures of SCD. (B) Ribbon diagram of the same superimposed SCD structures (same colour scheme as in
art of the loop displaying amino acids Tyr223 to Arg231 (Chen et al., 1999) is boxed and shown in different
genta in the crystal and yellow in the NMR structure). This figure has been produced using PyMol (DeLano,
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Future aims
The structures of the catalytic domain of stromelysin-1 in complex with inhibitors 3
and 4 have been solved to 2.4 and 2.5 Å, respectively. Comparisons to the already
published NMR structure in complex with inhibitor 1 (Li et al., 1998), which only
contains an additional isopropyl moiety as P1 group (Li et al., 1998) revealed
significant differences in the conformation of the flexible S1' loop (Gooley et al., 1996;
Chen et al., 1999; Li et al., 1998). Further studies could include further attempts to get
crystal structures of SCD in complex with the other inhibitors 1, 2, 5, 6, 7 and 8.
Particularly, structures with compounds 5 and 6 bound would be of great interest
because of their missing hydroxamic acid moiety (see Figure 132). Consequently, the
interactions with the catalytic zinc would have to be different.
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Appendix
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(taken from http://ecoliwiki.net/colipedia/index.php/pET-30_Xa/LIC) The map of the Novagen pET-30 Xa/LIC vector,
including cleavage sites of important restriction enzymes, the multiple cloning site (MCS, black arrow), the origin of
replication (ori), a kanamycin resistance marker (kan), the f1 phage origin and the gene encoding the lac-repressor (lacI).
Furthermore it encodes an aminoterminal hexa-histidine tag and contains a potentially cleavable Factor Xa site.
The map of the pEHISTEV vector including cleavage sites of important restriction enzymes, the multiple cloning site
(MCS), the origin of replication (ori), a kanamycin resistance marker (kan), the f1 phage origin and the gene encoding the
lac-repressor (lacI). Furthermore it encodes an N-terminal hexa-histidine tag and contains a tobacco etch virus (TEV)
protease cleavage site (Liu and Naismith, 2009).
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“Grid screens” around crystallisation conditions Classics # 74 and JCSG+ # 46
Starting condition: Classics, condition # 74
0.2 M CaCl2
0.1 M Hepes-Na pH 7.5
28 % PEG 400
0 mM Salt 100 mM Salt 200 mM Salt 300 mM Salt
CaCl2 1 2 3 4
MgCl2 1 5 6 7
All with 0.1 M Hepes-Na pH 7.5, 28 % PEG 400
All with 0.2 M CaCl2, 28 % PEG 400. Na-Cacodylate for pH 6.0-7.0, Hepes-Na for pH 7.1-8
% PEG
400
25 26 27 29 30 31 32 33 34 35
tube 18 19 20 21 22 23 24 25 26 27
All with 0.1 M Hepes-Na pH 7.5, 0.2 M CaCl2
Starting condition: JCSG+, condition # 46
0.2 M Calcium Acetate
0.1 M Na-Cacodylate pH 6.5
40 % PEG 300
0 mM Salt 100 mM Salt 200 mM Salt 300 mM Salt
Ca-Acetate 28 29 30 31
Mg-Acetate 32 33 34
All with 0.1 M Na-Cacodylate pH 6.5, 40 % PEG 300
All with 0.2 M Calcium Acetate, 40% PEG 300. Na-Cacodylate for pH 6-7.0, Hepes-Na for pH 7.1-8
%
PEG300
35 36 37 38 39 41 42 43 44 45
tube 45 46 47 48 49 50 51 52 53 54
All with 0.1 M Na-Cacodylate pH 6.5, 0.2 M Calcium Acetate
pH 6.0 6.2 6.4 6.6 6.8 7.0 7.1 7.3 7.7 8.0
tube 8 9 10 11 12 13 14 15 16 17
pH 6 6.2 6.4 6.6 6.8 7.0 7.1 7.3 7.7 8.0
tube 35 36 37 38 39 40 41 42 43 44
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“Grid screens” around crystallisation conditions JCSG+ # 2 and # 78
Starting condition: JCSG+, condition # 2
0.1 M tri-Sodium citrate pH 5.5
20 % PEG 3000
All with 20 % PEG 3000
pH 5.0 5.2 5.4 5.6 5.8 6.0
tube 4 5 6 7 8 9
All with 0.1 M tri-Sodium citrate, 20 % PEG 3000
% PEG
3000
17 18 19 21 22 23 24 25
tube 10 11 12 13 14 15 16 17
All with 0.1 M tri-Sodium citrate pH 5.5
Starting condition: JCSG+, condition # 78
0.2 M Na-malonate pH 7.0
20 % PEG 3350
0.1 M salt 0.2 M salt 0.3 M salt
Na-malonate
pH 7.0
18 19 20
All with 20 % PEG 3350
pH 6.6 6.8 7.2 7.4
tube 21 22 23 24
All with 0.2 M Na-malonate, 20 % PEG 3350
% PEG
3350
17 18 19 21 22 23 24 25
tube 25 26 27 28 29 30 31 32
All with 0.2 M Na-malonate, pH 7.0
0.05 M salt 0.1 M salt 0.2 M salt
Tri-Sodium citrate
pH 5.5
1 2 3
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“Grid screen” around crystallisation condition Classics # 5
Starting condition: Classics, condition # 5
0.1 M Hepes-Na pH 7.5
10 % 2-propanol
20 % PEG 4000
0.1 M HEPES-Na pH 7.1 pH 7.3 pH 7.5 pH 7.7 pH 7.9
Tube 1 2 3 4 5
All with 10 % 2-propanol, 20 % PEG 4000
All with Hepes-Na pH 7.5, 20 % PEG 4000
All with 0.1 M Hepes-Na pH 7.5, 10 % 2-propanol
“Grid screen” around crystallisation condition JSG+ # 46
Starting condition: JCSG+, condition # 46
0.2 M Calcium Acetate
0.1 M Na Cacodylate pH 6.5
40 % PEG 300
Ca-Acetate 100 mM Salt 200 mM Salt 300 mM Salt
tube 1 2 3
All with 0.1 M Na-Cacodylate pH 6.5, 40 % PEG 300
All with 0.2 M Calcium Acetate, 40% PEG 300
%
PEG300
35 36 37 38 39 41 42 43
tube 10 11 12 13 14 15 16 17
All with 0.1 M Na-Cacodylate pH 6.5, 0.2 M Calcium Acetate
2-propanol 5 % 6 % 7 % 8 % 9 % 11 % 12 % 13 % 14 % 15 %
tube 6 7 8 9 10 11 12 13 14 15
PEG
4000
15 % 16 % 17 % 18 % 19 % 21 % 22 % 23 % 24 % 25 %
tube 16 17 18 19 20 21 22 23 24 25
Na-cacodylate
pH
6 6.2 6.4 6.6 6.8 7.0
tube 4 5 6 7 8 9
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“Grid screens” around crystallisation conditions PEGs # 67, # 54 and # 76
starting condition: PEGs, condition # 67
0.2 M NH4NO3
20 % PEG 3350
All with 20 % PEG 3350
[PEG 3350] 15% 16% 17% 18% 19% 21% 22% 23% 24 % 25 %
Tube 6 7 8 9 10 11 12 13 14 15
All with 0.2 M NH4N03
starting condition: PEGs, condition # 54
0.2 M NaCl
20 % PEG 3350
All with 20 % PEG 3350
[PEG
3350]
15% 17% 19% 22% 25%
Tube 4 5 6 7 8
All with 0.2 M NaCl
starting condition: PEGs, condition #76
0.2 M Ca-Acetate
20 % PEG 3350
[Ca-Acetate] 0.1 M 0.15 M 0.2 M 0.25 M 0.3 M
0.2 M
(Mg-acetate
tetrahydrate
Tube 1 2 3 4 5 6
All with 20 % PEG 3350
All with 0.2 M Ca-Acetate
[NH4NO3] 0.1 M 0.15 M 0.2 M 0.25 M 0.3 M
Tube 1 2 3 4 5
[NaCl] 0.1 M 0.2 M 0.3 M
Tube 1 2 3
[PEG 3350] 15% 16% 17% 18% 19% 21% 22% 23% 24 % 25 %
Tube 7 8 9 10 11 12 13 14 15 16
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“Grid screens” around crystallisation conditions Classics # 82 and # 73
starting condition: Classics, condition # 82
0.01 M NiCl2 hexahydrate
0.1 M Tris-HCl, pH 8.5
20 % PEG 2000 MME
All with 0.1 M Tris-HCl, pH 8.5, 20 % PEG 2000 MME
All with 0.01 M NiCl2, 20 % PEG 2000 MME
All with 0.01 M NiCl2, 0.1 M Tris-HCl, pH 8.5
starting condition: Classics, condition # 73
0.1 M HEPES-Na pH 7.5
2 M (NH4)2SO4
2 % PEG 400
All with 0.1 M HEPES-Na, pH 7.5, 2 % PEG 400
0.1 M
HEPES-Na
pH 7.1 pH 7.3 pH 7.7
Tube 6 7 8
All with 2 M (NH4)2SO4, 2 % PEG 400
[PEG 400] 1 % 3 % 4 % 5 % 6 % 7 %
Tube 9 10 11 12 13 14
All with 2 M (NH4)2SO4, 0.1 M HEPES-Na, pH 7.5
All with 2 M (NH4)2SO4, 0.1 M HEPES-Na, pH 7.5, 2 % PEG 400
[NiCl2] 0 0.01 M 0.03 M 0.05 M 0.07 M 0.1 0.2
Tube 1 2 3 4 5 6 7
Tris-HCl pH 7.7 pH 7.9 pH 8.1 pH 8.4 pH 8.6
Tube 8 9 10 11 12
[PEG 2000
MME]
15% 16% 17% 18% 19% 21% 22% 23% 24 % 25 %
Tube 13 14 15 16 17 18 19 20 21 22
[(NH4)2SO4] 1.5 M 1.75 M 2 M 2.25 M 2.5 M
Tube 1 2 3 4 5
[Spermidine] 10 mM 15 mM 20 mM 25 mM 30 mM
Tube 7 8 9 10 11
